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 Multidrug binding proteins are able to recognize structurally unrelated 
compounds.  These proteins play a crucial role as drug resistant export proteins 
in both eukaryotic and prokaryotic cells.  Furthermore, multidrug binding proteins 
exist that regulate transcription of multidrug transporters and play an important 
role in responding to incoming toxins.  To study the function of multidrug binding 
proteins and exporters, AcrD of Escherichia coli (E. coli), CmeR of 
Campylobacter jejuni, and AcrR of E. coli were chosen as models.  AcrD, a 
multidrug efflux pump, functions to rid the bacterial cell of incoming hydrophilic 
substrates by harboring a diverse ligand binding cavity capable of recognizing 
the deleterious compounds.  By using fluorescence polarization and isothermal 
titration calorimetry, we show that AcrD specifically interacts with 
aminoglycosides and anthracyclines with dissociation constants in the low 
micromolar range.  By modeling the AcrD structure, hydrophilic patches were 
identified that could allow substrates to be captured from the cytoplasm or 
periplams and exported completely out of the bacterial cell. 
 The transcriptional regulators CmeR and AcrR interact with inducing 
ligands by utilizing a similar mechanism, whereby a diverse binding pocket exists 
allowing recognition of various substrates.  This work shows how CmeR 
recognizes large, negatively charged bile salts by harboring a large hydrophobic 
surface with appropriately spaced polar residues to stabilize bile acid binding.  
Furthermore, by comparing the structures of AcrR and CmeR, a model can be 
developed to describe transcriptional regulation.  Upon ligand interaction in the 
C-terminal domain, adjacent N-terminal domains separate, breaking bonds with 
the DNA operator, thus releasing repression.  Interestingly, kinetics studies 
reveal that AcrR, CmeR, and AcrD interact with ligands in the low micromolar 
range, which may be a critical feature of mutlidrug binding proteins.           
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CHAPTER 1. GENERAL INTRODUCTION 
DISSERTATION ORGANIZATION 
 
 This dissertation contains six chapters. 
 Chapter 1 is a general introduction to the dissertation organization and the 
research aims and significance of the studies. The two research aims stated in 
Chapter 1 are specifically addressed in Chapters 3-5. 
 Chapter 2 is a literature review of the resistance, nodulation, and cell division 
(RND) superfamily of transporters.  First, this review takes a look at the history and 
highlights specific experiments that have provided novel insights into the function of 
RND proteins.  In particular, studies focused on the well-studied RND transporters 
AcrB of E. coli and MexB of Pseudomonas aeruginosa (P. aeruginosa)  are 
discussed.  Recently obtained X-ray crystal structures of these two proteins are then 
closely examined.  Furthermore, the important roles other members of the RND 
family play in the life cycle of Gram-negative bacteria are closely examined.  Finally, 
the review highlights advances made in the development of efflux pump inhibitors 
(EPIs) and the implications of these molecules.    
 Chapter 3 addresses the first research aim of understanding the structure and 
function of RND transporters. In the first research aim, a crystallization protocol is 
developed to delve into the structure of the RND transporter AcrD of E. coli.  
Furthermore, biochemical and biophysical tools are used to understand the 
structure-function relationship of AcrD.  As the crystal structure yet eludes us, 
structural and binding site predictions are used to validate the available biochemical 
data and enhance the understanding of multiligand interaction.  Multidrug binding 
proteins similar to AcrD have been shown to harbor large binding cavities capable of 
interacting with structurally diverse ligands.  As AcrD is able to recognize a wide 
array of antibacterial compounds, including aminoglycosides, sodium dodecyl 
sulfate, tetracyclines, and bile salts, the docking predictions aid in providing valuable 
insights into the diverse ligand binding sites. To this point, AcrD harbors a large 
multifaceted uniquely polar binding cleft.  It is suggested that the wide range of polar 
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residues are employed to interact with structurally dissimilar hydrophilic ligands.  
Furthermore, we provide initial evidence that AcrD is able to recognize the 
anthracycline class of antibiotics through fluorescence polarization experiments 
using with the substrate daunorubicin HCl (DR).  The binding assays suggest that 
DR and gentamicin bind with similar affinity to AcrD, whereby dissociation constants 
of 6 µM and 3 µM are observed, respectively.     
 The 4th Chapter is a review article published in the journal BBA Proteins and 
Proteomics (1). This review is a compilation of research performed in our lab on the 
TetR family of transcriptional repressors.  Specifically, the repressors AcrR and 
CmeR of E. coli and C. jejuni, respectively, are discussed.  Additional work is 
included in the text describing recent studies on the transcriptional regulators AcrR 
and CmeR.  The work focuses on structural and functional characterization of these 
proteins.  Contributions to this work are described as follows: Mathew Routh 
collected binding data, peformed crystallization experiments on the AcrR-IR 
complex, and wrote the manuscript.  Chih-Chia Su performed modeling studies, 
collected data, and performed crystallization studies. Qijing Zhang prepared protein 
samples for crystallization and kinetic studies, and Edward Yu designed experiments 
and assisted in writing the manuscript.   
 The research presented in Chapter 5 is in preparation for submission to the 
Journal of Biochemistry.  This work describes the crystallization of CmeR in complex 
with the bile acids cholate and taurocholate, and identifies a novel, distinct binding 
site within CmeR.  Contributions made to this work include the following:  Mathew 
Routh resolved the structure, identified binding site, analyzed data, and wrote 
manuscript.  Zhangqi Shen prepared CmeR protein for crystallization.  Jack Su 
performed much of the crystallization experiments.  Qijing Zhang aided in 
experimental design and edited the manuscript, and Edward W. Yu assisted in the 
experimental design, data analysis, and manuscript writing.  
 Chapter 6 is the general conclusion of the studies addressed in the thesis.  
This chapter summarized the results from the structural and functional studies on 
AcrD that facilitated a greater understanding of RND transporters and how they are 
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able to recognize a diverse array of ligands.  Furthermore, the chapter concludes the 
work discussed in Chapters 4 and 5 on the TetR family of repressors.  Through the 
work in these chapters, a model can be suggested to show how these proteins 
regulate transcritption and allow rapid induction upon interaction with structurally 
dissimilar compounds.  Other topics in this chapter include future directions and 
potential applications deriving from the insights of this work. 
 
RESEARCH AIMS AND SIGNIFICANCE 
 
 Multidrug resistance has been called one of the world’s most pressing public 
health problems.  For epidemiological purposes, multidrug resistant (MDR) bacteria 
are defined as bacteria able to resist one or more classes of antimicrobials (2).  For 
instance, Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-
resistant enterococci (VRE) are resistant to most available antibacterial drugs and 
receive special attention in healthcare facilities (3).  Usually, MDR infections have 
similar clinical manifestations as those caused by susceptible pathogens.  However, 
treating the infections becomes increasingly difficult in resistant microorganisms.  
For example, vancomycin is one of the few effective treatments for MRSA and is 
considered the last line of defense against many resistant pathogens (4, 5).  
Although new antimicrobials are becoming available, resistance to each new agent 
has already emerged in clinical isolates (6-10).   
 Increased mortality has recently been associated with Salmonella 
typhimurium infections by linking data from the Danish Surveillance Registry for 
Enteric Pathogens with the Civil Registration System and the Danish National 
Discharge Registry (11).  This study suggests that patients infected with S. 
typhimurium infections resistant to ampicillin, chloramphenicol, streptomycin, 
sulfonamide, and tetracycline had a 2-year death rate 4.8 times higher, whereas 
additional quinolone resistance increased the mortality rate to 10.3 times the general 
population.  Comparatively, patients infected with drug susceptible strains were only 
2.3 times more likely to die 2 years after infection than people in the general Danish 
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population.  This study highlights the necessity to increase understanding of the 
fundamental mechanisms associated with drug resistance.   
 Drug resistant bacterial infections were first reported shortly after the initial 
mass production of antibiotics in the 1940’s.  In fact, a report published in 1947 
found that, of 100 staphylococcus infections tested, 38 were classified as highly 
resistant to penicillin (12).  This initial resistance was primarily associated with 
individual enzymes inactivating specific antibiotics, such as β-lactamases on 
penicillin.  As novel antibiotics were implemented to combat resistant pathogens, 
selective pressure led to fundamentally new methods of drug resistance.  Currently, 
there are roughly three major mechanisms utilized by bacteria to evade the toxic 
effects of biocidal agents, including enzymatic modification (Fig 1A), target alteration 
(Fig 1B), and reduced uptake due to the presence of drug efflux pumps (Fig 1D) or a 
decrease in porin expression (Fig 1C).  Enzymatic modification involves two classes 
of enzymes, including those that degrade specific antibiotics (13) and enzymes that 
chemically modify the antibacterial compound (14), thus decreasing drug toxicity.  
The second mechanism employed by bacteria is alteration of the drug target.  Nearly 
all relevant fluoroquinolone resistance has been attributed to target alteration, 
whereby specific mutations inhibit the drugs interaction to DNA gyrase and 
topoisomerase IV (15).  Although highly effective, these mechanisms are limited by 
inhibiting only specific classes of antibiotics.  A more critical issue is the broad 
spectrum of antibiotic resistance associated with multidrug efflux pumps. Ubiquitous 
in most living cells, multidrug efflux transporters have gained recognition as the 
major contributor to drug resistance observed in many pathogenic microorganisms 
(16, 17).  These transporters are capable of capturing and exporting toxic 
compounds before they reach their cellular target, thereby decreasing the 
effectiveness of the drug (18, 19).  The first drug transporter identified, TetA, in 1980 
(20), conferred tetracycline resistance to its host.  Following this breakthrough, 
ensuing discoveries identified proteins capable of eliminating various structurally 
unrelated compounds.   
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Recently, tremendous strides have been made to understand the mechanisms that 
govern RND transporter function.  These works have focused on both the 
transporters as well as the regulatory networks that control their expression.  To 
provide novel insights into multidrug resistance and the regulation of the associated 
export proteins, two specific aims have been pursued in this work. 
 Aim 1: Understanding the structure and molecular mechanism of the 
multidrug transport protein AcrD of E. coli.   
 Elucidating the three-dimensional structure of AcrD will provide fundamental 
insights to the mechanism of drug efflux. Furthermore, the protein structure is a 
pivotal tool in the design of effective efflux pump inhibitors.  Based on the 
homologous protein AcrB and previously obtained biochemical evidence on AcrD, 
we hypothesize that AcrD utilizes the proton-motive-force to transition through three 
functional states (access, binding, and extrusion) to export substrates.  It has been 
suggested that RND transport proteins harbor a multifaceted binding cleft capable of 
interacting with a diverse array of potential substrates (21-25).  The studies in 
chapter 3 help to delineate how AcrD is able to recognize structurally dissimilar 
ligands.  Additionally, initial clues to the AcrD transport mechanism are illustrated 
through the homology modeling experiments in the same chapter.          
 Aim 2: Providing insights to how MDR pumps are locally regulated by the 
TetR family of proteins.  
 The soluble regulators that govern multidrug efflux pump exression provided 
the initial clues to how multidrug binding proteins are able to recognize such 
dissimilar agents.  Crystallization experiments on QacR of Staphylococcus auerius 
first showed the multifaceted nature of the binding cavity, thus illustrating the 
importance of this feature (26).  Functionally, these proteins regulate transcription by 
interacting with the promoter sequence upstream of the open reading frame, thereby 
inhibiting polymerase initiation (27).  It seems the N-terminal domain of each 
regulator interacts with consecutive major grooves of the DNA.  We hypothesize that 
ligand interaction to the C-terminal domain of CmeR of C. jujuni and AcrR of E. coli 
initiates structural changes in the N-terminal domain forcing protein/DNA separation.  
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The work performed in Chapters 4 and 5 support this hypothesis by showing that, 
upon ligand interaction, the distance between N-terminal domains separate to ~54 Å 
in CmeR, although in unliganded AcrR, this distance is 37 Å.   
 A docking study showed that the hydrophobic tunnel of CmeR should be able 
to accommodate large, negatively charged bile acid molecules, such as taurocholate 
and cholate (28).  We hypothesized that bile acids should anchor to a mostly 
hydrophobic surface with appropriately positioned polar and positively charged 
residues.  Various hydrophobic residues are located throughout the binding cavity of 
CmeR, including H72, F99, F103, F137, S138, Y139, V163, C166, T167, K170 and 
H174.  The anionic bile acids suggested length would span nearly the entire ligand-
binding tunnel of the regulator, respectively. The large tunnel, possibly consisting of 
multiple mini-pockets that may be employed to interact with different ligands, is rich 
in aromatic residues and contains three positively charged amino acids (two 
histidines and one lysine).  We previously predicted that these positively charged 
residues would be crucial for CmeR to recognize negatively charged ligands.  The 
work in chapter 5 is based on this hyposthesis and provides clues to how CmeR is 
able to recognize both anionic and neutral ligand by employing various charged and 




















Figure 1 is a schematic diagram representing the major mechanisms bacteria utilize 
to resist drug toxicity. (A) Enzymatic breakdown of drug: the scissors represent 
inactivating enzymes while the red barbell shapes are active drugs and half barbells 
are inactive.  (B) Target site mutation: single point mutations in the drug’s target site 
can reduce affinity making the drug ineffective.  The target is represented in green 
and the drug is the red barbell.  (C)  Decrease of porin expression: Many drugs 
poorly spontaneously diffuse across the membrane and therefore must utilize porin 
molecules to enter the cell.  Mutations altering porin expression levels can reduce 
accumulation of drugs within the cell.  The porin molecules are colored green and 
drugs are the red barbell.  (D) Active efflux: As drugs enter the cell, drug exporters 
reduce the intracellular concentration of drug.  The blue, green, and orange 
molecules are a schematic representation of a inner membrane transporter, 
membrane fusion protein, and outer membrane channel of an RND efflux complex, 
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 Multidrug resistance (MDR) is a devastating problem associated with the 
treatment of many bacterial infections and chemotherapeutic resistant cancers. One 
mechanism of MDR is the expression of integral membrane efflux pumps that 
actively extrude an array of structurally dissimilar drugs as they cross the cell 
membrane (1, 2). When over expressed in cancerous cells, P-glycoprotein, an efflux 
pump in human cells, which naturally functions to prevent toxic molecules from 
crossing the blood-brain barrier, causes cancer cells to become resistant to various 
chemotherapeutic agents (3-5). Additionally, bacteria harbor a diverse range of 
efflux pumps capable of extruding a variety of antibacterial compounds. The efflux 
pumps effectively reduce the intracellular concentrations of the antibiotics and make 
eliminating the infection increasingly difficult (4, 6, 7). Treatment of these drug 
resistant bacterial strains is exacerbated by the ease at which resistant markers are 
genetically transferred between species. In fact, plasmid mediated genetic transfer 
has been implicated in quinolone and fluoroquinolone resistant infections in many 
human isolates. In 1998, a plasmid, qnrA1, was identified that harbored genes able 
to protect the bacterial pathogen by utilizing various mechanisms, including drug 
efflux by the innermembrane transporter QepA (8).  As efflux pumps are capable of 
exporting a library of structurally diverse ligands, the transfer of these resistance 
genes is a major concern due to the risk of an epidemic of multidrug resistant 
bacterial diseases (9). 
 Multidrug transporters are classified into five families based on sequence and 
functional similarities, these families include:  primary transporters of the ATP-
binding cassette (ABC) family (Fig. 1B) (10), and secondary transporters in the 
resistance-nodulation-division (RND) (Fig. 1A) (11), multidrug and toxic compound 
extrusion (MATE) (Fig. 1E) (12, 13), major facilitator (MF) (Fig. 1C) (14-16), and 
small multidrug resistance (SMR) families (Fig. 1D) (17).  Of these classes of efflux 
pumps, the RND family confers resistance to the broadest range of antibacterial 
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agents (18, 19) and is the major cause of multidrug resistance in many pathogenic 
Gram-negative bacteria, including Burkholderia pseudomallei, Escherichia coli 
O157:H7, Haemophilus influenzae, Neisseria gonorrhoeae, Neisseria meningitides, 
Pseudomonas aeruginosa, Salmonella typhimurium, Stenotrophomonas maltophilia, 
and Vibrio cholerae (20-23). This illustrates why RND transporters are considered a 
primary contributor to multidrug resistance associated with Gram-negative bacteria.  
Although members of the RND family have been identified that promote a drug 
resistant phenotype in primarily gram-negative bacteria, they are ubiquitous in all 
domains of life, including Gram-positive bacteria, archaea, and eukaryotes (11). The 
prevalence of these transporters highlights the critical need to fully understand the 
functional mechanism of these pumps. 
 Transporters in the RND family are energized through the proton-motive force 
(PFM) with proton translocation occurring in the transmembrane (TM) domain (24). 
RND pumps in Gram-negative bacteria generally function as tripartite efflux 
complexes in conjunction with a membrane fusion protein (25, 26) and an outer 
membrane channel (27, 28) (Fig. 1A) to export substrates completely out of the 
bacterial cell. The transporters share common structural features, including 12 
transmembrane (TM) helices that harbor large periplasmic loops between TM1 and 
2, and TM 7 and 8 which extend ~70 Å into the periplasm (11, 29-33). The outer 
membrane channel completely spans the outer membrane and extends an 
additional 100 Å into the periplasm.  The combined 170 Å allows the outer 
membrane channel and inner membrane transporter to make weak interactions.  
These contacts are further stabilized by membrane fusion proteins, which interact 
with both the outer and inner membrane proteins (34-36), thus providing a critical 
component of the tripartite complex. 
 The transport complexes AcrA-AcrB-TolC of E. coli and MexA-MexB-OprM of 
Pseudomonas aeruginosa are two well studied examples of RND efflux complexes, 
whereby AcrB and MexB function as inner membrane transporters. Crystal 
structures are available for both AcrB (29-33) and MexB (34). These structures 
indicate an asymmetric, functional rotating mechanism for ligand export (31-34). The 
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significant role that these pumps play in multidrug resistance associated with virulent 
strains of bacteria highlights the critical need to further understand the mechanism 
these transporters employ to recognize and expel structurally dissimilar antibiotics.  
This review will highlight the genetic, biochemical, and structural studies undertaken 
to gain valuable insights into RND transporters, with a particular focus on information 
garnered from the research on AcrB and MexB. 
 
BACKGROUND 
 The RND family of proteins was first described by Saier and colleagues, et al. 
1994 (35), and was based on homology between functionally related membrane 
proteins (Fig. 2).  Initially, five proteins were classified into the RND family (35) with 
two of those being previously identified as transporters conferring resistance to 
heavy-metal ion toxicity.  It was suggested that resistance was due to extrusion of 
heavy-metal ions via active transport.  The cobalt, cadium, zinc (Czc) (36-38) and 
the cobalt nickel resistant (Cnr) (39, 40) efflux systems were identified as close 
homologues to three other proteins involved in nodulation of legumes by rhizobia 
(NolGHI) (41, 42) and a protein which plays a role in cell division (EnvD) (43).  
Based on the variety of functions these proteins were implicated in, the 
resistance/nodulation/cell division family adopted its unique title.  With the genes for 
these membrane proteins being preceded upstream by genes transcribing a class of 
membrane fusion proteins, it was suggested that members of the RND family may 
similarly function to actively transport substrates across the inner and outer 
membranes of Gram-negative bacteria (35).  Although initially found in only Gram-
negative bacteria, further homology studies and hydophobicity analysis identified 
proteins belonging to the RND family in all domains of life (11).  Newly identified 
proteins from this phylogenetic analysis identified seven sub-families of RND 
transporters, including a protein implicated in Niemann-Pick type C (NP-C) disease, 
a lipid storage disorder in humans (44-46), as well as three sub-families associated 
with multidrug export (11).  Among the proteins classified as drug transporters, the 
acriflavine-resistance protein B (AcrB) (47) was identified as a member of the 
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primarily Gram-negative bacterial hydrophobe/amphiphile efflux-1 (HAE1) family 
(11).  A sequence alignment highlighting important residues and regions of AcrB with 
other members of the RND family is illustrated in figure 2. 
 Although AcrB was identified as a member of the RND family within the last 
ten years, the multidrug resistant phenotype associated with the acr gene locus was 
identified more then 40 years ago (48).  Intriguingly, during a study undertaken on E. 
coli strains resistant to the basic dye acriflavine, a cross-resistance to other basic 
dyes was also observed.  Nakamura, et al. 1965, identified a single locus 
responsible for the phenotype, and termed this resistance marker acrA (later called 
acrB).  It was observed that, after selecting for resistance to any one of the basic 
dyes, including acriflavine, methylene blue, toluidine blue, crystal violet, methyl 
green, and pyronine B, that cross-resistance to all the other dyes was acquired.  
Furthermore, he noticed that the resistance to the acidic dyes eosin Y and erythrosin 
were not affected by the acrA locus.  It was therefore suggested that the acrA gene 
product produced a membrane-associated factor that effected permeability to 
cationic dyes.  The proposed model, at that time, stated that acrA mutations affected 
the biosynthesis of a 58-kDa inner membrane protein and, in the mutant acrA strain; 
acriflavine, or other basic dyes, would bind to the protein resulting in the increased 
resistance (48).  Further studies indicated that resistance to structurally dissimilar 
compounds, including phenethyl alcohol, sodium dodecyl sulfate, as well as the 
antibiotics novobiocin and nalidixic acid were also mediated by the acrA locus.  This 
could not easily be explained by the previously hypothesized model; therefore 
further inquisition was needed to delineate the resistant mechanism (49).   
 Following the molecular cloning of the acrA DNA fragment, using a 
complementation test, it was discovered that the open-reading-frame (ORF) of acrA 
contained two genes, acrA and acrB (at the time termed acrE as the name acrB had 
already been used for another acriflavine-resistant gene) (50).  The acrA ORF 
encodes a 397-residue lipoprotein containing a 24-residue periplasmic signal 
peptide at the N-terminus, while the acrB gene product transcribes a 1049 amino 
acid transmembrane protein.  These gene products were identified as close 
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homologues to the previously identified E. coli proteins EnvC and EnvD (Fig. 2), 
respectively (50).  Sequence analysis identified AcrB as a membrane protein with 12 
membrane spanning sequences.  Moreover, it was surmised that AcrB may function 
as a transporter, which was hypothesized based on homology between AcrB and the 
heavy-metal transporter CzcA (50) (Fig. 2).  Characterization of AcrA suggested that 
this was a periplasmic protein that may aid in transport, but at the time of its 
discovery, little was known about the proteins function. 
 At the time that the acrA/acrB genes were cloned, another multidrug 
resistance determinant was identified in Pseudomonas aeruginosa (51).  It was 
observed that a siderophore-deficient P. aeruginosa mutant, when grown in an iron-
deficient media, became less susceptible to drug-induced toxicity compared to the 
wild-type strain.    Further investigation identified an ORF composed of three genes, 
multiple efflux genes A, B, and outer-membrane protein M (mexA/mexB/oprM, 
previously identified as orfA/orfB/orfC), associated with the drug-resistant 
phenotype.  Mutants defective in mexA, mexB, or oprM exhibited increased 
susceptibility to tetracycline, chloramphenicol, ciprofloxacin, streptonigrin, and 
dipyridyl, consistent with a role for these gene products in multiple antibiotic 
resistance.  It was further identified that MexA, MexB, and OprM exhibited sequence 
homology to AcrB, AcrA, and a previously described family of outer-membrane 
channels, respectively.  Based on this homology and the previous implication of the 
active transport of pyoverdine (a siderophore in P. aeruginosa) by MexA and MexB, 
it was suggested that these proteins most likely function as multidrug transporters 
(51).  
 The clinical implications of MexA/MexB/OprM were further explored in a study 
of 11 patients treated with with β-lactam antibiotics to combat a P. aeruginosa 
infection (52).  It was found, in addition to resistance to β-lactams, these bacterial 
strains acquired cross-resistance to various unrelated antibiotics, including 
quinolones, tetracyclines, and trimethoprim.  Using immunoblotting techniques, with 
polyclonal antibody raised against OprM, the cause of the multidrug resistance 
phenotype was identified as over-expression of MexA/MexB/OprM.  Additionally, 
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AcrB was shown to effectively promote a drug resistant phenotype.  In this case, 
inactivation of the constitutively expressed RND pump AcrB causes E. coli to 
become more susceptible to lipophilic β-lactams, whereby the minimum inhibitory 
concentrations (MIC) of lipophilic penicillin and cloxacillin is reduced from 512 µg/ml 
in the wild type strain to approximately 2 µg/ml in the mutant (53). 
 
RND FUNCTION 
 With these RND transporters being implicated in a majority of acquired and 
intrinsic multidrug resistance cases among Gram-negative organisms, it was 
important to understand the molecular mechanisms and recurring features that 
promote the phenotype.  Overall, the hallmarks of the RND family of transporters are 
a transmembrane domain consisting of 12 α-helical segments (TMS) along with two 
large-periplasmic domains located between TMS 1 and 2 and TMS 7 and 8 (29) 
(Fig. 3).  This overall architecture was first confirmed using the phoA gene fusion 
method to study the MexB protein.  Alkaline phosphatase is enzymatically activated 
only after it is translocated from the cytoplasm to the periplasm, thus allowing for 
determination of periplasmic spanning segments based on relative phosphatase 
activity (54).  Figure 3 is a schematic representation of the results of the phoA fusion 
experiments on MexB.  Similar experiments were performed to determine the 
architecture of the RND transporters MexD, also of P. aeruginosa (55), and CzcA, a 
heavy metal transporter from Ralstonia sp (56).  Based on the results, it was 
concluded that an overall similar topology exists throughout the RND family.  
Moreover, as the N- and C-terminal halves of these proteins share sequence 
similarities, it was suggested that the 1-plus-5 repeated architecture may have 
evolved via a tandem duplication event.  Interestingly, the three nodultation-
dependent RND proteins, NolGHI,  complex to form the full-length RND protein, 
whereby NolG, H, I are homologous to the N-terminal, middle, and C-terminal 
portions of AcrB, respectively (35).   
 Proteins among the RND family act as proton/ligand antiporters, in which the 
inner-membrane protein functions as the proton-motive-force (PMF) dependent 
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transporter (57).  Initially, indirect methods were used to provide evidence for this 
energy-driven efflux mechanism.  The PMF was examined using drug susceptibility 
studies of both AcrA/AcrB/TolC and MexA/MexB/OprM.  In whole-cell experiments, 
AcrB mutants of the putative proton-relay network increased the accumulation and 
thus, susceptibility to cephalothin and cephaloridine (58).  Similar results were 
obtained for MexA/MexB/OprM (59), whereby MexB-null mutants accumulated drugs 
more readily than wild-type strains.  Additionally, deenergization of the cytoplasmic 
membrane using the proton conductor carbonyl cyanide m-chlorophenylhydrazone 
(CCCP) always produced a strong increase in the accumulation level of substrates, 
which indicated a potential requirement of a proton gradient for drug efflux (59). 
Finally, a mutant overproducing MexAB-OprM accumulated less tetracycline and 
chloramphenicol than the parent strain and was more resistant to a wide range of 
antimicrobial compounds, including b-lactams (60).   
 In a novel series of experiments using Purified AcrB reconstituted into 
proteoliposomes, direct evidence was provided for a PMF-driven substrate transport 
mechanism (61).  In this extensive work, AcrB was shown to extrude a fluorescent 
derivative of phosphatidylethanolamine (PE), 7-nitrobenz-2-oxa-1,3-diazol-4-yl 
(NBD)-PE, in a proton-dependent manner.  As most of the natural AcrB substrates 
are lipophilic and readily diffuse across the membrane, attempts made to directly 
measure accumulation of these compounds into inverted vesicles were 
unsuccessful. It may be that the naturally slow kinetics (turnover rate of less than 
one per minute for most substrates (62)) of the pump and the removal of the 
membrane fusion protein, AcrA, during purification procedures may have further 
hindered the reconstitution experiments.  Previous to the NBD-PE studies, only 
inconsistent results could be obtained.  For example, using an everted vesicle 
system, it was suggested that AcrB may transport taurocholate, a bile acid with a 
pKa of ~1.5 that does not readily cross the lipid membrane, utilizing the PMF.  As 
those vesicles without AcrB also showed accumulation of taurocholate, these results 
were inconclusive (63).   
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 In this regard, an intuitive method was used to measure the transport of the 
NBD-PE, whereby AcrB was reconstituted into donor vesicles harboring 
fluorescently labeled PE and a rhodamine-PE derivative.  The rhodamine conjugate 
quenches the fluorescently labeled PE’s signal within the donor vessicle (61).  As 
NBD-PE molecules are transported, the quenching is diminished due to separation 
of the fluorescent signal and rhodamine quenching.  Presumably, the NBD-PE would 
become reinserted into the original membrane as it is expelled by the AcrB pump.  
To counteract this event, an excess of AcrB-free, non-labeled, (acceptor) vesicles 
were used to trap the extruded phospholipids.  In this fashion, the fluorescence 
signal is quenched in presence of rhodamine in the donor vesicles.  As the 
fluorescent-PE is exported by AcrB and trapped into the acceptor vesicles, AcrB 
activity can be measured through the increase of fluorescence signal.  Figure 4 
illustrates the overall experimental design.  These studies allowed for the 
examination of the effect of pH and the PMF on substrate transport by AcrB.   
 The results indicated that donor vesicles suspended in an acidic external 
environment were able to transport labeled PE.  Furthermore, using known 
substrates of AcrB, including bile acids, erythromycin, and cloxacillin, PE transport 
was eliminated.  This indicated that AcrB has a strong preference for these lipophilic 
molecules.  Additionally, by incorporating various drugs into the AcrB-containing 
proteoliposome system, proton efflux could be measured.   As the internal proton 
concentration increased beyond that of the external buffer during transport, proton 
translocation provided compelling evidence of the involvement of a proton-
dependent transport system.   To more directly observe proton/drug antiport, the 
proteoliposome system was energized via the valinomycin-induced flux of K+, which 
was converted into a proton gradient in the presence of KCl.  Using the fluorescent 
pH indicator pyranine, proton efflux, associated with drug influx, could be confirmed 
by directly measuring the the change in intravesicular pH.  Interestingly, the addition 
of the membrane fusion protein AcrA accelerated extrusion of substrates (61), which 
was interpreted as AcrA connecting the donor and acceptor vesicles.  An Alternative 
explanation later surfaced, whereby AcrA may be required to activate the pumping 
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mechanism. This was suggested based on results stemming from a series of studies 
using another RND transporter purified into proteoliposomes.  Although the exact 
mechanism of membrane fusion protein activation remains unresolved, the critical 
importance to RND transporters was illustrated in experiments using the AcrB 
homologue AcrD of E. coli.   
 In contrast to AcrB, AcrD transports many hydrophilic compounds including 
aminoglycosides that do not readily traverse the cellular membrane.  After 
purification and reconstitution of AcrD into inverted membrane vesicles, it was 
shown that aminoglycoside transport only occurred when AcrA was supplemented 
into the proteoliposome (equivalent to periplasm) (64).  It was previously recognized 
that AcrA was required for AcrD activity in viable cells (65), but this was not 
unexpected as AcrA is required to make appropriate stabililizing contacts between 
the outer membrane channel TolC and AcrD.  Interestingly, in AcrD-
proteoliposomes, the tripartite complex is not required, thus these results strongly 
suggest MF proteins may perform a critical function in activating RND transporters.   
 In Similar experiments using the heavy-metal ion exporter CzcA, it was 
observed that this RND protein was able to transport toxic divalent cations such as 
Zn2+, Co2+, or Cd2+.  The Requirent of a proton gradient for substrate transport was 
again observed using inverted membrane vesicles.  The proton gradient was created 
by dilluting the external buffer and thus forming a higher internal (periplasmic) proton 
concentration (56).  This provided initial indications for a cation/proton antiporter for 
the CzcA system as well.  Supporting results were obtained when the vesicle interior 
was acidified using the diffusion of NH3 from proteoliposomes loaded with 0.5 M 
NH4Cl.  Data from these experiments using Zn2+ indicated sigmoidal kinetics with a 
Hill coefficient of 2. Furthermore, these studies showed that the transport was 
saturable and that this channel may function by a two-channel mechanism, whereby 
one channel may be used to transport metal ions and the other used to import 
protons.   
 Additional results from the CzcA inverted-vesicle system suggested the 
importance of well-conserved, charged residues, including Asp402, Asp408, and 
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Glu415, located in TM-helix 4 of CzcA (56).  The significance of the charged 
residues was observed following a single-point mutation of each amino acid. 
Following the mutation, divalent-cation transport was completely abolished.  This 
report was later corroborated by site-directed mutagenesis studies of MexB (67).   In 
MexB, the Asp402 and Asp408 of CzcA are replaced by a tandem pair of aspartate 
residues, Asp407 and Asp408 on transmembrane segment (TMS) 4.  As was the 
case in CzcA, both of the Asp residues were critical for the function of MexB. 
Additionally, Lys939, located in TMS 10, was also found to be essential to drug 
export (67).  Finally, Thr978 of AcrB of TMS-11 was identified as another vital 
component (68).  Together, it is suggested that these residues constitute a proton-
relay system that allows for the active transport of RND substrates.  The alignment 
in table 1 further identifies the residues critical to the proton-relay network. 
 
SUBSTRATE CAPTURE AND TRANSPORT 
 RND transporters, including AcrB and MexB, seemingly provide multidrug 
resistance to the widest range of deleterious compounds among multidrug export 
proteins.  Understanding the nature of multiligand recognition and substrate 
transport is a primary focus of the work on these proteins.  To this point, AcrB has 
been shown to provide significant levels of resistance to various structurally 
unrelated compounds, including detergents, simple organic solvents, bile acids, 
various cationic dyes, and antibiotics such as penicillins, cephalosporins, 
fluoroquinolones, macrolides, chloramphenicol, tetracyclines, novobiocin, fusidic 
acid, oxazolidinones, and rifampicin (69, 70).  Recently, direct evidence from the 
crystal structures of AcrB-ligand complexes has provided details into ligand 
recognition.  This will be discussed below (30).  Prior to the resolution of the AcrB 
crystal structures, an abundance of data was available to provide insights into the 
drug uptake, recognition, and extrusion mechanisms of RND transporters.   
 
 Drug entry: In the early days of studies on AcrB, it was presumed that this 
protein, along with other members of the RND family, acted simply as cytosolic 
vacuum cleaners.  This hypothesis seemed likely since AcrB transverses the inner 
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membrane and utilizes a membrane fusion protein and outer-membrane channel to 
completely rid the cell of substrates.  Early indications that an additional periplasmic 
or cytoplasmic membrane entry point also existed arose initially from insights into P-
glycoprotein, an ABC-transporter that could potentially capture ligands directly from 
the plasma membrane (71).  Additionally, it was observed that ceftriaxone, a 
dianionic β-lactam not able to passively diffuse across the cytoplasmic membrane, 
could be extruded from drug resistant strains of P. aeruginosa overexpressing MexB 
(72).  From this, it was postulated that MexB could capture substrates from either the 
periplasm or from the outer leaflet of the cytoplasmic membrane.  Analogous to this 
work, it was observed that a strong correlation exists between the lipophilicity of β-
lactam side-chains and the efficiency to which they are exported by AcrB.  By 
comparing MIC values between an AcrB-knockout mutant and a wild-type 
Salmonella typhimurium strain overproducing AcrB, It seemed that highly lipophilic 
compounds, including nafcillin and cloxacillin, were better substrates and more 
readily transported by the multidrug exporter (73).  In contrast, compounds 
presenting hydrophilic side chains were not exported as efficiently.  Importantly, 
since it was previously suggested that resistance to these antibiotics primarily 
occurred due to β-lactamase hydrolytic activity, Salmonella typhimurium lacking the 
hydrolyzing enzyme were utilized.  The previously established resistance model had 
to be reevaluated. The work on AcrB initiated a paradigm shift, whereby lactam-
antibiotic resistance could be enhanced through the presence of multidrug exporters 
that capture and export the antibiotics from the periplasm to the cytoplasm, 
respectively.  
 Intriguingly, multidrug efflux pumps can illicit a more-than-additive resistance 
phenotype by working synergistically with various simple pumps.  For instance, 
MexAB/OprM alone produces a modest 4 µg/ml MIC to tetracycline, but functioning 
in conjunction with the inner-membrane spanning tetracycline efflux pump TetA, the 
MIC increases to ~512 µg/ml.  These results suggest that TetA specifically exports 
tetracycline from the cytoplasm to the periplasmic space, which alone produces 
minimal resistance.  As the antibiotic accumulates, the periplasmic vacuum 
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MexAB/OprM ultimately eliminates tetracycline completely from the cell.  This 
indirectly supports the presence of a periplasmic entry points for ligands.  
Furthermore, this work illustrates how bacteria can adapt to toxic environments and 
evade antibiotic toxicity by utilizing cooperating efflux pumps, an avenue that 
requires further exploration (74).      
 The most convincing evidence for the presence of a periplasmic, substrate 
entry point was established using, the previously mentioned, AcrD-inverted 
proteoliposome experiments.  In these experiments, aminoglycoside ligands induced 
proton transport when the substrates were present in either the exterior (cytoplasm) 
or interior (periplasm) of the lipid vesicle (64).  This provided evidence for a 
substrate entry point from both the cytoplasm, as well as the periplasmic space to 
the RND transporters, since aminoglycosides used in the experiments do not 
passively transverse the membrane. 
   
 Periplasmic drug binding: Structural studies (discussed below) from AcrB 
have provided the most intriguing evidence regarding ligand recognition and capture.  
Prior to the availability of these three-dimensional structures, three independent 
examples were published suggesting that the two large periplasmic loops (between 
TMS 1-2 and TMS 7-8) were critical in ligand recognition.  Two of those, published in 
2002, utilized protein chimeras from the fusion of two RND proteins that differ in 
substrate specificities to analyze the critical binding regions.  One chimera was 
constructed using the N-terminal residues of AcrB and C-terminal residues of MexB 
(75).  AcrB and MexB have strikingly similar substrate specificities; however they are 
highlighted by varying degrees of resistance levels to those substrates.  These 
differences were utilized for experimental analysis of the chimeric proteins.  First, 
MexAB-OprM provides increased resistance to cinoxacin, while AcrAB-TolC 
expression shows higher resistant levels for positively charged ethidium bromide 
and oleandomycin.  Taking this into consideration, when expressing chimeras in E. 
coli harboring the appropriate MFP and OM components, the experiments revealed 
the critical regions required for substrate interaction.  These regions are located 
 23
primarily within the periplasmic loops of the RND transporters.  In fact, these studies 
showed that the 200 C-terminal residues of MexB were sufficient to convert the 
specificity of AcrB to the ligands ethidium bromide, oleandomycin, and cinoxacin to a 
more typical MexB phenotype.  Additionally, the N-terminal residues 1-60 and 612-
849 seem to affect the specificities of these hybrid transporters (75).   
 Elkins and Nikaido, et al. 2002, corroborated this analysis using AcrB/AcrD 
hybrids (76).  Having high sequence similarity, yet strikingly different substrate 
profiles, these chimeras provided strong evidence to support the notion that the 
periplasmic loops are responsible for ligand recognition.  Chimeras were constructed 
by replacing the two ~300 amino acid residue loop regions between TMS 1-2 and 7-
8 of either AcrB or AcrD with the corresponding region of the other RND-transporter.  
Results illustrated that if the periplasmic loops of AcrD were replaced with the 
corresponding region of AcrB, an AcrB-specific substrate resistance profile was 
acquired.  Similarly, by introducing the loops of AcrD into AcrB, this AcrB/AcrD 
chimera was able to recognize aminoglycosides, which are generally specific to 
AcrD.  Importantly, since AcrA and TolC are utilized by both efflux pumps, these 
results can not be explained due to a variation in the MFP or OM channel (76). 
 Finally, in a study using a different approach, spontaneous point mutations 
were identified within another RND transporter that altered specificity.  Single-point 
mutations were identified in MexD of P aeruginosa that increased the range of 
substrates it could recognize (77).  Intriguingly, all of these single-point mutations 
were located within the two periplasmic loops of the protein.  Specifically, Q34K, 
E89K, A292V and P328L were found in the first loop, located between 
transmembrane domains (TMD) 1 and 2, whereas F608S and N673K were 
contained in the second loop, located between TMD7 and TMD8. Together, these 
examples highlight the proposed mechanism, whereby substrates enter the 
transporter through the periplasm, or potentially the outer-leaflet of the inner 
membrane, and are captured in specific binding sites within the periplasmic loop 
regions for transport.    
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 In the years after this series of insightful experiments, more evidence 
accumulated to suggest the periplasmic domain was indeed responsible for ligand 
recognition.  In 2004, in vitro random mutagenesis was carried out on the mexB 
gene to test for substrate specificity (78).  Many of the mutations that garnered 
decreased sensitivity were isolated to the putative proton-relay network or Gly220, a 
residue stabilizing the trimer.  The most interesting mutations appeared in the 
periplasmic domain, a region later identified as the binding cleft.  Mutations that 
increased substrate induced toxicity included Ala618 and Arg716 which are located 
on the opposing walls of the proposed binding cleft, a region which will be discussed 
in more detail later in the text.  Additionally, studies on the AcrB homologue YhiV 
also suggested the importance of the periplasmic domain in substrate recognition 
(79).  An E. coli strain overproducing YhiV (lacking AcrB and AcrF) showed 
increased resistance to levofloxacin and other aromatic substrates after repeated 
exposure to levofloxacin.  The higher resistance levels were attributed to a 
periplasmic loop mutation of Val610 into an aromatic phenylalanine residue.  
Interestingly, this mutation decreased resistance levels to non-aromatic compounds, 
which further highlights the importance of the local environment formed within the 
substrate binding site. 
    
STRUCTURAL STUDIES OF AcrB 
               Structural information provides an important means to understand how 
proteins function.  As a major step in uncovering the transport mechanism of RND 
tranporters, the high-resolution (3.5Å) crystal structure was solved for AcrB in the 
spacegroup R32 in 2002 (29).  The structure revealed a single AcrB monomer within 
an asymmetric unit.  The AcrB homo-trimer was produced by utilizing the inherent 
three-fold crystallographic symmetry of the R32 spacegroup.  Overall, AcrB takes on 
a compact topology, initially described as a jellyfish appearance, with a 
transmembrane (TM) domain comprised of 12 transmembrane helices from each 
monomer.  The periplasmic portion of AcrB, which extends ~70Å into the periplasm, 
is divided into the TolC-docking domain and the porter (pore) domain.  Figure 5 
displays a single monomer with specific domains and subdomains indicated.   
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 TM domain: The transmembrane domain of AcrB, a 50Å-thick membrane 
spanning region, is composed of 12 membrane spanning α-helices from each 
monomer, which confirmed earlier topological predictions (Figure 5).  The TM 
domain has been identified as the location for proton import and functions to 
sequester the energy from the proton-motive-force to drive substrate translocation.  
Within the TM domain, a central core composed of helices α4 and α10 is surrounded 
by the rest of the TM domain helices.  The central core of each monomer harbors 
three titratable residues implicated in proton transport.  These residues, D407 (TM4), 
D408 (TM4), and K940 (TM10) have been proposed to drive the conformational 
changes required for ligand export by sequentially transferring protons down their 
concentration gradient through various transition states of the transport cycle (29) 
(Figure 6).  Site-directed mutagenesis studies, discussed previously for CzcA, AcrB 
and MexB (56, 61, 67), have provided supporting evidence to this model, whereby 
substitution of the amino acids eliminates effective drug resistance.  Similar results 
were observed for AcrB.  Using matrix-assisted laser desorption ionization time-of-
flight (MALDI-TOF) mass spectrometry, it was shown that D408 specifically reacts 
with dicyclohexylcarbodiimide (DCCD), which, In a pH-dependent manner, can be 
used to react with and measure pKa values for membrane-buried carboxylates (80). 
The apparent pKa of the amino acid D408 (7.4) would allow binding and release of 
protons under physiological conditions. Not surprisingly, D408 was not protected 
from carbodiimide labeling while substrates were incorporated into the system, thus 
providing evidence to the working model that states drug and proton transport are 
spatially separated. Furthermore, this work suggests the importance of D408 as a 
critical element in the proton translocation pathway.   In fact, crystallization 
experiments were performed using mutants of the putative proton-relay network 
(81).  In this work, site-directed mutagenesis was used to mutate residues D407, 
D408, K940, and T978 (helix 11) to alanine.  Previously, using alanine scanning 
experiments it was observed that Thr978, a polar residue in close proximity to 
Asp407, also plays an essential role in the proton translocation pathway.  The 
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resulting structures of the mutant proteins were essentially identical which suggested 
the relevance of the observed conformations.  Interestingly, the structures were 
strikingly different from the previously identified AcrB crystal forms.  At that time, it 
was hypothesized that these mutant proteins revealed a transient state that existed 
during the transport cycle (81).  Figure 6 identifies the local conformational shifts 
resulting from the proton-relay mutants and highlights key residues in the proton-
relay network.        
  
 Periplasmic region: The periplasmic region extends from the TM domain to 
approximately 70Å into the periplasmic space and can be divided into two stacked 
domains.  Adjacent to the transmembrane domain, the porter domain (formerly 
described as the pore domain) extends 40Å into the periplasm. The upper part, 
distal to the inner membrane, extends the additional 30Å and is referred to as the 
TolC docking domain (29) (Figures 5, 7, 8).  
 
 TolC docking domain: The TolC docking domain is composed of two 
homologous subdomains termed DN and DC (Figure 5) (29).  These subdomains 
are each comprised of a four-stranded mixed β-sheet, whereby two antiparallel β-
strands are located parallel to an additional β-sheet hairpin structure incorporated 
from the other half of the protomer or one of the other monomers.  Additionally, a 
vertical hairpin motif is located at the apex of each of the subdomains.  As the three 
TolC docking domains, one from each monomer, come together, a funnel-like 
structure is formed with a larger opening at the top.  Intriguingly, this opening is 
similar in diameter to the bottom of the outer membrane channel TolC.  The six 
vertical haipins of AcrB coincide with the six α-helix-turn-α-helix motifs at the bottom 
of TolC (the TolC structure will be discussed below) (82). The funnel narrows as it 
extends down the TolC docking domain and leads to the central pore of the porter 
domain.     
  
 Porter domain: The porter domain can be divided into four additional 
subdomains which include PN1, PN2, PC1, and PC2 (figures 5, 7, 8b) (29).  The 
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PN1 and PN2 subdomains comprise the segment between the transmembrane 
helices TM1 and TM2, while the PC1 and PC2 subdomains form a similar segment 
between TM7 and TM8.  Structurally, a commonality exists between all of the 
subdomains, whereby each subdomain is comprised of a repeat of two β-strand-α-
helix-β-strand motifs sandwiched together. In this repeated motif, the helices are 
located externally to the four-stranded antiparallel β-sheets.  Additionally, the PN1 
and PC1 domains consist of an extra antiparallel β-strand, thus forming a five-
stranded antiparallel β-sheet.  In the trimeric AcrB structure, three porter domains, 
one from each monomer, come together to form a central pore that extends 
perpendicular to the membrane plane to the TolC docking domain funnel.  The most 
interesting features of AcrB may be the vestibules that are open to the periplasm 
which are located at monomer interfaces as well as the deep cleft located between 
subdomains PC1 and PC2.  Figures 7 and 8 depict ribbon diagrams and surface 
electrostatics of the trimeric AcrB protein and highlight the previously mentioned 
vestibules and clefts.   
 The vestibules lead directly to a large central cavity (Fig 8A), which was 
initially proposed to be the location for ligand recognition.  It was suggested that 
ligands may enter the central cavity through the vestibules, located at the monomer 
interfaces, positioned just above the inner-membrane plane (29, 30).  This would 
allow entry from either the periplasmic space or the outer-leaflet of the inner 
membrane. Indeed, the first crystal structure solved for AcrB/ligand complexes, 
including co-crystallization with ethidium bromide (Et), dequalinium (Dq), rhodamine 
6G (R6G), and ciprofloxacin (Cip), indicated that the central cavity, may be the 
ligand binding site (30).  The crystallographic structures of trimeric AcrB co-
crystallized with these four structurally dissimilar ligands showed that they bound to 
the upper portion of the 5000 cubic angstrom central cavity using distinct but 
overlapping binding sites, whereby a majority of the important contacts were formed 
from residues within the TM domain.  It was proposed that upon binding, the ligands 
may exit through the central pore (30).  Intriguingly, the central pore, the predicted 
exit pathway for ligands, extending from the central cavity to the TolC docking 
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domain was blocked by Asn109 of the porter domain, therefore contradicting the 
mechanistic claim.  Furthermore, these results conflicted with previous experiments, 
whereby studies using domain swapping (previously mentioned in the text) indicated 
the periplasmic domain plays the most critical role in determining the ligand 
recognition profile (75, 76).  It was suspected that ligands could be interacting with 
non-specific hydrophobic patches without being on the correct path for ligand export 
(76).   
  To answer these contradictions and attempt to delineate the correct 
mechanism and pathway for ligand extrusion, Asn109 of AcrB was mutated to 
alanine and crystallized with various ligands, including Cip, R6G, Et, nafcillin (Naf), 
and Phe-Arg-β-napthylamide (83).  In wild-type AcrB, Asn109 blocks the most direct 
pathway from the central cavity to the central pore by protruding into the pore 
interior.  Thus, mutating the residue presumably would open the exit route and allow 
for further analysis of the extrusion pathway.  Although AcrB function was not 
significantly altered, based on observed MIC values, a second substrate binding site 
was identified.  The ligands were located in a region that corresponds to the binding 
cleft, located 15Å above the membrane plane (Fig. 8).  The cleft, which lies 
perpendicular to the membrane plane, is approximately 40Å in lenth, 20Å in width, 
and penetrates AcrB ~15Å.  The cleft was originally speculated to be the site of AcrA 
interaction.  Figure 8b highlights the cleft by removing the TolC-docking domain and 
the TM domain.  In attempts to determine if this binding was physiologically relevant, 
site-directed mutagenesis was performed on those amino acids that specifically 
interacted with bound ligands (83).  Mutating these residues, which included 
Phe664, Phe666, or Glu673 severely inhibited AcrB function, determined by testing 
the MIC in correlation with substrate accumulation experiments.  Importantly, the 
results suggested the relevance of this periplasmic binding site. Additional questions 
remained regarding the periplasmic substrate binding site.  As inhibition could have 
occurred as a result of a mechanism unrelated to ligand recognition, further analysis 
of the binding cleft is needed.  Moreover, these results still lack a fundamental 
mechanism to explain how drug export occurs and more specifically, where the 
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actual exit pathway for ligand export resides.  An alternative hypothesis exists, 
whereby ligands may enter the second binding site through the clefts and completely 
bypass the central cavity.  Indeed, based on the recent crystal structures of AcrB in 
an asymmetric conformation (discussed below) the binding site in the cleft region 
seems to be the most likely candidate for ligand recognition.  In either instance, the 
central pore is the likely exit pathway for ligand extrusion.  
 
ASYMMETRIC AcrB 
 Recently, three groups have independently solved the crystal structure of 
AcrB in an asymmetric form (31-33). These structures have provided valuable 
insights and provided a working model for the detailed mechanism of RND 
transporter function.  The structures suggest a functional rotating model to describe 
substrate efflux.  The new asymmetric structures indicate that individual 
protomers adopt distinct conformations that correspond to one of three functional 
states during drug export.  Based on the role each protomer plays, these states have 
been denoted as access, binding and extrusion.  Initially, drugs are able to enter 
into a hydrophobic binding pocket in the access protomoer, but are unable to make 
appropriate binding contacts due to the diminished size of the tunnel interior.  A 
conformational shift results in a transition from the access state to the binding state.  
In the binding state the size of the tunnel increases and allows AcrB to 
accommodate substrates. Indeed, an asymmetric structure presented by Murakami 
and Yamaguchi unequivocally identified 9-bromo-minocyclin (brominated minocycin 
derivative) and doxorubicin in only the binding protomer, indicating the physiological 
relevance of the binding state (31).   Ligand recognition occurs within the binding 
cavity, whereby the substrates primarily interact with aromatic and hydrophobic 
patches in the cavity.  Intriguingly, during the binding state, the access tunnel 
remains open.  This may allow those compounds that are not AcrB substrates to 
exit the tunnel before being exported.  In another asymmetric structure, two tunnels 
were identified that led to the binding protomer of AcrB.  It was proposed that tunnel 
1 may provide an entrance point from the outer leaflet of the inner membrane while 
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tunnel 2, positioned ~15Å above the membrane would allow entrance or exit of 
molecules from or into the perisplasmic space, respectively (32).  Transition from the 
binding to the extrusion state closes the entrance tunnels and opens the exit tunnel 
leading to the central pore and the TolC-docking domain funnel.  The ligand is forced 
out of the binding cavity owing to the decrease in volume associated with a switch to 
the expulsion state.  This transition allows AcrB to transfer the bound ligand to TolC 
completing ligand export and initiating a transition back to the access state.  Figure 9 
illustrates the differences among the three protomers and highlights the proposed 
exit pathway in the asymmetric AcrB model.  Based on structural evidence, the 
transition from the binding to the expulsion state is the rate-limiting and energy 
sequestering step in drug transport.  The tirtratable residues Asp407, Asp408, and 
Lys940 undergo small conformational changes in the expulsion state presumably 
due to protonation of Asp407 and Asp408 which leads to cycling between the 
various states.   
 
MexB STRUCTURE 
 Following the identification of the asymmetric conformations of AcrB, the 3.0Å 
resolution crystal structure of MexB from P. aeruginosa was solved (34).  
Intriguingly, MexB shares a similar topology as AcrB and also adopts an aymmetric 
conformation.  As is the case for AcrB, each subunit of MexB resides in a distinct 
conformational state.  The MexB crystal structure provided support to the proposed 
transport model, whereby the subunits transition through three states in a functional 
rotating fashion to drive substrate export.   
 Not surprisingly, with a 69.8% identity and an 83.2% similarity in sequence, a 
high degree of structural relatedness exists between AcrB and MexB (34).  
Superimposition of the tripartite structures revealed an RMSD (root mean squared 
deviation) between models of 1.4Å.  Furthermore, with a common functional role in 
the TM domain and the sequences being nearly identical, a higher degree of 
structural similarity exits in this domain (rmsd < 1).  This indicates proton 
 31
translocation may function identically among RND proteins and drive similar 
conformational changes throughout the protein.    
 The most intriguing structural differences between MexB and AcrB locate to 
the porter domain and specifically the access conformation.  Compared to the 
binding and extrusion states, which show an RMSD of 1.0Å, when superimposed 
over the same AcrB protomers, the Access subunit exhibits striking differences 
(RMSD of 1.6Å).  Interestingly, in the access state of MexB, the entrance channel 
leading to the binding pocket is closed.  Upon transition to the binding conformation, 
the entrance channel opens.  This seems to be the result of the PC2 subdomain 
shifting towards the TM domain and PC1.  It was suggested that this conformational 
difference is due to the specificity for its cognate MFP MexA, whereby the pore 
domain is suggested to make stabilizing contacts to the MFP.  Indeed, a chimeric 
analysis of MexB and AcrB indicated that residues 589-612 of the PC1 subdomain 
are notably required for specificity to their respective MFP (75).  Additionally, T578 
also of PC1 of MexB seems to play a pivotal role in MFP binding (84).  The pivotal 
role of the porter domain and the MFP in forming the entire tripartite complex is 
further highlighted by the docking domain.  The outer-membrane channel is thought 
to interact transiently with low affinity to the RND protein without the presence of the 
MFP.  Thus, it was not surprising that the docking domains of MexB and AcrB were 
highly similar.   
 Fortuitously, an n-dodecyl-D-maltoside (DDM) molecule was identified in the 
binding cleft of the Binding protomer (34).  The detergent DDM was used to 
solubilize the membrane protein.  This substate-bound crystal structure further 
highlights the critical features of multidrug binding identified previously in the 
AcrB/substrate co-crystals.  Briefly, a large cavity rich in exposed aromatic amino 
acids harboring pockets of polar residues highlights the multifaceted binding pocket.  
Results indicate the binding pockets harbor distinct but overlapping sites for ligand 
recognition.  The polar residues seem to perform a role in ligand specificity, whereby 
the DDM forms hydrogen bonds with an asparagine and a serine residue.  
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 The altered conformation of MexB compared to AcrB indicates some degree 
of structural flexibility.  Furthermore the flexibility previously observed in various 
crystal structures of both AcrB (29-33) as well as the associated MFP proteins MexA 
(85, 86) and AcrA (87) suggests a critical need for mobility.  The flexibility 
presumably plays a role for both tripartite association and pump function.  
Importantly, the structure of MexB-DDM along with the genetic evidence discussed 
below further supports the functional rotating model of substrate transport.           
 
EVIDENCE TO SUPPORT THE ASYMMETRIC MODEL 
 Genetic evidence supporting the functional rotating mechanism to describe 
substrate export has been established using two ingenious approaches.  First, 
Takatsku, et al. 2007 (88) and Seeger, et al. 2008 (89), Introduced cysteine residues 
at appropriate locations in AcrB monomers by using site-directed mutagenesis.  The 
idea was as follows: when two cysteine residues come within 6.4Å, the sulfur atoms 
from their side chains would form disulfide bonds. If the asymmetric structure is 
correct, it should be possible to detect the transition between the access, binding, 
and extrusion states in these mutants.  As subdomains change in conformation, 
cross-links would form and inhibit any further changes in transition states.  Indeed, 
the results suggested that the disulfide bonds did lock AcrB from transitioning 
between states, thus inhibiting drug export.  One specific example supports the 
presence of the extrusion conformation, whereby disulfide formation between the 
PC2 subdomain and TM7 inhibited export activity (88).  The access and binding 
conformations reveal an approximately 10Å distance between these cysteine 
residues, while a mere 3.3 Å separates the corresponding cysteines in the extrusion 
state of the S562C_T837C mutant.  This result implies that AcrB, at least partially, 
exists in a conformation resembling the extrusion state, whereby PC2 and TM7 
transition closer together.  Intriguingly, this inhibition is alleviated with the addition of 
the reducing agent di-thiothreitol (DTT).  These results, illustrating the existence of 
the extrusion conformation, support the crystallographic structure of AcrB in complex 
with designed ankyrin repeat protein inhibitors (DARPins), whereby the DARPins 
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bound to the access and binding states, but did not interact with the extrusion 
protomer (33).  Furthermore, in another series of experiments, a covalently-linked 
AcrB trimer (with a short linker sequence connecting each monomer) was developed 
to test the functional rotating mechanism (90).  In this way, a single protomer within 
the trimer could be manipulated.  MIC values of the linked trimer indicated that this 
protein complex was completely functional.  Intriguingly, after point mutations were 
introduced into the proton-relay network of just one protomer, the linked AcrB trimer 
became nonfunctional.  Additionally, inhibiting a single AcrB protomer by introducing 
disulfide bonds in the external cleft of the periplasmic domain inhibited drug 
transport for the entire complex (90). Together, these studies provide supporting 
evidence to the functionally rotating mechanism and indicate the 
physiological importance of the transition through the three distinct monomeric 
states.  
 Although it has been illustrated that the AcrB binding cleft is critical to ligand 
recognition and export, it is difficult to determine if the central cavity harbors ligand 
binding sites relevant to extrusion, or if crystal structures identifying ligands within 
the central cavity are simply an artifact of high ligand concentrations used during 
crystallization.  The question remains as to how the substrates may enter the central 
pore during export.  Furthermore, it is difficult to ascertain how AcrB manages to 
export such a diverse range of compounds without eliciting the multifaceted central 
cavity to recognize these molecules.  It seems, with these newly resolved 
asymmetric structures more time is needed to answer the questions that remain on 
the function of RND transporters.  Of those questions, the most important work 
seems to be on understanding the roles played by the membrane fusion protein 
AcrA and outer membrane channel TolC 
 
TolC STRUCTURE 
 At 2.1Å resolution, the TolC homotrimer is seen as a tapered cylinder 
approximately 140Å in length (82). This comprises a 40Å long Outer membrane β-
barrel domain, which anchors a contiguous α-helical barrel domain that projects 100 
 34
Å across the periplasmic space.  A third subdomain, of mixed α/β structure, forms a 
strap around the mid-section of the α-helical barrel. The average accessible interior 
diameter of the single central TolC pore is 19.8 Å. Three TolC monomers each 
contribute four β-strands to form the twelve-stranded β-barrel, which is constitutively 
open to the cell exterior. The periplasmic barrel comprises twelve antiparallel α-
helices (two continuous long helices and two pairs of shorter helices from each 
monomer) that pack laterally side-by-side and form two separate interfaces. The 
helices follow a left-handed superhelical twist that tends to be less tightly wound in 
the upper half compared to helices in a conventional two-stranded coiled coil, 
enabling the helices to lie on the surface of a cylinder. In the lower half of the a 
barrel, neighboring helices form six pairs of regular two-stranded coiled coils, but 
one from each monomer folds inward at the periplasmic end. This constricts the 
entrance to TolC and establishes a resting state with a closed opening, whereby an 
effective diameter of approximately 3.9Å is established.  The closed state is reflected 
in the small conductance of TolC in lipid bilayers (91).  After the TolC and AcrB 
crystal structures were resolved, it was proposed that TolC and AcrB may directly 
interact with each other by virtue of their extended periplasmic domains.  With TolC 
harboring the 100 Å periplasmic α-helical domain and AcrB protruding 70 Å into the 
periplasm, this notion seems very likely.  The first experiments indicating this 
resulted from a study showing disulfide bond formation between engineered cysteine 
residues located on the periplasmic hairpin turns of AcrB and the coiled-coil region 
of TolC (92).  Furthermore, it has been illustrated that the outermembrane channels 
TolC and OprM weakly interact with AcrB and MexB, respectively (93, 94).  This 
interaction can be further stabilized by the membrane fusion proteins AcrA and 
MexB, thus highlighting the function of these membrane fusion proteins (Figure 10).  
 
AcrA STRUCTURE 
 Membrane fusion proteins act as a bridge to fasten the inner membrane 
transporter to its cognate outer membrane channel.  The crystal structure of 
approximately two-thirds of AcrA (res 45-312), the membrane fusion protein of the 
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AcrB/AcrA/TolC tripartite complex, was elucidated in 2006 (87, 95).  This structure 
revealed a protein with an overall topology similar to that of the previously resolved 
MexA structure (85, 86).  Briefly, the three-dimensional structure of AcrA revealed a 
linear-arranged three-domain protein.  The domains identified include an alpha-
helical hairpin domain composed of two α-helices connected by a hairpin-turn that 
forms a 105 Å long structure, a lipoyl domain with two sets of four β-strand lipoyl half 
motifs connected by an α-helical linker, and a β-barrel domain composed of six anti-
parallel β-strands along with a single α-helix.  An additional membrane proximal 
(MP) domain, identified through re-examination of the homologous MexA 
crystallographic data, and a yet unresolved C-terminal domain are intrinsically 
disordered in the AcrA crystals and, thus lacking in the AcrA structure (85-87, 95).  
 Recently, successful cross-linking experiments of AcrA to both AcrB and TolC 
(86) along with extensive biochemical and genetic data have helped to illustrate the 
intermolecular contacts in the tripartite complex.  The compiled data indicates that 
the α-helical hairpin domain, which is the least conserved of the domains, contacts 
TolC while the three other domains interact exclusively with AcrB (Figure 10).  A 
more detailed description of the formation of the tripartite efflux complex is discussed 
below. 
 Membrane fusion proteins, once thought to only function as adaptor 
molecules, have recently gained recognition as critical components in drug efflux.  
How the proteins aid in transport is an unanswered question.  To this point, it has 
been shown that AcrA is essential for aminoglycoside transport by the RND 
transporter AcrD (64).  In inverted membrane vesicles, AcrD was unable to transport 
aminoglycosides without the addition of AcrA to the internal portion of the vesicle, 
which corresponded to the periplasmic space in the experiment.  Moreover, the 
membrane fusion protein MacA is critical for optimal catalytic efficiency of the ABC-
type drug transporter MacB, increasing the rate of ATP-hydrolysis 45-fold (96).  
Together, this data indicates that membrane fusion proteins may stimulate substrate 
export through a direct interaction with the transporter possibly allowing efficient 
transition through transient states.  Other evidence suggests that membrane fusion 
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proteins may interact directly with substrates to facilitate drug efflux.  Indeed, 
conformational changes are induced in EmrA (97) and CusB (98) when they bind 
their respective ligands, indicating a possible transport role for these proteins.  
Dissociation constants in the nM and µM range have been identified for CusB and 
EmrA to their substrates, respectively (97, 98).  Furthermore, the crystal structure of 
CusB bound to its cognate heavy metal ions was recently solved, illustrating the 
binding capacity of this membrane fusion protein (99).  A three-dimensional structure 
of the entire tripartite complex may be needed to understand the role(s) of 
membrane fusion proteins. Using the three-dimensional structures of AcrA, AcrB, 
and TolC it became possible to develop a model of the elusive complex.    
 
AcrA/AcrB/TolC COMPLEX 
 By utilizing extensive cross-linking experiments along with previously 
published crystal structures, Symmons and Koronakis et al. 2009 were able to 
propose a structure for the complete AcrA/AcrB/TolC complex and expand on the 
previously suggested efflux mechanism (86).  Overall, the cross-liking experiments 
revealed a 610 kD 270Å long complex with a stoichiometry of AcrB3-AcrA3-TolC3 
per transporter.  Docking of AcrA onto AcrB occurs along the exposed interface 
between adjacent subdomains PN1-PN2 and PC1-PC2 of the AcrB porter domain.  
Binding to AcrB orients AcrA slightly askew from vertical creating an appropriate 
distance for TolC to interact with both AcrA and AcrB.  This interaction forces TolC to 
shift from a closed to an open state, which may allow antibiotics to be transported 
without any additional conformational shifts in TolC, whereby ligands traverse TolC 
through natural diffusion.  It has been proposed that information regarding the bound 
state may be transduced from the asymmetrical structures of AcrB to AcrA and 
ultimately TolC, suggesting the membrane fusion and outer membrane proteins 
could perform a functional role in drug export. The proposed mechanism describes 
these two proteins to be functioning as a sort of peristaltic pump by pushing ligands 
out as they enter the TolC channel in a manner similar to food passage through the 
digestive tract.  The modeled tripartite complex can be viewed in Figure 10.  To gain 
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further insights and decipher a final mechanism for multidrug efflux, the crystal 
structure of the AcrA/AcrB/TolC awaits. 
 
OTHER RND PROTEINS 
AcrB and MexB are the most characterized members of the RND transporter 
family and play important roles in drug resistance.  Importantly, multidrug resistance 
is a feature displayed by organisms other than E. coli and P. aeruginos.  Notably, 
this section will highlight the roles played by RND transporters in the biocidal 
resistance associated with other Gram-negative bacterial species, including 
Campylobacter jejuni and Neisseria gonorrhoeae.   
C. jejuni is the major causative agent of human enterocolitis and is 
responsible for more than 400 million cases of diarrhea each year worldwide (100). 
The Gram-negative microbe generally resides in the intestinal tracts of animals.  
Furthermore, it can be transmitted to humans via contaminated food, water, or raw 
milk. For antibiotic treatment of human campylobacteriosis, fluoroquinolones and 
macrolides are frequently prescribed (101). Unfortunately, Campylobacter has 
developed resistance to both classes of antimicrobials, especially to 
fluoroquinolones (102-104).  In part, this resistance is due to the expression of drug 
efflux transporters. 
C. jejuni harbors multiple drug efflux transporters of different families (105). 
Among them, CmeABC, an RND-type efflux pump, is the primary antibiotic efflux 
system and is the best functionally characterized transporter in Campylobacter (106, 
107). CmeABC consists of three components including an outer membrane protein 
(CmeC), an inner membrane drug transporter (CmeB), and a periplasmic fusion 
protein (CmeA). CmeABC contributes significantly to the intrinsic and acquired 
resistance of Campylobacter to structurally diverse antimicrobials including 
fluoroquinolones and macrolides (106-111). It has been found that CmeABC 
functions synergistically with target mutations in conferring and maintaining high-
level resistance to fluoroquinolones and macrolides (108, 109, 111-113). This efflux 
pump also plays an important role in the emergence of fluoroquinolone-resistant 
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Campylobacter under selection pressure (114). Inactivation of CmeABC reduced the 
frequency of emergence of fluoroquinolone-resistant mutants, while overexpression 
of CmeABC increased the frequency of emergence of the mutants (114).  
In addition to conferring antibiotic resistance, CmeABC also has important 
physiological functions. It has been shown that CmeABC is functionally interactive 
with CmeDEF, another RND-type efflux pump, in maintaining optimal cell viability in 
Campylobacter, possibly by extruding endogenous toxic metabolites (115). Double 
mutations in CmeABC and CmeDEF appeared to be lethal to C. jejuni strain 11168 
and significantly reduced the growth of strain 81-176 in conventional media. Another 
important function of CmeABC is bile resistance. As an enteric pathogen, C. jejuni 
must possess means to adapt in the animal intestinal tract, where bile acids are 
commonly present. Mutations of CmeB in C. jejuni resulted in a drastic increase in 
the susceptibility to various bile acids and a severe growth defect in bile-containing 
media or in chicken intestinal extracts (116). When inoculated into chickens, the 
CmeB mutant failed to colonize the inoculated birds. These findings provide 
compelling evidence that CmeABC, by mediating the resistance to bile acids, is 
essential for Campylobacter adaptation to the intestinal environment. These findings 
also strongly suggest that bile resistance is a natural function of this RND-type efflux 
pump. 
Within the strict human pathogen N. gonorrhoeae, the mtr (multiple 
transferable resistance) system was first identified by Maness and Sparling (117) 
when they isolated a spontaneous mutant that exhibited increased resistance to 
multiple, structurally diverse antimicrobial hydrophobic compounds. Similar to the 
story of AcrB and MexB, It was originally thought that mtr modified outer membrane 
permeability (118). However, subsequent cloning/sequencing experiments (119-122) 
showed that the mutation was located within a gene encoding a transcriptional 
repressor (MtrR) of a downstream, but transcriptionally divergent, operon (mtrCDE) 
encoding the tripartite MtrCDE efflux pump.  Similar to other RND-type pumps of 
Gram-negative bacteria, the three proteins are a cytoplasmic membrane transporter 
(MtrD), a membrane fusion protein (MtrC) and an outer membrane channel protein 
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(MtrE).  Directly or indirectly, other proteins also participate in efflux mediated by the 
pump.  Veal and Shafer (123) identified an accessory protein (MtrF) which, for 
reasons that are not yet clear, is required for efflux activity when the host strain is 
expressing high levels of the pump during stressful conditions.  Energy supplied by 
the TonB-ExbB-ExbD system is also needed for inducible antimicrobial resistance 
mediated by MtrC-MtrD-MtrE (124).  
There is evidence that gonococcal efflux pumps can contribute to levels of 
bacterial resistance to classical antibiotics since inactivation of efflux pump-encoding 
genes can enhance susceptibility to pump substrates (121,122, 125).  Moreover, 
mutations that increase efflux pump gene expression can also increase antimicrobial 
resistance of N. gonorrhoeae. From a clinical perspective, the important question is 
whether efflux pumps can influence the efficacy of antibiotic treatment. In this 
respect, work on the MtrCDE efflux pump in clinical isolates indicates that this is 
indeed the case.  As an example, over-expression of the mtrCDE operon due to 
mutations in the mtrR-coding sequence, which encodes a repressor of mtrCDE 
expression, or its promoter can provide gonococci with a two-fold increase in 
resistance to penicillin (125).  However, when strains have co-resident mutations in 
other chromosomal genes that influence affinity of penicillin for penicillin-binding 
proteins (PBPs) or drug influx, resistance can become clinically significant (≥ 2.0 
µg/ml).  The outbreak of penicillin-resistant gonorrhea that occurred in Durham, NC 
in the 1980s (126) due to a strain (termed FA6140) that had mtrR mutations as well 
as other mutations that both decreased binding of penicillin to PBP-1 and PBP-2 and 
influx of penicillin (127) is an example of the impact efflux can have on gonococcal 
resistance to antibiotics.  Thus, while introduction of the mtrR mutations from 
penicillin-resistant strain FA6140 by transformation into highly penicillin-sensitive 
strain FA19 resulted in only a two-fold increase in resistance, inactivation of the mtrD 
gene, which encodes the inner membrane transporter protein, in resistant strain 
FA6140 decreased resistance from 4 to 0.25 µg/ml. This decrease in resistance, due 
to loss of efflux activity, was intriguing, as it represented a transition from clinical 
resistance to sensitivity and provides support for the notion that inhibitors of efflux 
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pumps could reverse antibiotic resistance exhibited in pathogenic organisms.  In 
addition to penicillin, gonococcal clinical isolates bearing mtrR mutations can 
express decreased susceptibility to macrolides and tetracycline (128). In fact, a 
cluster of azithromycin-resistant gonococci identified in patients was found to be 
overexpressing the mtrCDE genes (129). 
 It has been suggested (130) that efflux pumps endow bacteria with the ability 
to resist natural or man-made antimicrobial agents in their local environment and 
that such resistance is important for their survival in ecosystems. For strict human 
pathogens, such as gonococci, that do not naturally exist for long periods of time 
outside the human body, these antimicrobial agents would be compounds (e.g., 
antimicrobial peptides, long chain fatty acids, bile salts, certain hormones) that are at 
the front-line of the innate host defense system.  In this respect, the MtrCDE efflux 
pump appears to recognize certain antimicrobial peptides (131), progesterone (122) 
and bile salts (122).  In support of the hypothesis that efflux pumps can promote 
bacterial survival during infection, Jerse et al. (132) found that the MtrCDE efflux 
pump is required for survival of gonococci in the lower genital tract of experimentally-
infected female mice (122). This is a unique example of how a mechanism of 
antibiotic resistance can actually increase in vivo fitness and is likely due to the 
ability of the MtrC-MtrD-MtrE pump to recognize both classical antibiotics (e.g., 
penicillin) and host-derived antimicrobials.   
 
INHIBITION 
 Information may be extracted from the structural data of multi-drug binding 
proteins that could potentially aid in the rational design of drugs able to act as efflux 
pump inhibitors (EPIs).  These EPIs would inhibit the function of MDR pumps and 
combat multidrug resistant bacteria.  Multidrug export may be blocked in various 
fashions, including altering regulation, inhibiting assembly, closing or plugging the 
outer membrane channel, collapsing the energy coupling mechanism, or creating a 
binding competitor.   
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 To inhibit protein expression, incorporating antisense oligonucleotides that 
interfere with transcription of the RND genes could reasonably be employed.  
Additionally, small interfering oligonucleotides would also function in inhibiting 
translation of the export proteins.  Intriguingly, using the antisense strategy has 
previously shown promise, whereby the function of AcrAB was severely inhibited 
(133).  Furthermore, studies indicated that chlorpromazine, an anti-psychosis 
compound, reduced expression of acrB.  Unfortunately, the required concentrations 
of chlorpromazine to inhibit expression are extremely high and would produce 
deleterious side-effects if administered at those levels (134) 
 A potential lead compound to block the assembly of the RND complex has yet 
to be identified, although a natural peptidase inhibitor has shown promise as a 
successful blocking agent.  The use of this type of adjuvant may prove to be a useful 
mechanism to inhibit drug resistance.  It is known that the assembly of the efflux 
complex is required for function.  Indeed, globomycin, an inhibitor of the signal 
peptidase II (135, 136), which removes lipoprotein signal sequences from exported 
membrane proteins, may block the assembly of the complex and specifically inhibit 
AcrA.  Initial results using globomycin showed that, when used at subinhibitory 
concentrations, the inhibitor could restore chloramphenicol transport and reduce 
resistance levels (137).   
 One of the most attractive ideas is to design an EPI that would block the exit 
pathway of the outer membrane channel. In E. coli, TolC is utilized by various inner 
membrane transporters to export substrates, thus making it an ideal inhibitory target.  
In vitro assays showed that hexammine cobalt can severely inhibit the conductivity 
of TolC after reconstitution (138).  To examine these results, TolC was co-
crystallized with hexammine cobalt.  The Hexammine cobalt was shown to form 
hydrogen bonds with Asp374 of each of the TolC monomers with strikingly high 
affinity (20 nM) (138).  Although hexammine cobalt is not a potential EPI due to its 
harmful effects on cell viability, this illustrates how a blocker of an outer membrane 
channel could function and may suggest a design strategy for such an inhibitor.   
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 Energy uncouplers such as carbonyl cyanide m-chlorophenylhydrazone 
(CCCP) and potassium cyanide are used in the laboratory settings to abolish 
substrate efflux by RND proteins (139).  They presumably reduce the viability of the 
bacterium and cause cell death via the dissipation of the proton-motive force of the 
membrane. The downfall of these molecules is they are highly noxious and 
cytotoxic.  This is exacerbated by the fact that these molecules are also substrates 
of the RND transporters themselves.  
 The most promising EPIs have been designed and synthesized as antibiotic 
antagonists.  Interestingly, these compounds exert no antibacterial effect on their 
own, but when co-administered with antibacterial compounds they are able to 
effectively reduce the MIC of co-administered antibiotics.  Studies suggest that these 
EPIs, such as phenylalanyl arginyl b-naphthylamide (PAbN), are able to restore 
antibiotic activity in efflux mediated MDR bacteria by competing favorably for 
substrate recognition (139).  The competition results in an increase in the 
intracellular concentration of the antibiotic to levels required for antimicrobial activity.   
In a study in 1999, PAbN and other homologous EPI compounds were 
characterized.  It was observed that a group of peptidomimetic molecules were 
active at preventing fluoroquinolone efflux in P. aeruginosa strains overexpressing 
the MexAB efflux system (140).  Several derivatives were made from this lead 
compound.  Of these, PAbN along with two other derivatives that effectively inhibit 
efflux of quinolones, including levofloxacin were identified.  Intriguingly, PAbN 
showed a broad range of activity against many efflux pumps of E. coli and other 
Gram-negative organisms (140).  Importantly, it seems that PAbN may be effective 
against specific compounds that interact with overlapping regions, while not 
inhibiting efflux of other structurally distinct molecules.  Indeed, the inhibitor PAbN 
only minimally affected the MIC of carbenicillin, although the MICs of erythromycin 
and levofloxacin were reduced to a degree similar to removal of the efflux pump.  
Presumably, this observation may be due to the unaffected molecules binding to a 
distinct site within the large binding cleft.  This distinct binding site may remain 
unaltered by the EPI.  Using this model for the rational design of an inhibitor, it may 
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be possible to design an EPI with the ability to inhibit efflux of a broad range of 
structurally dissimilar substrates.  As shown, this EPI may be globally effective 
against efflux pumps from various infectious microorganisms.  
 
OTHER FUNCTIONS 
 Although this review has focused primarily on RND transporters and their 
function on multidrug resistance, this does not seem to be the primary function of 
these transporters.  In fact, RND efflux systems are critical to the virulence of various 
microorganisms (142).  The findings suggest that their physiological role in virulence 
is primarily the evasion of host derived antibacterial compounds, including bile salts, 
fatty acids, and steroid hormones.  The efflux, thus allows the microorganism to 
survive in a deleterious environment.  Indeed, studies indicate that AcrB has a much 
higher affinity to host derived bile acids, which reside within the intestinal 
environment, than for many antibiotics (143).  This indicates that AcrB may have 
initially evolved as a bile acid efflux protein with its antibiotic efflux capacity only 
developing later.  Furthermore, expression levels of AcrAB of Salmonella 
typhimurium (144) and AcrD, AcrE, EmrK, MdtA, and MdtE of E. coli (145) are 
increased in the presence of indole, a substrate within the intestinal tract, which 
promotes survival of the invasive bacteria in this deleterious niche.  In a similar case, 
during macrophage infection by Salmonella, the expression levels of the MFS efflux 
gene emrAB and the RND transporter genes mdsABC and mdtABC are increased, 
suggesting a role during virulence (146) 
 An intriguing study using strains of P. aeruginosa lacking MexAB-OprM 
further illustrated the importance of efflux pumps during infection (147).  The strains 
lacking MexAB-OprM showed reduced ability to invade Madin-Darby Canine Kidney 
(MDCK) cells.  P. aeruginosa invasiveness was restored using two methods.  Not 
surprisingly, infectivity could be restored through the complementation of the 
disrupted genes.  The second method involved the addition of the culture 
supernatant from MDCK cells previously infected with wild-type P. aeruginosa 
(harboring MexAB-OprM).  Following addition of the supernatant, the invasiveness 
was completely restored.  Intriguingly, this suggests that this RND efflux system 
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exports a virulence factor during macrophage infection that can be used to 
complement the deficient P. aeruginosa strain.   
 
CONCLUDING REMARKS 
 The availability of the three-dimensional structures of these efflux transporters 
has, for the first time, allowed us to propose a fundamental model of substrate 
export.  However, there is still quite a mountain to climb in understanding the 
function of these proteins.  To date, no RND transporter structures have been 
published outside of the HAE1 subfamily, although our group has recently solved the 
structure for the first RND protein outside of this subfamily (148).  The crystal 
structure is of an RND protein among the heavy-metal efflux (HME-RND) subfamily 
of transporters.  Interestingly, structures for the HME-RND protein from CusA of E. 
coli, solved in both apo-form and a liganded conformation, may illustrate a distinct 
mechanism to describe substrate transport.  CusA, in the silver and copper bound 
form does not crystallize in an asymmetric conformation, thus proposing a possible 
new model, whereby a swinging arm motion in the periplasmic domain driven by the 
PMF may provide the conformational shifts that facilitate substrate export.  
Furthermore, the crystal structures of AcrB, MexB, and CusA are all from Gram-
negative bacteria.  As RND transporters exist in all other domains of organisms, it 
will be interesting to see structural and functional differences that exist for those 
RND transporters that do not utilize membrane fusion proteins or outer membrane 
channels to operate.  Questions still remain as to how these RND proteins operate 
and whether the functional rotating model can be used to describe all RND 
transporters, or is this mechanism specific to transporters among the HAE1 
subfamily?  Among the HAE1 subfamily, the entire role for membrane fusion 
proteins in transporter activation also remains to be determined.  Crystal structures 
of other RND proteins and a structure of the entire tripartite complex may be needed 
to answer these intriguing questions.  Furthermore, as new crystal structures are 
published, it may be possible to design efflux pump inhibitors capable of knocking 
out an entire subfamily of multidrug exporters.  An inhibitor capable of this would 
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make once futile antibiotics functional once again.  Finally, as many of these 
transporters are globally as well as locally regulated, understanding the regulatory 
network that controls each of these RND pumps (discussed in chapters three and 
four) will provide futher insights into the complexity of multidrug resistance.  










































Figure 1 displays a schematic diagram of the five families of multidrug exporters.  
(A) The resistance/nodulation/cell division family (teal) illustrated as a tripartite 
complex with a membrane fusion protein (red) and outer membrane channel (blue).  
(B) The ATP binding cassette family utilizes the energy derived from ATP hydrolysis 
to drive drug export.  The ATP binding domains are shown in yellow and the 
Transmembrane domains are dark blue.  (C) The major facilitator family shown as a 
red and blue dimer.  (D) The small multidrug resistance family is shown as a teal 
dimer.  (E) The recently discovered multidrug and toxic compound extrusion family 
utilizes either sodium ion or proton influx to drive drug extrusion.  A structure for this 


















                                                         TM1    
EnvD           ----MANFFIRRPIFAWVLAIILMMAGALAILQLPVAQYPTIAPPAVSVSANYPGADAQT 56 
AcrB            ----MPNFFIDRPIFAWVIAIIIMLAGGLAILKLPVAQYPTIAPPAVTISASYPGADAKT 56 
MexB           ----MSKFFIDRPIFAWVIALVIMLAGGLSILSLPVNQYPAIAPPAIAVQVSYPGASAET 56 
Cnr             MIESILSGSVRYRWLVLFLTAVVAVIGAWQLNLLPIDVTPDITNKQVQINSVVPTMSPVE 60 
Czc             MIKDFIETALRNRITTIITAIVAVLFGIWAWIDIRKEAYSDIADTQVRLIAKFPGKAAVE 60 
                    : .  :     . . : :  : *      :     . *:   : :    *   .   
 
EnvD            VQDTVTQVIEQNMNGIDNLMYMSSTSDSAGSVTITLTFQSGTDPDIAQVQVQNKLQLATP 116 
AcrB            VQDTVTQVIEQNMNGIDNLMYMSSNSDSTGTVQITLTFESGTDADIAQVQVQNKLQLAMP 116 
mexb            VQDTVVQVIEQQMNGIDNLRYISSESNSDGSMTITVTFEQGTDPDIAQVQVQNKLQLATP 116 
Cnr             VEKRVTYPIETAIAGLNGVESTRSMSRN-GFSQVTVIFKESANLYFMRHEVSERLAQARP 119 
Czc             VEERVTLPIERVLNAIPKVAVRRSRTIN-GLVVFQFVFEDGTDDYFARMRLMERVADAD- 118 
                *:. *.  **  : .:  :    * : . *   . . *:..::  : : .: :::  *   
 
EnvD            LLPQEVQQQGISVEK------------------------------SSSSYLMVAGFVSDN 146 
AcrB            LLPQEVQQQGVSVEK------------------------------SSSSFLMVVGVINTD 146 
mexb            LLPQEVQRQGIRVTK------------------------------AVKNFLMVVGVVSTD 146 
Cnr             NLPENVEPQMGPVSTGLGEVFHYSVEYQYPDGTGASIKDGEPGWQSDGSFLTERGERLDD 179 
Czc             -IPEDVHPALGPMSS--------------------------------PVGEIYRYVLESS 145 
                 :*::*.     : .                                            . 
 
EnvD            PGTTQDDISDYVASNVKDTLSRLNGVGDVQLFG-AQYAMRIWLDADLLNKYKLTPVDVIN 205 
AcrB            GTMTQEDISDYVAANMKDAISRTSGVGDVQLFG-SQYAMRIWMNPNELNKFQLTPVDVIT 205 
mexb            GSMTKEDLSNYIVSNIQDPLSRTKGVGDFQVFG-SQYSMRIWLDPAKLNSYQLTPGDVSA 205 
Cnr             RVSRLAYLRTVQDWIIRPQLRTTPGVADVDSLGGYVKQFVVEPDTGKMAAYGVSYADLAR 239 
Czc             ENHTPMELRTIQDWIVMPKMLQIPGIADVVTFGGLPKQYHVVTSPDKLIRYKLTIGDVIR 205 
                       :       :   :    *:.*.  :*       :  ..  :  : ::  *:   
 
EnvD            QLKVQNDQIAAGQLGGTPALPGQQLNASIIAQTRFKNPEEFGKVTLRVNSDGSVVRLKDV 265 
AcrB            AIKAQNAQVAAGQLGGTPPVKGQQLNASIIAQTRLTSTEEFGKILLKVNQDGSRVLLRDV 265 
mexb            AIQAQNVQISSGQLGGLPAVKGQQLNATIIGKTRLQTAEQFEKILLKVNPDGSQVRLKDV 265 
Cnr             ALEDTNLSVGAN------FIRRSGESYLVRADARIKSADEISRAVIAHG--KMSHHVGQV 291 
Czc             AIQENNLNTGGN------LLLQGEQGFPIRSLGAIRDPKHIENIVVKTVN-GVPVFIRDL 258 
                 ::  * . ...       :     .  : .   :  ...: .  :          : :: 
 
EnvD            ARVELGGENYNVIARINGK----------PAAGLGIKLATGANALDTAKAIKAKLAELQP 315 
AcrB            AKIELGGENYDIIAEFNGQ----------PASGLGIKLATGANALDTAAAIRAELAKMEP 315 
mexb            ADVGLGGQDYSINAQFNGS----------PASGIAIKLATGANALDTAKAIRQTIANLEP 315 
Cnr             ARVKIGGELRSGAASRNGN----------ETVVGSALMLVGANSRTVAQAVGDKLEQISK 341 
Czc             GSVEISHPIPSGVLGYTVQNDEEGLIDVDSSVQGLVAMRRWGDPNEMGERIREKVKEINE 318 
                . : :.    .     . .           :      :   .:.   .  :   : ::.  
                                                                                          TM2                           TM3 
EnvD            -FFPQGMKVLYPYDTTPFVQLSIHEVVKTLFEAIMLVFLVMYLFLQNMRATLIPTIAVPV 374 
AcrB            -FFPSGLKIVYPYDTTPFVKISIHEVVKTLVEAIILVFLVMYLFLQNFRATLIPTIAVPV 374 
mexb            -FMPQGMKVVYPYDTTPVVSASIHEVVKTLGEAILLVFLVMYLFLQNFRATLIPTIAVPV 374 
Cnr             -TLPPGVVIVPTLNRSQLVIATIETVAKNLIEGALLVVAILFALLGNWRAATIAALVIPL 400 
Czc             NYLPKGVQLRNTYDRTDLVNYTLRTIGKTLVEGVVVVSLVLIFFIGSVRASLVVVATIPF 378 
                  :* *: :  . : : .*  ::. : *.* *. ::*  ::  :: . **: : . .:*. 
                                                                                 TM4 
EnvD            VLLGTFAILAAFGYSINTLTMFGMVLAIGLLVDDAIVVVENVERVMMEDKLPPK------ 428 
AcrB            VLLGTFAVLAAFGFSINTLTMFGMVLAIGLLVDDAIVVVENVERVMAEEGLPPK------ 428 
mexb            VLLGTFGVLAAFGFSINTLTMFGMVLAIGLLVDDAIVVVENVERVMAEEGLSPR------ 428 
Cnr             SLLVSAIGMNQFHISGNLMSLG--ALDFGLIIDGAVIIVENSLRRLAERQHREGRLLTLD 458 
Czc             AMLFAFLLMNMTGIPASLLSLG--AIDFGIIVDGAVIMVENIMRRYRDATPEEKSHG--- 433 
                 :* :   :     . . :::   .: :*:::*.*:::***  *   :             






                                                                   TM5                                 TM6 
EnvD            ---EATEKSMSQIQGALVGIAMVLSAVFIPMAFFGGSTGAIYRQFSITIVSAMALSVLVA 485 
AcrB            ---EATRKSMGQIQGALVGIAMVLSAVFVPMAFFGGSTGAIYRQFSITIVSAMALSVLVA 485 
mexb            ---EAARKSMGQIQGALVGIAMVLSAVFLPMAFFGGSTGVIYRQFSITIVSAMALSVIVA 485 
Cnr             DRLQEVVQSSREMVRPTVYGQLVIFMVFLPSLTFQGVEGKMFSPMVITLMLALASAFVLS 518 
Czc             -ILAFTRDAASEVGTEILFSILIIILAYLPIFSFERIEGRLFKPMAFTISFAILGALVFA 492 
                     . .:  ::    :   :::  .::*   *    * ::  : :*:  *:  :.:.: 
EnvD            LILTPALCATLLKPVS-AEHHENKGGFFGWFNTTFDHSVNHYTNSVGKILGSTGRYLLIY 544 
AcrB            LILTPALCATMLKPIAKGDHGEGKKGFFGWFNRMFEKSTHHYTDSVGGILRSTGRYLVLY 545 
mexb            LILTPALCATMLKPIEKGDHGEHKGGFFGWFNRMFLSTTHGYERGVASILKHRAPYLLIY 545 
Cnr             LTFVPAMVAVMLRKKVAETEVR-----------VIVATKESYRPWLEHAVARPMPFIGAG 567 
Czc             MAVIPVIMSIIYKHYFESKNPGP----IEWHNPFYDWIEARYKRLIEFIVDRSKKAVRYT 548 
                : . *.: : : :      .                     *   :   :      :    
                        TM7 
EnvD            ALIVAGMVVLFLR-LPSSFLPEEDQG-VFLTMIQLPAGATQERTQKVLDQVTDYYLKNEK 602 
AcrB            LIIVVGMAYLFVR-LPSSFLPDEDQG-VFMTMVQLPAGATQERTQKVLNEVTHYYLTKEK 603 
mexb            VVIVAGMIWMFTR-IPTAFLPDEDQG-VLFAQVQTPPGSTAERTQVVVDSMREYLLEKES 603 
Cnr             IATVAVATVAFTF-VGREFMPTLDELNLNLSSVRIPSTSIDQSVAIDLPLERAVLSLPEV 626 
Czc             FSVVTIFLAIGMFSLGTEFLPEMDEGGFNIRIFFPVGISLPEARKFMPKIRQTVYKNEQV 608 
                   *.         :   *:*  *:  . :  .     :  :                :  
 
EnvD            ANVESVFTVNGFSFSGQAQNAGMAFVSLKPWEERNGDENSAEAVIHRAKMELGKIRDGFV 662 
AcrB            NNVESVFAVNGFGFAGRGQNTGIAFVSLKDWADRPGEENKVEAITMRATRAFSQIKDAMV 663 
mexb            SSVSSVFTVTGFNFAGRGQSSGMAFIMLKPWEERPGGENSVFELAKRAQMHFFSFKDAMV 663 
Cnr             QTVYSKAGTASLAADPMPPNASDNYIILKPKSEWPEGVTTKEQVIERIREKTAPMVGNNY 686 
Czc             SVVISQLGRNDDGTDPLPPNRLEVLIGLKDYSKWKEKITKQELLLRMKNDLEATLPGARI 668 
                  * *     .        .     : **   .     ..   :          : .    
 
EnvD            IPFNMPAIVELGTATGFDFELIDQAGLGHDALTQARNQLLGMAAQHPASLVSVRPNGLED 722 
AcrB            FAFNLPAIVELGTATGFDFELIDQAGLGHEKLTQARNQLLAEAAKHPDMLTSVRPNGLED 723 
mexb            FAFAPPSVLELGNATGFDLFLQDQAGVGHEVLLQARNKFLMLASQNP-ALQRVRPNGMSD 722 
Cnr             DVTQPIEMRFNELIGGVRSDVAVKVYGENLDELAATAQRIAAVLKKTPGATDVRVPLTSG 746 
Czc             SFSQPIMDNLSEAIMGTIADLAVFVSGNDLKIMRGIGNEVLKEIKEMKGASEYGIEQEAE 728 
                               *    :   .   .     .  : :    :.               
 
EnvD            TAQFKLEVDQEKAQALGVSLSDINQTISTALGGTYVNDFIDRGR--------VKKLYVQA 774 
AcrB            TPQFKIDIDQEKAQALGVSINDINTTLGAAWGGSYVNDFIDRGR--------VKKVYVMS 775 
mexb            EPQYKLEIDDEKASALGVSLADINSTISIAWGSSYVNDFIDRGR--------VKRVYLQG 774 
Cnr             FPTFDIVFDRAAIARYGLTVKEVADTISTAMAGRPAGQIFDGDR--------RFDIVIRL 798 
Czc             SPQLTISINREAAARFGINVIDIQQMIEAAIGMQRISTLYEGPSDIPPKTPARFGIVVRF 788 
                 .   : .:       *:.: ::   :  * .    . : :              : :   
 
EnvD            DAKFRMLPEDVDKLYVRSANGE-----MVPFSAFTTSHWVYGSPRLERYNGLPSMEIQGE 829 
AcrB            EAKYRMLPDDIGDWYVRAADGQ-----MVPFSAFSSSRWEYGSPRLERYNGLPSMEILGQ 830 
mexb            RPDARMNPDDLSKWYVRNDKGE-----MVPFNAFATGKWEYGSPKLERYNGVPAMEILGE 829 
Cnr             PGEQRENLDVLGALPVMLPLSEGQARASVPLRQLVQFRFTQGLNEVSRDNGKRRVYVEAN 858 
Czc             SKDYRASKQAIENMPIISPKGE-----RIPLSQLADIEVIDGPTMIFRQEGRRVVTVRTN 843 
                  . *   : :    :    .:      :*:  :   .   *   : * :*   : :  : 
                                                                                                                                      TM8 
EnvD            AAPG--TSSGDAMALMENLASKLPAGIGYDWTGMSYQERLSGNQAPALVAISFVVVFLCL 887 
AcrB            AAPG--KSTGEAMELMEQLASKLPTGVGYDWTGMSYQERLSGNQAPSLYAISLIVVFLCL 888 
mexb            PAPG--LSSGDAMAAVEEIVKQLPKGVGYSWTGLSYEERLSGSQAPALYALSLLVVFLCL 887 
Cnr             VGGRDLGSFVDDAAARIAKEVKLPPGMYIEWGGQFQNLQAATKRLAIIVPLCFILIAATL 918 
Czc             IRGRDQGGFVSELQKRVKKKIKLPDGYEIRFGGQYENLSRVGKKLGIVIPITVLIIFGVL 903 
                       .  .          :** *    : *   :     .:   : .: .:::   * 
                                                       TM9                                     YM10 
EnvD            AALYESWSIPVSVMLVVPLGIVGVLLAATLFNQKNDVYFMVGLLTTIGLSAKNAILIVEF 947 
AcrB            AALYESWSIPFSVMLVVPLGVIGALLAATFRGLTNDVYFQVGLLTTIGLSAKNAILIVEF 948 
mexb            AALYESWSIPFSVMLVVPLGVIGALLATSMRGLSNDVFFQVGLLTTIGLSAKNAILIVEF 947 
Cnr             YMAIGSAALTATVLTASPLALAGGVFALLLRGIPFSISAAVGFIAVSGVAVLNGLVLISA 978 
Czc             YLLYRNLKYVYVALACIPLSLLGGIYALLLRGYYFNVSGGVGFISLFGIATMAGVLFVSR 963 
                     .      .:   **.: * : *  : .   .:   **:::  *::.  .::::.  
                                                    
 49
                                                                                                   TM11 
EnvD            AKDLMEK-EGKGVVEATLMAVRMRLRPILMTSLAFILGVLPLAISNGAGSGAQNAVGIGV 1006 
AcrB            AKDLMDK-EGKGLIEATLDAVRMRLRPILMTSLAFILGVMPLVISTGAGSGAQNAVGTGV 1007 
mexb            AKELHE--QGKGIVEAAIEACRMRLRPIVMTSLAFILGVVPLAISTGAGSGSQHAIGTGV 1005 
Cnr             IRKRLD--DGMAPDAAVIEGAMERVRPVLMTALVASLGFVPMAIATGTGAEVQKPLATVV 1036 
Czc             TNHLLVEEPDISTKAAVKKAAVIQLRPMLMTMLLALLGLIPATLGTGVGSDVQRPLATVI 1023 
                 ..      . .   *.  .   ::**::** *   **.:* .:..*.*:  *..:.  : 
                            TM12 
EnvD            MGGMVSATLLAIFFVPVFFVVIRRCFKG-------------------------------- 1034 
AcrB            MGGMVTATVLAIFFVPVFFVVVRRRFSRKNEDIEHSHTVDHH------------------ 1049 
mexb            IGGMVTATVLAIFWVPLFYVAVSTLFKDEASKQQAEAEKGQ------------------- 1046 
Cnr             IGGLVTATVLTLFVLPALCGIVLKRRTAGRPEAQAALEA--------------------- 1075 
Czc             VGGLFSAMCLVLTILPSLYLVVVGERKPSAEELEEMSHKKHIPFLDFVNELSEEPLEEED 1083 
                :**:.:*  *.:  :* :   :    .                                  
 
EnvD            -------------------- 
AcrB            -------------------- 
mexb            -------------------- 
Cnr             -------------------- 
Czc             EDDEPVSKKKKKPAKKRKKT 1103 
 
 
Figure 2: A sequence alignment of members of the RND transporter family using 
ClustalW.  TM segments are highlighted as follows: α1 and α7 are yellow, α2 and α8 
are green, α3 and α9 are teal, α4 and α10 are magenta, α5 and α11 are gray, and 
α6 and α12 are highlighted red.  Residues critical to the proton relay pathway are 
colored blue. Alighnment was performed using clustalw (149).  Transmembrane 

















Figure 3: Schematic representation of the topologyof the MexB protein and 
members of the family. Symbols: filled circle, positively charged amino acid; shaded 
circle, negatively charged amino acid; open circle, uncharged amino acid. Amino 
acid residues in transmembrane segments were expressed by a one-letter code. 
Arrow: one-letter code number in parentheses represents the fusion site-amino acid 
residue-AP activity (units). Shaded rectangles around circles, putative TMS. a 
through e are weak hydrophobic segments.  The overall topology is suggested to be 










Figure 4. A schematic representation of the phospholipids extrusion assay of 
reconstituted AcrB (blue rectangles).  AcrB was mixed with acceptor liposomes, 
wictout any protein or labeled lipids.  The NBD fluorescence from the NBD-labeled 
phosphatidylethanolamine (orange) in the donor vesicles is initially quenched by 
fluorescent emission energy transfer to the rhodamine-labeled 
phosphatidylethanolamine (red).  Following export of phospholipids to the acceptor 
vesicles, the fluorescent emission increases from NBD as the surface density of 
labeled phospholipids decreases indicating transport.  The diagram was taken from 












Figure 5 is a ribbon model of a single AcrB monomer taken from pdb accession 
code 1IWG.  Subdomains are individually colored, whereby TM helices 1-6 are 
brown, TM helices 7-12 are purple, PC1 is Green, PC2 is yellow, PN1 is blue, PN2 is 
red, DC is orange, and DN is colored cyan.  Subdomains PC1, PC2, PN1, and PN2 
comprise the porter domain of AcrB, while the DN and DC subdomains come 
together to form the TolC-docking domain, respectively.  The image was created 





Figure 6.  A) A close-up depiction of the proton relay network of wild-type AcrB.  
Residues D408, K940, D407, and T978 are all within hydrogen bond distance of less 
than 3.2Å.  The image was rendered using pymol and PDB accession code 1IWG. 
B) A similar view of Mutated T978A, and non functional AcrB.  In this ribbon diagram 
the proton relay network is disturbed, therefore no efflux antibiotic efflux occurs.  The 










Figure 7.  A ribbon model of AcrB viewed from the top, perpendicular to the 
membrane plane.  Features illustrated include the central pore (purple circle) which 
extends from the central cavity to the TolC docking domain funnel (orange circle).  
The vestibules, which are located at the monomer interfaces and lead to the central 
cavity, are depicted with purple arcs.  Additionally, the suggested binding clefts are 
displayed as teal arcs.  Individual AcrB monomers are displayed as red, green, and 

























Figure 8.  A) Surface electrostatic potential of AcrB with bound R6G (yellow).  The 
model was built using PDB 1T9V, which has a mutated Asp109 to alanine.  This 
mutation allowed R6G to enter a second binding site, with the first being the central 
binding cavity (entrance from the vestibules) and the second locating to the binding 
cleft.  B) After removal of the TolC-docking domain and transmembrane domain, the 
binding cleft can be easily displayed along with bound R6G (yellow).   Subdomains, 
vestibules and binding clefts are labeled black, purple, and teal, respectively.  Both 







Figure 9. Tunnels in the porter domain of trimeric AcrB peristaltic drug efflux pump. 
The AcrB monomers are presented in blue (access), yellow (binding) and red 
(extrusion). The tunnels are highlighted as green surfaces in a ribbon model of the 
AcrB trimer and might function as transport paths of drugs. Tunnel 1 might serve as 
entrance for drugs from the outer leaflet of the inner membrane towards the 
hydrophobic substrate binding pocket. Tunnel 2 might serve as an alternative 
entrance for substrates entering via the periplasm or as an exit duct for non-
substrates. Tunnel 3 in the open monomer is the exit pathway for substrates towards 
TolC and the outside medium. Inset: in the T monomer (yellow), a hydrophobic 
pocket is defined by phenylalanine, valine, isoleucine and tyrosine side chains at the 
PN2/PC1 interface. Bound minocycline is depicted with the observed electron 
density in a 2Fo-Fc electron density map contoured 1 s (T. Eicher, M. Seeger, K.M. 
Pos and colleagues, unpublished data). Panels (A) and (B) represent in each case a 
one-third conversion of a cycle.  This figure was originally published by Eicher, 








Figure 10. Schematic drawing based on the X-ray structures of the tripartite 
multidrug efflux system AcrAB–TolC of Gram-negative E. coli. AcrB (RND 
component, in blue color) resides in the inner membrane and is responsible for 
substrate recognition/selection and energy transduction. Drugs are captured at the 
outer leaflet of the inner membrane and extruded in a coupled exchange with 
protons. TolC (OMF component, yellow) forms a pore in the outer membrane which 
is extended by a long periplasmic conduit. AcrA (MFP component, red) mediates 
contact between AcrB and TolC. The presence of all three components is essential 
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CHAPTER 3. STRUCTURAL AND FUNCTIONAL STUDIES OF AcrD 
 
ABSTRACT 
 Here, we report the crystallization and preliminary X-ray data analysis of the 
multidrug efflux pump AcrD of Escherichia coli (E. coli).  AcrD is a cytoplasmic 
membrane protein consisting of 1037 amino-acid residues.  The transport protein 
belongs to the previously characterized resistance, nodulation, and cell division 
(RND) superfamily of transporters.  Substrates of AcrD include polar, hydrophilic 
aminoglycosides such as amikacin, gentamicin, and kanamycin.  Furthermore, AcrD 
presumably transports other structurally unrelated toxic compounds, including 
sodium dodecyl sulfate (SDS), novobiocin, tetracycline, nalidixic acid, norfloxacin, 
fosfomycin, and bile acids.  The recombinant AcrD protein was expressed in E. coli 
and purified to greater than 95% using a combination of hydroxyapatite, metal 
affinity, and size exclusion chromatography.  The protein was crystallized using the 
hanging-drop vapor diffusion method.  X-ray diffraction data were collected from 
cryo-cooled crystals at a synchrotron light source.  The best crystal diffracted to 4.2 
Å and diffraction data were complete to 5.8 Å resolution.  The spacegroup was 
determined to be P2, with unit-cell parameters: a = 114.0, b = 117.2, c = 178.4 Å.  
Additionally, binding studies utilizing fluorescence polarization and STD-NMR 
techniques were used to analyze protein-ligand interactions. Intriguingly, we 
illustrate that the anthracyline family of chemotherapeutic agents is recognized by 
AcrD.  Furthermore, we identify the binding epitope of gentamic using STD-NMR.  
Finally, as the crystal structure yet eludes us, we use computer-aided modeling to 
suggest the AcrD structure and identify the ligand binding region within a cleft in the 
porter domain.  Interestingly, a possible second binding site is located in the TolC-
docking domain, which suggests a probable substrate pathway from the cell interior 






 The multidrug restant (MDR) phenotype in bacteria has been primarily 
attributed to transporters within the cytoplasmic membrane (1).  These pumps are 
capable of exporting a wide range of antibacterial compounds and their 
overproduction causes increased resistance to antimicrobial agents.  The multidrug 
resistance associated with these proteins has become a major concern with 
increasing occurrences of resistant pathogens in the clinical setting (2). Multidrug 
resistance efflux pumps are grouped into five families of transporters.  These 
families include primary transporters belonging to the ATP-binding cassette (ABC) 
family (3) and secondary transporters among the major facilitator superfamilies 
(MFS) (4,5), as well as the multidrug and toxic compound extrusion (MATE) (6-8), 
the resistance nodulation division (RND) (9), and the small multidrug resistance 
(SMR) families (10). Among the five known families of multidrug transporters, the 
RND family tends to play major roles in the intrinsic resistance of gram-negative 
bacteria (11, 12). In fact, E. coli harbor 37 putative multidrug efflux transporters (13, 
14).  Thus far, ~20 of these transporters have been identified as contributors to 
multidrug resistance (14) with seven belonging to the RND family of exporters. 
 The E. coli efflux pump AcrD is a prototypical member of the RND family of 
multidrug transporters.  As a member of the RND family, it is suggested that AcrD is 
a trimeric protein comprised of topological features including 12 transmembrane 
(TM) α-helices with two large (~300 residue each) periplasmic extensions between 
TMs 1-2 and TMS 7-8 from each monomer (9, 15). The transporter AcrD is 
homologus to the well-characterized MDR efflux pump AcrB.  Intriguingly, it has 
been suggested that AcrD is able to sequester ligands from both the periplasmic 
space and the cytoplasmic interior, which has not been shown for AcrB (16).  This 
disparity may be due to the nature of the inducing ligands.  AcrB recognizes mainly 
negatively charged and hydrophobic drugs that readily pass the inner membrane, 
which may make a cytoplasmic entry point unnecessary (1, 17, 18).  The 
aminoglycosides that are extruded by AcrD are positively charged and extremely 
hydrophilic molecules.  Presumably, these drugs are not able to cross the 
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membrane efficiently so a cytoplasmic entrance to AcrD is critical to protect the 
bacterial cell (19).   
Aminoglycosides are an important class of antibacterial compounds that are 
commonly used as a broad-spectrum antibiotic and are reemerging as key 
treatments of drug resistant infections.  First discovered in 1944, aminoglycosides 
disrupt the integrity of the cell membrane and inhibit protein synthesis by binding the 
16S rRNA of bacteria (20, 21).  Understanding the binding mode of these 
aminoglycosides as well as other AcrD substrates will provide valuable insights into 
the novel mechanism of ligand capture and extrusion.  Additionally, the 
determination of subtrate recognition profiles will facilitate the discovery of novel 
aminoglycosides that may not be recognized by AcrD or the development of efflux 
pump inhibitors that may block AcrD-substrate interaction.  Importantly, the array of 
ligands AcrD recognizes is distinct of those for AcrB and the detailed ligand binding 
mechanism will provide information as to how a MDR efflux pump is able to 
recognize and extrude cationic, hydrophilic compounds.   
 
PROTEIN PRODUCTION 
 Expression: The C-6XHis AcrD protein was overproduced in E. coli BL21 
Gold/pSport1_acrD cells.  After optimizing expression conditions, a protocol 
developed in our lab was used to purify AcrD.  In brief, the AcrD-pSport1 vector was 
transformed into the BL21 Gold and grown overnight at 37ºC in a 10 ml liquid Luria–
Bertani (LB) broth culture.  Following overnight growth, cells were transferred to four 
1-liter LB cultures supplemented with 100 µg/ml of ampicillin.  The culture was grown 
with shaking (210 rev min-1) at 310 K. Expression of AcrD was induced by 1 mM 
isopropyl β-d-1-thiogalactopyranoside (IPTG) after the OD600  reached .4.  Cells were 
then harvested by centrifugation at 6000 rev min-1 for 10 minutes at 277 K and 
frozen and stored at 193 K.   
 
 Purification: The membrane protein was extracted and purified as follows.  
Briefly, the cells were suspended in low-salt buffer containing 100mM sodium 
 76
phosphate (pH7.2), 10% glycerol, 1mM EDTA, and 1mM 
phenylmethylsulfonylfluoride (PMSF), and then disrupted by passing through a 
French press three times. The membrane fraction of the pellet was collected and 
washed twice with a high-salt buffer containing 20mM sodium phosphate (pH7.2), 
2M KCl, 10% glycerol, 1mM EDTA, and 1mM PMSF and once with 20 mM HEPES-
NaOH buffer (pH7.5). The membrane protein was then solubilized in 2% (w/v) n-
dodecy-β-D-maltoside (β-DDM). Insoluble material was removed by 
ultracentrifugation at 100,000×g. The extracted membrane protein was subsequently 
loaded into a Hydroxy Apatite column and eluted with 8 mM Na-phosphate buffer 
(pH 7.0) supplemented with 1% β-DDM.  This elution was then added to a Nickel-
affinity column, washed with a buffer containing 20mM HEPES-NaOH (pH7.5), 
50mM imidazole, and 0.05% β-DDM, and eluted in a buffer consisting of 20mM 
HEPES-NaOH (pH7.5), 400mM imidazole, and 0.05% β-DDM. The eluted protein 
fractions were collected and dialyzed against 20mM HEPES-NaOH (pH7.5) buffer 
and concentrated to 20 mg/ml for crystallization.  The C-6XHis AcrD protein was 
concentrated to 20 mg/ml in a solution containing 20 mM Na-HEPES (pH 7.5) and 
.05% β-DDM (or other detergent as indicated).  Exchange of primary detergents was 
performed using gel filtration chromatography.  The purity of C-6XHis AcrD protein 
was judged using a10% SDS–PAGE stained with Coomassie Brilliant Blue.  Western 
blots were used to detect the 6X his-tag and determine the presence of purified C-
6XHis AcrD.  Typical starting and ending volumes were 15 ml and 1 ml, respectively.  
A YM-50 Centriprep concentrator (Millipore, 50 kDa molecular-weight cutoff) was 
used for concentrating protein.  Generally, 10-20 mg of purified C-6XHis AcrD was 
obtained.   
 
 Detergent exchange: Detergent exchange to any of the six detergents used 
for crystallization was performed using a G-200 sizing colulmn.  β-DDM solubilized 
AcrD was loaded onto the sizing column, which was pre-equilibrated with a buffer 
containing 20 mM Na-HEPES (pH 7.5) and the indicated detergent.  The volume and 
length of the G-200 sizing column was 120 ml and 60 cm, respectively.  A flow rate 
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of 0.5 ml min-1 was used to collect 2 ml fractions.  The fractions were analyzed for 
the presence of AcrD using a 10% SDS–PAGE stained with Coomassie Brilliant 
Blue.  Fractions harboring AcrD were pooled and concentrated using the YM-50 
Centriprep concentrator to 20 mg/mL and and were subsequently used for 
crystallization.   
 Following extensive crystallization trials with the detergents exchanged 
through gel-filtration chromatography, it was determined which of the six primary 
detergents were most suitable for crystallization.  After choosing the optimal 
detergents, steps were taken to solubilize AcrD from the membrane fraction.  During 
exchange through the gel-filtration column, residual β-DDM may remain in the 
detergent-AcrD micelle, therefore hindering crystallization.  To avoid this, the 
identical purification protocol was used, but the primary solubilizing detergent was 
replaced with either Fos-choline 12 (FC-12) or Cymal-6.    
 
CRYSTALLIZATION 
 The full-length C-6XHis AcrD protein was crystallized in 24-well plates using 
the hanging drop vapor-diffusion method.  As an initial step to understanding how 
the RND family transporter AcrD functions, crystallization trials were performed in 
the absence of ligands. Typically, AcrD crystals were grown using the hanging-drop 
vapor diffusion method with a 20mg/ml protein solution in 20mM tris (8.5) and .05% 
β-DDM.  An ambient temperature of 25ºC was maintained throughout crystal growth.  
Initial crystallization trials were performed using Hampton reagents, including Crystal 
Screen 1, 2, Lite, and Membfrac. Initially, Reagent 15 of Crystal Screen Light 
produced the most promising results.  This condition was optimized by manipulating 
buffers, precipitants, salts, detergents and additive solutions.   
 In the beginning, all crystallization trials were carried out using β-DDM as the 
primary detergent.  Following rigorous screening, the best quality AcrD- β-DDM 
crystals grew in a mother solution containing PEG 1500 15.5%, .25M NaCl, .1M tris 
8.5, and 3% Glycerol.   
 
 78
 Detergents: With initial X-ray diffraction only achieving 15Å, steps were taken 
to improve cystal packing.  It has previously been shown that the choice of primary 
and addition of secondary detergents is a crucial factor in the success of crystal 
formation for membrane proteins.  Indeed, crystallization of the Na+/H+ Antiporter 
NhaA was attempted in the presence of ten various detergents, although crystal 
growth was achieved in only Fos-choline 12, α-DDM, and β-DDM.  Of these 
detergents, high-quality diffraction was obtained with only α-DDM and the addition of 
a secondary detergent n-Octyl-β-D-Glucopyranoside (β-OG), which was identified 
following an extensive screen of secondary detergents (22).  In this regard, we 
initially set up secondary detergent screens using Detergent Kits 1, 2, and 3 from 
Hampton Research to improve results.  Using our previously established conditions, 
the addition of n-Octyl-b-D-thiomaltoside (OTM), FC-12, CHAPS, Cymal-6, dodecyl 
dimethyl glycine, and tetra DM improved the AcrD- β-DDM crystal quality.  The most 
dramatic improvement was observed using CHAPS as the secondary detergent.  
The addition of 1% CHAPS improved resolution limits to ~5.0 Å with a complete data 
set complete to 5.8 Å.  Figure 1 displays a representative diffraction image with 
diffraction statistics highlighted in table 1.  
 Detergent selection is a critical factor in membrane protein crystallization.  
The tendency of a detergent to aid in crystallization or possibly denature the protein 
is a fine line.  Qualitatively, predictions can be made about the deleterious effects of 
a detergent by considering the size and charge of the polar headgroup along with 
the length of the alkyl tail.  These factors affect the CMC and size of the micelle (23).  
This was taken into consideration when selecting primary detergents, thus a range 
of detergents varying in these parameters were chosen.  Using gel-filtration 
chromatography, β-DDM was exchanged with various detergents, including FC-12, 
Cymal-6, Cymal-5, CHAPS, β-OG, OTM, and Lauryldimethylamine-oxide (LDAO).  
The most promising results were established with FC-12 and Cymal-6. Therefore, 
the ensuing steps involved purification of AcrD and solubilization with these two 
detergents.  After purification, crystallization with AcrD-Cymal-6 only produced 
needle shaped (poor quality) crystals, while AcrD-FOS-choline-12 crystals had 
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improved birefringence, which indicated higher qualtity crystals (Figure 2).  Both 
crystal forms were produced in nearly identical conditions, which highlights the 
necessity for the correct choice of primary detergent.  Additionally, secondary 
detergents were once again screened, although this did not improve diffraction 
quality.  Table (2) illustrates the screening experiments and corresponding results.   
The needle shaped cymal-6-AcrD crystals did not diffract while the FC-12 solubilized 
AcrD protein diffracted to ~10Å. Although, the diffraction quality did not improve 
beyond the AcrD-β-DDM crystal, these experiments outline the importantce of 
correct detergent selection.   
 
DATA COLLECTION 
 For data collection, a single native crystal of C-6XHis AcrD was flash-cooled 
in a cryoprotectant solution containing the mother solution (PEG 1500 15.5%, .25M 
NaCl, .1M tris 8.5, and 3% Glycerol) plus 25% glycerol at 100 K.  The glycerol 
concentration was gradually increased to 25% by 5% increments.  The best crystal 
diffracted anisotropically to a resolution of 5 Å. Fig. 1 depicts one of the diffraction 
images of the native AcrD crystal. Diffraction data sets were obtained from the native 
C-6XHis AcrD crystals at the Advanced Photon Source (APS, beamline 24IDC) at 
cryogenic temperature (100 K) using an ADSC Quantum 315 CCD-based detector. 
The beam size was 50 X 20 mm.  
 
AcrD-LIGAND CRYSTALLIZATION 
 The integral membrane protein AcrD plays an important role in protecting the 
bacterial cell from various toxic chemicals, including aminoglycosides and other 
antibiotic compounds (14, 19).  The addition of substrates and other small molecules 
has been shown to stabilize transport proteins and aid in crystallization.  In lieu of 
this, attempts were made to improve diffraction limits by adding the antibiotic 
substrates.  Initially, gentamicin and daunorubicin HCl (DR) were soaked into 
preformed crystals.  Trials to soak in antibiotics and co-crystallize the drug/protein 
were not able to improve resolution.  Crystals of the AcrD-gentamicin complex had 
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similar diffraction as apo-AcrD and crystallized in the identical space group.  
Therefore, co-crystallization of AcrD with the same two ligands was initiated.  Co-
crystallization successfully produced crystals, although these were poor quality 
crystals with data sets complete to less than 10Å. 
 
FLUORESCENT POLARIZATION 
 Fluorescence polarization assays were used to determine the drug binding 
affinities of AcrD. The experiments were done using a ligand binding solution 
containing 20 mM HEPES (pH 7.5), 0.05% DDM, and 1 µM DR. The AcrD protein 
solution and 1 µM DR was titrated into the ligand binding solution until the 
polarization (P) became saturated. In this assay, the protein–drug interaction would 
reach equilibrium within 1 min. As this is a steady-state approach, fluorescence 
polarization measurements were taken after incubation for 5 min at each 
corresponding concentration of the protein and drug to ensure that the binding had 
reached equilibrium. It should be noted that the detergent concentration was kept 
constant at all times to eliminate the change in polarization generated by drug–DDM 
micelle interaction. All measurements were performed at 25 °C using a PerkinElmer 
LS55 spectrofluorometer equipped with a Hamamatsu R928 photomultiplier.  The 
excitation wavelength was 485 nm. Fluorescence polarization signals (in ∆P) were 
measured at an emission wavelength of 595 nm, respectively.  Each titration point 
recorded was an average of 15 measurements. Data were analyzed using the 
equation, P={(Pbound-Pfree)[protein]/(KD+[protein])}+Pfree, where P is the polarization 
measured at a given total protein concentration, Pfree is the initial polarization of 
free ligand, Pbound is the maximum polarization of specifically bound ligand, and 
[protein] is the protein concentration. The titration experiments were repeated three 
times to obtain the average KD value. Curve fitting was accomplished using the 
program ORIGIN (24). 
   
 In order to determine if detergent solubilized AcrD is present in an active state 
and able to bind gentamicin and DR, binding assays were performed to test 
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substrate-AcrD interaction.  Importantly, the fluorescence studies identified an 
antibacterial compound, DR, from the anthracycline family that is recognized by 
AcrD.  Binding kinetics were assayed using fluorescence polarization, a technique 
that measures the tumbling rates of fluorescent molecules.  Using a constant 
concentration of 1 µM DR, the concentration of AcrD was increased from 2 to 150 
µM to create the curve indicated in Figure 3.  The dissociation constant of 6 µM, 
suggests that AcrD is fully functional and binds DR in a range previously observed 
between AcrB and its hydrophobic substrates (25).  As gentamicin does not harbor 
fluorescent characteristics, isothermal titration calorimetry was performed to develop 
a better understanding of AcrD function.      
 
ISOTHERMAL TITRATION CALORIMETRY (ITC): 
 Previously purified AcrD protein was dialyzed against sodium phosphate 
buffer (7.2) with additional .02% β-DDM (buffer A) using a dialysis cassette with a 
20,000 MWCO.  Dialyzed AcrD was then used in all ensuing ITC experiments.  All 
calorimetric experiments were performed with a VP−ITC MicroCalorimeter 
(MicroCal, Inc., Northampton, MA) in buffer A, at 25 °C. All solutions were thoroughly 
degassed under vacuum for 5 min before being used. Ligand (gentamicin) was 
prepared in the dialysate of the protein buffer to minimize artifacts due to different 
compositions of solutions. The reaction cell contained 1.4 mL of protein in buffer A, 
and the reference cell contained distilled water only. The injection syringe was filled 
with ligand solution and rotated at 310 rpm during equilibration and experimentation. 
Titration experiments consisted of 61 injections. The volume of the first injection was 
2.5 µL, and the subsequent injection volumes were 5 µL. Injection speed was 0.5 
µL/s with 2-min intervals between injections. For blank experiments, separate 
titrations of the ligand solution in the buffer were performed to determine the heat of 
ligand dilution. The blank run was subtracted from the experimental ITC to 
counteract the effects of the heat from ligand dilution.  The heat of dilution was 
subtracted prior to analysis of the data.  
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A Leverber−Marquardt algorithm performed by MicroCal Origin scientific plotting 




where V0 is the volume of the sample solution. For the model of the single set of 




where n is the stoichiometry of the binding reaction, [P]t is the total AcrD 
concentration in the sample vessel, Hb is the binding enthalpy, and Kb is the binding 
constant. The binding entropies, Sb, were calculated using the following equation of 




Standard deviations for Hb, Sb, and Kb were calculated from multiple titration runs. 
 The calorimetry experiments revealed a stoichiometry of .398:1 
gentamicin:AcrD or 1.2 gentamicin molecules per AcrD trimer, respectively.  
Additionally, a dissociation constant of 3.8 ± .95 µM was estimated.  The system is 
exothermic with a heat change of -906.1 ± 39.9 kcal/mole and is driven entropically, 
whereby the change in entropy is 21.8 e.u (Figure 4).  Not surprisingly, the binding 
constant of gentamicin is distinctly similar to that of daunorubicin, although they 





 To assess the interaction between AcrD and gentamicin, novel saturation 
transfer difference-nuclear magnetic resonance (STD-NMR) studies were 
undertaken.  STD-NMR is a powerful technique used for studying protein-ligand 
interactions. The STD NMR experiment is based on transfer of saturation from the 
protein to a bound ligand.  This method is capable of identifying the binding epitope 
of a ligand when bound to protein. Ligand-protons that are in close contact with the 
receptor receive a higher degree of saturation, and as a result stronger STD NMR 
signals can be observed.   
 All NMR experiments were performed on a Bruker Avance DRX 900-MHz 
spectrometer equipped with a 5-mm inverse triple-resonance probe head at 300 K.  
NMR samples were prepared as described above then dialyzed 3X against 500 µL 
of 99.9% D2O Sodium Phosphate buffer (pH 7.0). Protein concentrations in the NMR 
samples were in a range between 1 and 50 µM.  Gentamicin concentration ranged 
from 1 to 4 mM.   
 The pulse scheme of the 1D STD NMR spectra is previously described by 
Mayer (26). Subtraction of the 1D STD spectra were performed internally via phase 
cycling after every scan to minimize artifacts arising from temperature and magnet 
instability. For samples with higher concentrations of H2O, the water suppression by 
gradient tailored excitation (WATERGATE) scheme for suppression of the residual 
HDO signal was employed (27).   The on-resonance irradiation of the protein was 
performed at a chemical shift of .25 ppm. Off-resonance irradiation was applied at 30 
ppm, where no protein signals were present. 1D STD NMR spectra were multiplied 
by an exponential line-broadening function of 1−3 Hz prior to Fourier transformation. 
The irradiation power of the selective pulses in all STD NMR experiments was set to 
(γ/2π)B1 = 86 Hz. Selective presaturation of the protein was achieved by a train of 
Gauss-shaped pulses of 50-ms each, separated by a 1-ms delay. The number of 
selective pulses n determines the presaturation period, and the standard value was 
40 pulses, leading to a total length of the saturation train of 2.04 s. The additional 
delay (d1) was set to 100 ms in all STD experiments. The total number of scans was 
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256 or 512.  Also, 16 dummy scans were applied, typically using 12 ppm spectral 
widths for the 1D STD NMR spectra. All 1D STD spectra of samples containing 
ligands were recorded with a 30-ms spin-lock pulse, or so-called T1ρ filter, after the 
π/2 pulse with a strength of (γ/2π)B1 = 4960 Hz, which eliminates the background 
protein resonances to facilitate analysis.  
For the group epitope mapping analysis, the STD integrals of the individual protons 
of gentamicin are referenced to the strongest STD signal in each spectrum, which is 
assigned to a value of 100%. Proton peaks were previously identified in NMR 
experiments for gentamicin by Deubner et al. 2003 (28). The differential STD effects 
within gentamicin then yield information on the proximity of the individual protons to 
the protein surface.  
 Indeed, the STD-NMR results indicated that gentamicin does interact with 
AcrD.  The studies suggest that protons at positions C22, C24, C26, C7, C13, C11 
form the closest interactions with AcrD, whereby their percent saturation, relative to 
the maximum (max std is group C22), is above 60% (Fig 5 and Table 3).  A 
representative STD-NMR experiment is presented in Figure 6, with Figure 5 and 
Table 3 highlighting the experimental results.   
 
STRUCTURAL MODELING 
 To build a structural model for AcrD, the ESyPred3D Web Server 1.0 was 
used (29).  In the ESyPred3D system, alignments are obtained by combining, 
weighting and screening the results of several multiple alignment programs. The 
final three dimensional structures are built using the modeling package MODELLER 
(30).  To build the model, the crystal structure of MexB, accession code 2V50, was 
utilized.  The homologous MexB protein shares 60.7% identity with AcrD.  The 
output result, from the computer-aided modeling, was a single AcrD monomer, with 
overall structural features similar to that of AcrB and MexB.  The transmembrane 
domain (TM) was comprised of 12 α-helical segments.  In the periplasmic region two 
individual domains are formed from various smaller subdomains.  The subdomains 
PC1, PC2, PN1, and PN2 (utilized from AcrB nomenclature) combine to make up the 
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porter domain, while the TolC-docking domain is comprised of the subdomains DC 
and DN, respectively (Fig. 7).   
 To model the trimeric state of AcrD, monomeric AcrD was superimposed over 
each of the individual protomers of trimeric AcrB (accession code 1IWG) using the 
program COOT (31) (Fig. 8).  The AcrD trimer displayed intriguing features, 
including a large central cavity, vestibules at monomer interfaces, and clefts located 
between subdomains PC1 and PC2 that are also present in the AcrB trimeric 
structure(Fig. 9).  Previously, AcrB had been suggested to bind ligands within the 
central cavity, which is located in the transmembrane region.  Ligands presumably 
could enter this central cavity through adjacently located vestibules.  Alternatively, 
recent evidence suggests that ligands may interact within the clefts, which are 
located approximately 15Å above the membrane plane (Fig. 9).  To further evaluate 
AcrD-ligand interaction, AutoDock vina was used to predict the most favored binding 
modes of ten previously identified ligands (32), including sodium dodecyl sulfate 
(SDS), fosfomycin (Fos), Gen, amikacin (Amk), norfloxacin (Nor), novobiocin (Nov), 
deoxycholic acid (Dca), tetracycline (Tet), nalidixic acid (Nal), and DR.  Table 4 lists 
the ligands along with the associated minimum inhibitory concentrations (MIC) of 
plasmids with and without AcrD.  Daunorubicin is not listed in table 4, as the work 
reported here describes, for the first time, AcrD-DR interaction.  Intriguingly, 
AutoDock Vina identified two distinct binding sites within AcrD, with neither locating 
within the central binding cavity.  Binding site 1 is located directly in the hydrophilic 
binding cleft (Fig. 10).  This is nearly identical to the location of bound minocycline in 
the recently solved asymmetric crystal structure of AcrB (33).  However, in the AcrD 
binding groove many of the hydrophobic phenylalanines present in AcrB are 
replaced with hydrophilic residues, including F615 to Ser, F617 to Pro, and F178 to 
Tyr.  Additionally, binding site 1 seems to harbor multiple binding patches capable 
allowing AcrD to recognize diverse substrates.  For instance, a more hydrophobic 
patch exists within the binding cavity allowing AcrD to accommodate the 
hydrophobic tail of SDS (Fig. 11F).  The aminoglycosides Gen and Amk appear to 
bind in an overlapping location that may be the primary drug recognition site 
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(Figures 11A and 11B), as seven of the ten docked molecules have at least partial 
interaction in this region.  Figure 10A displays binding site 1 with all docked drugs, 
while 10B provides a closer view of the binding site while removing overlapping 
ligands.   
 The most interesting results from the docking experiment were the 
identification of a possible second binding site.  The second site was identified in a 
location stacked between the TolC-docking domain and the porter domain.  
Autodock identified a binding site in this region for each of the tested substrates (Fig. 
12). Table 5 lists each ligand along with the binding energy for each binding site.  
Similar to binding site 1, this second binding site is multifaceted and capable of 
recognizing diverse ligands.  Figures 13A through 13J illustrate the individual binding 
sites of each drug.   
 Presumably, drugs could interact with binding site 1 initiating conformational 
shifts that transfer the ligand to the second site.  To identify a possible exit pathway, 
Caver was used to identify tunnels that pass through AcrD (34).  The starting point 
was set as the Gen binding site, which allowed for the identification of tunnels 
leading into and out of the suggested cavity.  As displayed in figure 14, a passage 
was identified leading from the the central cavity as well as the periplasmic space to 
binding site 1.  Furthermore, the tunnel extended from binding site 1 to binding site 2 
and ultimately exited toward the TolC-docking domain funnel.   
         
DICUSSION 
 The studies reported here describe the function and suggest the structure of 
the RND transporter AcrD.  As indicated, the results of these studies indicate that 
AcrD does indeed specifically interact with the aminoglycoside Gen by primarily 
associating with the R1 and R2 groups (figure 5).  The binding assay with Gen, 
using ITC revealed a KD of 3.8 ± .95 µM.  Not surprisingly, it was observed that the 
chemotherapeutic drug DR, of the anthracycline family, also binds to AcrD with a 
similar affinity (KD = 6 µM).  We hypothesize, this dissociation constants is in an ideal 
range, whereby AcrD is able to export substrates while they are still at sublethal 
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concentrations.  Interestingly, in similar experiments using the homologus protein 
AcrB, binding affinities to AcrB substrates were nearly identical.  Using fluorescence 
polarization, dissociation constants were observed for ethidium bromide, proflavin, 
and rhodamine 6G of 8.7, 14.5, and 5.5 µM, respectively (25). 
 Along with the binding studies we attempted crystallization of AcrD in both 
apo and ligand-bound forms utilizing diverse primary and secondary detergents.  To 
this point, diffraction limits have been obtained to lower than 5Å.  Although diffraction 
limits have been drastically improved, there is still a mountain to climb in determing 
the three-dimensional structure of AcrD.  Therefore, this challenge was 
circumvented using structural modeling of AcrD.  A model was created using MexB 
as a template, whereby the overall architecture generally observed in RND 
transporters was maintained.  After docking several ligands into the AcrD model, two 
distinct binding sites were located.  It seems possible that ligands may enter binding 
site 1 through the central cavity (cytoplasm) or simply be captured from the 
periplasmic space from the binding cleft.  We suggest that substrate interaction will 
close binding site 1, forcing the ligand into the second binding site and ultimately out 
of the transporter.  Alternatively, the second binding site may not be functional in 
substrate recognition or expulsion.  As the Autodock program searches for probable 
binding sites, it may have located this area due to its large hydrophobic area.  
Currently, no other RND protein has been identified to bind ligands in this region.  
Using CAVER to highlight solvent channels a specific pathway was suggested 
leading through both binding sites to the TolC-docking domain.  At this point, the 
substrate could enter the interior of TolC and be ushered completely out of the 
bacterial cell.   
 Although this suggests a possible pathway in provides clues to the 
mechanism, detailed structural changes are yet undefined.  A model to describe the 
function of RND transporters AcrB and MexB has recently been described (33, 35-
37), whereby a functionally rotating mechanism guides drug export.  A similar 
situation may occur, but our modeling studies fail to detect such subtle 
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conformational differences.   In order to improve the AcrD model, the crystal 
structure of both apo-AcrD and substrate-bound AcrD awaits.    






























Figure 1. A representative diffraction image of AcrD-β-DDM crystals along with a 
close-up view (red box) displaying resolution to approximately 6.8Å.  A synchrotron 
light source at the APS facility at Argonne National Laboratories was used to collect 














Table 1  
 
Table 1.  Diffraction statistics of the highest diffracting crystal (AcrD- β-DDM with 


















Figure 2:  Crystal shapes obtained through screening of various primary and 























crystallization       
Primary Detergent 
Secondary 
Detergent Crystals diffraction 
β-DDM Fos-choline 12 rectangular 8-9 Å 
 (figure 2b) CHAPS rectangular 6-7 Å  
 (figure 2a) None    cubic 12-15 Å  
 (figure 2e) Cymal-6 Bar 10-12 Å 
 (figure 2f) OTM Rectangular 8-9 Å 
Fos-chol 12 (figure 
2d) Cymal-4 Cubic salt 
 (figure 2c) Cymal-6 Diamond 9-11 Å 
Cymal-6 OTM needle none 
Cymal-5 None no crystals   
CHAPS None no crystals   
β-OG None no crystals   
OTM  None no crystals   
LDAO None no crystals   
 
 
Table 2. Table displaying the various primary and secondary detergents used during 
crystallization trials and the resulting crystals and resolution. AcrD-β-DDM crystals 



















Figure 3. A) Representative fluorescence polarization of AcrD with Daunorubicin 
(DR). Statistical analysis revealed a KD of 6 ± 0.3 µM. B) schematic representation of 




















Figure 4. A) Binding isotherm of AcrD-gentamicin interaction.  Isothermal titration 
calorimetry suggested a KD value of 3.8 µM.  The stoichiometry suggests that 
approximately .398 gentamicin molecules bind an AcrD monomer (1.2 
molecules/trimer).  In the asymmetric model, only the binding protomer interacts with 
extruding ligands.  The ITC data may provide supporting evidence to the asymmetric 
model, whereby a gentamicin molecule may only be recognized by the binding 










Figure 5.  The components of gentamicin are displayed.  Five varieties of 
gentamicin can be identified after purification with differences indicated in R1, R2, or 
R3 groups.  Circled in red are those protons with the strongest STD-NMR signals.  
Labeled withing the gentamicin schematic diagram are the corresponding peaks 














Table 1.  Three STD-NMR experiments were run in replicate to identifify the binding 
epitope of gentamicin.  Results suggest that protons at positions 26, 27, 7, 22, 24, 
















Figure 6.  Representative STD-NMR spectrum of gentamicin with AcrD.  20 peaks 
are identified and labeled based on the proton number from figure 3.  Top is 
reference spectrum, while bottom is spectrum after saturation transfer from AcrD to 
















Figure 7. A ribbon diagram representing the modeled structure of AcrD.  Coloring 
scheme is as follows: TM1-TM6, raspberry; TM7-TM12, split pea; PC1, marine; PC2, 
yellow; PN1, orange; PN2, hot pink; DN, Deep teal; DC, ruby.  The model was 
generating using ESyPred3D with MexB (PDB accession 2V50) as the homologus 











Figure 8. Ribbon diagram representation of Trimeric AcrD with protomers colored 
red, blue, and green, respectively.  Monomer was generated by ESyPred3D, while 
the trimer was created by superimposing three monomeric models of AcrD over 
trimeric AcrB (PDB accession code 1IWG) using the program coot.  Image was 
















Figure 9.  A Top view (perpendicular to the membrane) of the predicted AcrD 
trimeric structure.  Displayed in this view are the suggested ligand entry points 
including the vestibules (violet), binding clefts (teal), central pore (purple), The TolC 
docking domain funnel (orange).  Individual monomers are colored blue, green, and 










Antibiotics recognized by AcrD and MIC 
  
     
Compound Drug Family 
WT MIC 
(µg/ml) 
AcrD expressing MIC 
(µg/ml) Reference 
Tetracyline Tetracyclines 0.39 0.78 14 
Nalidixic Acid Quinolone* 0.78 1.56 14 
Norfloxacin Fluoroquinolone 0.0025 0.05 14 
Fosfomycin Epoxide** 1.56 3.13 14 
Novobiocin aminocoumarin 1.56 6.25 14 
SDS 
anionic 
detergent 50                                     >400 14 
Deoxycholic 
Acid Bile Acid 1.25                                 >40000 14 
Gentamicin aminoglycoside 1.5 6 19 
Amikacin aminoglycoside 0.8 3 19 
     
 *first synthetic quinolone   
 **only member of the epoxide family of antibiotics  
 
Table 4 lists the substrates used for docking studies along with the associated drug 
family.  Additionally, MIC values for the various ligands with and without AcrD 
expression are listed in µg/ml.  The MIC was not tested for Daunorubicin HCL, 
















Substrate binding energy and binding site 
  Amikacin Deoxycholate Daunorubicin Fosfomycin Gentamicin 
  kCal/mol  site kCal/mol  site kCal/mol  site kCal/mol  site kCal/mol  site 
1 -9.0           2* -8.7           2* -10.0         2* -4.7           2* -10.2         2* 
2 -8.6           2 -8.2           1* -9.5           2 -4.6           2 -9.8           1* 
3 -8.1           1* -8.2           2 -9.3           O -4.5           2 -9.6           1 
4 -8.0           1 -8.1           2 -8.2           1* -4.5           2 -9.6           1 
5 -7.9           1 -8.1           O -9.1           1 -4.3           1* -9.6           1 
6 -7.9           2 -8.0           1 -9.1           2 -4.2           1 -9.5           2 
7 -7.6           2 -8.0           2 -9.1           O -4.2           2 -9.3           2 
8 -7.6           2 -8.0           1 -9.1           1 -4.2           2 -9.2           1 
9 -7.5           1 -8.0           2 -8.9           1 -4.1           2 -9.2           1 
 
  Naldixic acid Norfloxacin Novobiocin SDS Tetracycline 
  kCal/mol  site kCal/mol  site kCal/mol  site kCal/mol  site kCal/mol  site 
1 -7.3           2* -8.7           2* -10.1         2* -5.9           1* -10.4         2* 
2 -7.2           2 -8.3           2 -10.3         2 -5.5           1 -9.9           1* 
3 -7.2           2 -8.2           O -9.9           2 -5.3           O -9.3           O 
4 -7.2           1* -8.2           1* -9.8           2 -5.3           2* -9.3           1 
5 -7.1           2 -7.9           2 -9.5           2 -5.3           2 -9.2           2 
6 -7.1           O -7.9           2 -9.4           2 -5.3           2 -9.1           2 
7 -6.9           O -7.9           2 -9.3           1* -5.2           2 -9.0           2 
8 -6.9           2 -7.8           2 -9.2           1 -5.2           2 -9.0           2 
9 -6.9           1 -7.7           1 -9.0           1 -5.2           1 -8.9           1 
 
Table 5 lists the substrates used for docking studies along with the associated 
binding energies and binding site.  Binding sites are indicated as 1, 2, and O for the 
binding cleft site, TolC-docking domain site, and other, respectively.  Those 













Figure 10.  As a result of docking studies using the program Autodock Vina, two 
suggested and distinct binding regions were located.  Illustrated in figure 8A is an 
overlay of the substrates in binding site 1, which is located in the binding cleft 
between subdomain PC1 and PC2.  B) A zoomed in view of binding site 1 highlights 
the multifaceted binding site.  Withing binding site 1, amikacin (yellow), tetracycline 
(pink), SDS (teal), and nalidixic acid (blue-grey) binding to distinct but overlapping 
















Figure 11.  Binding site 1 of AcrD identified using Autodock Vina with displayed 
surface electrostatic potential around docked ligands.  The prevailing features of the 
individual binding sites include charged and hydrophilic surfaces. A) Amikacin 
(yellow) B) Gentamicin (purple) C) Daunorubicin (gray) D) Norfloxacin (white) E) 
Fosfomycin (orange) F) SDS (tan) G) Deoxycholic acid (dark blue) H) Nalidixic acid 
(dark green) I) Novobiocin (Brown) J) Tetracyline (light pink).  Oxygen and nitrogen 
atoms are diplayed as red and blue, respectively. Positive (blue) and negative (red) 






Figure 12    
 
Figure 12. The second binding site suggested from Autodock Vina is highlighted in 
figure 10.  Illustrated in figure 8A is an overlay of the substrates in binding site 2, 
which is located in the region between the porter domain and TolC-docking domain  
B) A zoomed in view of binding site 2 highlights the multifaceted binding site.  
Withing binding site 2, Duanorubicin (orange), tetracycline (pink), nalidixic acid 
(gray), and gentamicin (purple) bind to distinct but overlapping locations.  The image 














Figure 13.  Binding site 2 of AcrD identified using Autodock Vina with displayed 
surface electrostatic potential around docked ligands.  The prevailing features of the 
individual binding sites include charged and hydrophilic surfaces. A) Amikacin 
(yellow) B) Deoxycholic acid (dark blue) C) Daunorubicin (gray) D) Gentamicin 
(purple) E) Fosfomycin (orange) F) Nalidixic acid (dark green) G) Norfloxacin (white) 
H) Novobiocin (Brown) I) SDS (tan) J) Tetracyline (light pink).  Oxygen and nitrogen 
atoms are diplayed as red and blue, respectively. Positive (blue) and negative (red) 











Figure 14. To identify if there were tunnels connecting the binding sites to the 
exterior solvent, Caver was used to generate probably ligand entrance and exit 
pathways.  A) Using the amikacin binding site 1 as a starting point, it was intriguing 
to identify an entrance from the cleft as well as the central cavity.  Furthermore, a 
tunnel can be observed leading to the second binding site and ultimately out of the 
AcrD TolC-docking domain funnel. B) top view of the tunnels generated by caver 
showing the exit pathway of suggested ligands.  Pictures were generated using 
Pymol, whereby AcrD is displayed in trimeric form in green ribbon, while the tunnel 
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Abstract 
 The transcriptional regulators of the TetR family act as chemical sensors to 
monitor the cellular environment in many bacterial species. To perform this function, 
members of the TetR family harbor a diverse ligand-binding domain capable of 
recognizing the same series of compounds as the transporters they regulate. Many 
of the regulators can be induced by a wide array of structurally unrelated 
compounds. Binding of these structurally unrelated ligands, to the regulator, results 
in a conformational change that is transmitted to the DNA-binding region causing the 
repressor to lose its DNA-binding capacity and allowing for the initiation of 
transcription. The multi-drug binding proteins AcrR of Escherichia coli and CmeR 
from Campylobacter jejuni are members of the TetR family of transcriptional 
repressors that regulate the expression of the multidrug resistant efflux pumps 
AcrAB and CmeABC, respectively. To gain insights into the mechanisms of 
transcriptional regulation and how multiple ligands induce the same physiological 
response, we determined the crystal structures of the AcrR and CmeR regulatory 
proteins. In this review, we will summarize the new findings with AcrR and CmeR, 
and discuss the novel features of these two proteins in comparison with other 
regulators in the TetR family.  
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 Bacterial infections are commonly treated with various classes of antibiotics. 
The clinical treatment is necessary for curing infectious diseases, but an unintended 
consequence of the treatment is the selection of bacterial pathogens with elevated 
levels of resistance to antibiotics. Constant emergence and spread of antibiotic 
resistance has become a major threat to the health of humans and animals (1). 
Bacterial organisms utilize multiple mechanisms to combat antibiotics and 
antimicrobial agents. One important mechanism that gives rise to multidrug 
resistance (MDR) is the expression of multidrug efflux transporters that are capable 
of reducing the intracellular concentration of toxic compounds (2-7). The expression 
of these transporters is tightly controlled at the transcriptional level by global and 
local regulators (2). Transcriptional regulators serve as the cellular intermediate 
between chemical stress and response.  In most cases, the regulators recognize the 
same series of compounds as the transporters they regulate (7).  Transcriptional 
activators, belonging to one of three families, including MerR, AraC, and LysR, are 
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able to drive transcription of MDR pumps through their interaction with their cognate 
promoters and RNA polymerase (8, 9).  The global activators SoxS, Rob, and MarA 
(belonging to the AraC family of regulators) in Escherichia coli are able to activate a 
group of 40 promoters (known as the mara/soxs/rob regulon) through their 
interaction with the marbox (10).  Due to variations in affinity between the activators 
and the marbox, each of the 40 promoters in the mara/soxs/rob regulon will respond 
differently to varying levels of the activators and allow for stress specific responses.   
 Local transcriptional regulation of MDR pumps is achieved by the action of 
DNA binding proteins capable modulating expression levels of specific proteins.  In 
bacteria, local transcriptional regulation can involve either one-component or two-
component regulatory systems. Two-component regulatory systems control protein 
expression through the function of a membrane-bound sensor kinase and a 
cytoplasmic response regulator, which is a DNA-binding protein (10-18). The 
membrane-bound kinase is responsible for receiving external signals and 
transmitting the information into the cell by phosphorylating the DNA-binding protein. 
The phosphorylated DNA-binding protein then modulates gene transcription by 
interacting with its cognate DNA. A key feature of two-component regulatory 
systems is the phosphorylation between sensor kinase and response regulator. On 
the other hand, One-component bacterial transcriptional regulators modulate gene 
expression levels using a single two-domain protein where one domain receives 
signals and the other domain binds specific DNA sequences to regulate transcription 
(8, 9, 19). Information flow between the two domains is through conformational 
changes, contrasting the phosphorylation events required in two-component 
systems. Structural analyses revealed that almost 95% of all known prokaryotic 
transcriptional factors employ the helix–turn–helix (HTH) motif to bind their target 
DNAs (9). Prokaryotic transcriptional repressors are classified in families based on 
their functional and sequence similarities and include proteins that belong to the 
TetR, MarR, or LacI family or of repressors (8, 9, 19).  Generally, repressors bind 
their cognate operator region as a dimer to locally inhibit transcription and upon 
ligand induction, the repressor will release from the operator to allow transcription of 
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the adjacent MDR transporter. Members of the TetR family, such as AcrR of E. coli, 
are two-domain proteins and bind a specific inverse repeat (IR) operator site through 
the interaction of their N-terminal HTH motif.  Inducing ligands interact with the 
protein inside a ligand binding pocket located in the C-terminal region of the protein 
which induces a conformational change in the DNA binding region, resulting in the 
repressor releasing from the operator site.  The transcriptional regulation that is 
provided by the activators and repressors creates a tightly controlled cellular 
environment that is able to respond rapidly to various cellular stresses.  Presumably, 
these transcriptional factors act as cytosolic chemical sensors by responding to 
threatening levels of toxic compounds  (8, 9, 19).  
 Naming of the TetR family comes from the most completely characterized 
member of the family, the TetR protein (19).  TetR regulates transcription of the tetA 
gene.  TetA confers resistance to tetracycline by pumping the antibiotic out of the 
bacterial cell (19-23).  Members of the TetR family are defined based on structural, 
sequence, and functional similarities.  Structurally, the TetR repressors are all-helical 
proteins that harbor two distinct domains, a larger C-terminal domain and a smaller 
N-terminal domain (19).  Sequence similarities exist, most notably, in the N-terminal 
domain of the protein, which in all characterized TetR family members is the DNA-
binding domain.  In most cases, the N-terminal domain contains three α helices with 
two of the helices forming the signature HTH motif characterized by this family. Most 
likely due to the varying array of ligands that TetR family members recognize, 
sequence similarities do not exist in the C-terminal ligand-binding domain although 
the crystal structures reveal an overall similar topology among members of the TetR 
family.  It is predicted that the structural similarities in the C-terminal domain can be 
attributed to a common mechanism of ligand induction used by these regulatory 
proteins (19).   
Insights into the function of the TetR family have come from the crystal structures of 
the QacR in various conformations (24, 25).  QacR is a transcriptional regulator that 
represses the transcription of the qacA gene.  QacA is a membrane associated MDR 
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pump of the MFS family of transporters.  Its expression is associated with increased 
resistance levels of Staphylococcus aureus to quaternary ammonium compounds.  
Interestingly, QacR binds to its 28 bp cognate operator site (upstream of QacA) in a 
dimer to DNA ration of 2:1 (25).  The interaction seems to be cooperative, in which 
the binding of one dimer initiates a change in the local DNA structure, altering the 
distance between consecutive major grooves in B-form DNA from 34Å to 37Å, which 
drives the binding of the other dimer.  This DNA-binding mode is in direct contrast to 
that seen for TetR, where a single TetR dimer binds to a 15bp operator sequence.  
In spite of the number of dimers involved in DNA-binding, it seems that the 
interactions of QacR, TetR, and possibly other members of the TetR family bind the 
palindromic operator with a similar mechanism.  In both QacR and TetR, The N-
terminal DNA binding domain consists of 3 α-helices, of which α3, known as the 
recognition helix, makes the most base-specific DNA interactions.  Helices α1 and 
α2 are associated with mainly non-sequence specific interactions to the phosphate 
backbone of the DNA strands. 
 QacR can be induced by a wide array of structurally dissimilar cytotoxic 
compounds.  Many of these ligands, including ethidium bromide, dequalinium, 
rhodamine 6G, malachite green, berberine, crystal violet, proflavin, DB75, DB359, 
pentamidine, and hexamidine have been co-crystallized with QacR to provide 
information of ligand induction and multi-drug recognition (25-28).  Briefly, an 
inducing ligand binds inside the ligand-binding pocket of the C-terminal domain with 
a ratio of one ligand per dimer.  Structurally distinct drugs are recognized inside the 
binding pocket due to the presence of at least two distinct, multi-faceted binding 
sites.  Binding initiates a helix-to-coil transition of α5 and elongates the C-terminal of 
the helix by one turn in one of the two QacR monomers.  This transition relocates α6 
and the tethered DNA-binding domain, increasing the distance between the two 
DNA-binding domains by 11Å (from 37Å to 48Å) compared to the DNA-bound 
structure.  The increased distance between the DNA-binding domains disrupts the 
interactions between QacR and DNA resulting in QacR releasing from its cognate 
operator (29).  Induction of TetR occurs through a mechanism distinct from that 
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observed in QacR. Tetracycline-Mg2+ binding in both monomers causes helix α6 to 
shift creating a β-turn which pushes the loop between helices α6 and α7 closer to 
the inducer.  Contacts are made between tetracycline-Mg2+ and this loop region 
resulting in the movement of helix α6.  Due to van der Waals contacts, the 
movement of α6 drives the movement of helix α4.  Helix α4 acts as a pendulum that 
separates helix α3 and α3´ by 3Å in the ligand-bound conformation which allows 
TetR to release from the operator (19).  The ligand-bound structure of CmeR will be 
discussed later in this review to provide additional information on the C-terminal 
domain and ligand recognition.  It is important to note that, as revealed by the QacR 
and TetR crytstal structures, proteins that are homologous in structure and function 
may utilizize slightly different mechanisms to perform the same function, i.e., 
repression.  Thus, it is critical to understand the regulatory mechanism of other 
members of the TetR family. 
 Understanding the molecular mechanisms of transcriptional regulation is vital 
due to the potential that these regulatory proteins can offer for new drug targets. 
Recently, the crystal structures of AcrR (30) and (31), a transcriptional regulator of 
the AcrAB efflux pump in Escherichia coli, and CmeR (32), a regulator that 
represses the expression of CmeABC in Campylobacter jejuni, have been 
determined. Induction of AcrR is initiated through an interaction of cationic and 
neutral ligands. In contrast, CmeR more favorably recognizes anionic and 
uncharged compounds. In this review we will describe the structural features of 
these two regulatory proteins and discuss the valuable insights that they provide for 
delineating the mechanisms of gene regulation and multidrug recognition by these 
TetR family regulators. The details described in this manuscript will add to the model 
provided by QacR and TetR.  
THE AcrR REGULATOR 
E. coli AcrB is a prototypical multidrug transporter that belongs to the resistance-
nodulation-division (RND) superfamily of MDR pumps (33) and (34). Of all currently 
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characterized multidrug transporters, AcrB possesses the widest range of ligand 
recognition. It is capable of recognizing many structurally dissimilar compounds, 
including most of the currently administered antibiotics, chemotherapeutic agents, 
bile salts, dyes, and detergents (35) and (36). This inner membrane efflux pump 
functions in conjunction with the periplasmic membrane fusion protein, AcrA (37), 
and the outer membrane channel protein, TolC (38), to export a diverse range of 
compounds completely out of the bacterial cell. 
The expression of AcrAB is modulated by the transcriptional regulator AcrR, whose 
open reading frame is located 141 bp upstream of the acrAB operon and is 
transcribed divergently (39). Transcription of the acrR gene gives rise to a 215 
amino acid protein, which shares N-terminal sequence and structural similarities to 
members of the TetR family (19). The signatures of the TetR family of regulators 
include a homologous N-terminal three-helix DNA-binding domain and a diverse C-
terminal ligand-binding domain (19). Experimental evidence suggests that the 24 
base pair palindromic inverted repeat (IR) sequence 
(5′TACATACATTTGTGAATGTATGTA3′), located between the acrR and acrAB 
genes and overlapping with the acrAB promoter, is the target DNA for AcrR (39) and 
(40). It has been demonstrated through fluorescence polarization and gel filtration 
that AcrR binds to this IR as a dimer of dimers, with a dissociation constant (KD) of 
20.2 nM (30) and (40). This suggests that the binding of AcrR to its IR resembles 
that of QacR, which binds a 28 bp IR1 sequence as a dimer of dimers, but is distinct 
from many other members of the TetR family where the interaction consists of a 
dimer bound to an  15 bp IR (19), (41), (42) and (43). The diverse C-terminal 
region of the TetR family of regulators possesses unique sequences, which allows 
different regulators in the family to accommodate specific sets of inducing ligands. 
Upon ligand binding, the AcrR regulator is presumed to dissociate from its target 
DNA to allow the expression of the AcrAB efflux complex which, in turn, protects the 
bacterial cell from toxic substances. 
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Recent studies indicate that AcrR interacts with the same set of antimicrobial agents 
as AcrB with strikingly similar affinities (40) and (44). Su et al. (40) demonstrated 
that AcrR binds ethidium bromide (Et), proflavin (Pf), and rhodamine 6G (R6G) with 
dissociation constants of 4.2, 10.1, and 10.7 µM (40); while the KD values for AcrB 
with these ligands are 8.7, 14.5, and 5.5 µM (44), respectively. These affinities also 
coincide with those observed for QacR (45), BmrR (46), and TtgV (47). The KDs in 
this range may be optimal to initiate the expression of MDR pumps while the 
antibiotic concentration is at the sub-inhibitory level. Each AcrR monomer binds an 
inducing ligand, and thus a dimer can accommodate two identical molecules. 
Fluorescence polarization assays also suggest that AcrR binds many structurally 
unrelated ligands in distinct but possibly overlapping binding sites(40). For instance, 
Et-saturated AcrR can accommodate Pf with equal affinity as apo-AcrR while Et and 
R6G seem to be competing for the same binding site (40). The 1:1 ligand-to-
monomeric AcrR stoichiometry is similar to that of TetR (41), but distinct from the 1:2 
ligand-to-monomer ratio of QacR (42). AcrR is unique in that its ligand binding mode 
is similar to TetR while its mode of DNA-binding is related to that of QacR. 
Exploration of the AcrR induction may provide us with new insight into the 
mechanisms that the TetR family utilizes to regulate genes. 
 Crystal structure of AcrR in space group of P2221: The crystal structure of 
AcrR in space group P2221 (30) is illustrated in Fig. 1a. It reveals a dimeric protein 
composed almost entirely of α-helices with an overall architecture similar to 
members of the TetR family, including TetR (42) and (48), QacR (41) and (49), EthR 
(50) and (51), CprB (52), CmeR (32), ActR (53), HapR (54), and IcaR (55). Each 
subunit in the dimer comprises nine helices (α1 to α9 and α1′ to α9′). Of this two-
domain protein, helices α1 to α3 make up the N-terminal DNA binding domain while 
the larger C-terminal ligand-binding domain consists of helices α4 through α9. A high 
degree of conservation exists in the DNA-binding region among members of the 
TetR family of transcriptional regulators (30). This can be attributed to the critical role 
of specific amino acids in contacting the phosphate backbone of the DNA strand and 
to the overall function of the TetR family proteins in transcriptional repression. When 
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the N-terminal domain of AcrR (amino acids 12–62) is aligned against QacR and 
CmeR, 43% amino acid identity is observed in both cases (30). Superimposition of 
this domain to QacR reveals a very similar overall structure, which is reflected by an 
overall rmsd of 1.2 Å calculated over the Cα atoms. 
 As the DNA-binding mode of AcrR is expected to be similar to that of QacR, a 
speculative model of DNA-bound AcrR (Fig. 1b) was generated by aligning its 
domains to those of DNA-bound QacR (30). This model suggests that R45, G46, 
Y49, W50, H51 and K55 are important for IR binding. Among these residues, R45 
interacts directly with four different bases of the DNA, confirming its critical role for 
IR recognition. Therefore, it is not surprising that a recent sampling indicated six of 
36 isolated fluoroquinolone-resistant E. coli strains had a mutation at codon 45 
(Arg → Cys), and all six R45C mutants showed evaluated resistance to multiple 
antibiotics (56). 
 The C-terminal regulatory domain of AcrR comprises six helices, including 
helices α4 through α9. Helices α8 and α9 form the majority of the dimerization 
surface with small contributions from helices α6 and α7, creating a 
2002 Å2/monomer buried, mostly hydrophobic contact region (30). Owing to 
differences in inducing ligands and varying specificity, the C-terminal domain of AcrR 
possesses little sequence homology to other members of the TetR family of 
transcription regulators. It is intriguing that superposition of AcrR (30), QacR (49), 
and CmeR (32) reveals significant topological similarities in the C-terminal domains. 
This, in part, may be attributed to a similar functional role that the C-terminal 
domains play in recognizing inducing ligands and transmitting the signal to the N-
terminal DNA-binding regions. Like other members of the TetR family, a large 
internal cavity, with a total volume of 350 Å3 is formed in the C-terminal region of 
AcrR (Fig. 1c). This cavity, surrounded by helices α4 through α8 of each monomer, 
is predicted to form the multidrug-binding pocket in AcrR (30). It should be noted that 
the C-terminal domain of apo-QacR does not have a ligand-binding cavity. A unique 
characteristic of AcrR is the presence of three openings to the drug-binding pocket. 
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Two of the openings are located at the front and side surfaces of each monomer and 
appear to be orthogonal to each other. The loop between helices α4a and α4b 
contributes to form part of the openings. The other opening is located at the dimer 
interface and is partially blocked by the loop between helices α8′ and α9′ from the 
second subunit. It is likely that drug molecules may enter AcrR through the loop 
region between helices α4a and α4b. 
Docking of ligands into the AcrR structure suggested that the large cavity created by 
helices α4 to α8 could accommodate different drugs, including Et, Pf and 
ciprofloxacin (Cip) (30). In each case, the bound drug was completely buried in the 
AcrR molecule, and strong interaction was observed between bound drug and the 
regulator. Predictions also indicated that the binding sites for Et, Pf and Cip are 
distinct, but partially overlapped in each monomer of AcrR. Fig. 1d depicts the multi-
drug binding site formed by the C-terminal domain of the regulator. The extensive 
binding pocket, which is created by helices α4 through α8, is mostly hydrophobic in 
nature, with W63, I70 and F114 predicted to make important hydrophobic contacts 
with the inducing ligands. In addition to these hydrophobic interactions, residues E67 
and Q130 are predicted to make electrostatic interactions with bound drug to secure 
the binding. Among these amino acids, E67 seems to be of particular importance for 
drug recognition. It was found that a mutation of this residue by an alanine, E67A, 
abolished the binding of Pf, Et and R6G to the regulator (30). 
 Crystal structure of AcrR in space group of P31: Recently, a new crystal 
structure of AcrR with space group P31 (31), which is distinct from the P2221 space 
group structure, was determined. A comparison of these two structures reveals 
considerable conformational changes at both the N-terminal and C-terminal regions, 
suggesting that these two structures represent different conformational states of 
AcrR. These crystal structures have provided valuable insight into the mechanisms 
of ligand binding and AcrR regulation. 
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 The overall structure of AcrR with the space group P31 is quite similar to the 
P2221 space group structure. A detailed comparison, however, reveals a significant 
change in conformation at the N-terminal DNA-binding domain. This change results 
in an overall rmsd of 2.8 Å calculated over the Cα atoms at the N-terminal domains 
(residues 7–65), in contrast to the < 0.7 Å rmsd of the C-terminal domains (residues 
73–210) (13). Fig. 2 illustrates a superposition of these two AcrR structures using 
the program ESCET 57). 
 Conformational changes between the P31 and P2221 structures seem to be 
predominantly rigid-body translation and rotation at the N-terminal domain. These 
movements lead to a downward shift of the entire N-terminal DNA-binding domain of 
the P31 structure (with respect to the orientation shown in Fig. 1a) by 2.6 Å, and a 
rotation of 10° towards the subunit interface of the  dimer when compared with that of 
the structure of P2221 (Fig. 2). As a consequence of these movements, the two N-
terminal domains of the AcrR dimer, in the P31 structure, move closer to each other 
by approximately 2 Å. The center-to-center distance between recognition helices α3 
and α3′ (as measured by the distance between Cα atoms of Y49 and Y49′) 
decreases from 42 Å in the P2221 structure to 39 Å in the P31 structure (31). To bind 
two consecutive major grooves of B-DNA, the center-to-center distance has to be 
 34 Å. This distance is thought to increase upon drug binding, which in turn inhibits 
the binding of the regulator to its operator DNA. With the observed center-to-center 
distances in the crystal structures, it is likely that the conformation of the DNA-bound 
form of AcrR is more similar to theP31 structure, while its drug-bound form is more 
closely related to the P2221 structure. In addition to these differences, R45, an N-
terminal amino acid previously identified to be critical for DNA binding and AcrR 
regulation (56), undergoes a significant conformational change. The Cα–Cα distance 
between R45 and R45′ decreases from 40 Å in the P2221 structure to 35 Å in the 
P31 structure (31). 
 When examining the C-terminal domain, the most striking conformational 
change involves the amino acid E67. This residue may act as a molecular switch 
 125
that drives the change of conformations throughout the AcrR molecule. 
Superimposition of the two AcrR structures reveals that the Cα atom of E67 shifts by 
4.2 Å. This shift initiates considerable changes in the C-terminal domain of AcrR, 
including helix α4a shifting towards the N-terminal domain by 2.3 Å and a local 
unwinding of the N-terminal end of helix α6 which shortens the helix by one turn. The 
local unwinding and overall change result in the disruption of the hydrogen bonded 
network connecting the N- and C-terminal domains. In the P2221 structure, it was 
found that R106 is H-bonded with E67 in the drug binding site, and the C-terminal 
domain residue R105 is H-bonded with the N-terminal domain residues Q14 and 
D18, respectively (Fig. 1a) (30) and (31). These H-bonds are missing in the P31 
structure. 
Based on the P31 and P2221 structures of AcrR, we suspect that the changes in 
conformation of the N-terminal DNA-binding and C-terminal drug-binding domains of 
AcrR are cooperative, due to the formation of H-bonds at the interface between 
these two domains (Fig. 1a). In the DNA-bound form of AcrR, the structure of the 
regulator may be closer to the P31 structure. Thus, the side chain of E67 may point 
outside the drug-binding pocket, exposed to the solvent. Drug-binding within the C-
terminal domain may induce structural changes resulting in a conformation more 
closely related to the P2221 structure, in which the side chain of E67 flips into the 
interior of the hydrophobic core. This change may also be accompanied by the 
formation of new H-bonds between E67 and R106, R105 and Q14, and R105 and 
D18. The crystal structures of both DNA-bound and drug-bound AcrR would be 
necessary to confirm the change in conformation upon DNA and drug binding. 
 Crystallization of AcrR-IR: In efforts to further understand the 
conformational changes that take place throughout AcrR, crystallization attempts 
were made with C-6XHis AcrR and Double stranded DNA helices of various lengths 
(IR1-IR4, table X) (Integrated DNA technologies).  Initially, C-6XHis AcrR was 
purified as outlined previously (12).  The purified C-6XHis AcrR protein was mixed 
with the indicated IR fragment in a 4:1 molar ratio and subsequently passed through 
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a G-200 gel fitration column pre equilibrated with buffer.  Fractions were collected 
and analyzed with 15% SDS–PAGE stained with Coomassie Brilliant Blue to detect 
AcrR.  Furthermore, a 1% agarose gel was used on fractions containing AcrR to 
further detect the presence of DNA.  Those fractions with AcrR-IR were pooled and 
concentrated to 20 mg/ml using a YM-10 Centriprep concentrator. A gel-mobility-
shift assay was performed to further confirm AcrR-IR interaction.     
 The full-length C-6XHis AcrR protein was crystallized in 24-well plates using 
the hanging drop vapor-diffusion method crystals.  An ambient temperature of 25ºC 
was maintained throughout crystal growth.  Initial crystallization trials were 
performed using Hampton reagents, including Crystal Screen 1, 2, and Lite. With 
little success, subsequent screens were performed by mixing various polyethylene 
glycols (PEGs ranging from PEG 200 to PEG 20000) with different buffers (between 
pH 3.5 and pH 9.5), salts, and additives.  Following extensive screening, a mother 
solution containing PEG 6000 14%, .3M CaCl2, .02M MgCl2, .1M NaMES (6.5), 
Glycerol 5%, and 20 mM dithiothreitol produced the highest diffracting crystal (Figure 
3).  With this condition, the four distinct IR strands were screened with the IR2- C-
6XHis AcrD complex crystals diffracting to 3.2 Å (Figure 4).     
 For data collection, a single native crystal of IR2- C-6XHis AcrD was flash-
cooled in a cryoprotectant solution containing the mother solution plus 25% glycerol 
at 100 K.  The glycerol concentration was gradually increased to 25% by 5% 
increments.  The diffracted anisotropically to a resolution of 3.2 Å. Fig. X depicts one 
of the diffraction images of the native crystal. Diffraction data sets were obtained 
from the native IR2- C-6XHis AcrD crystals at the Advanced Photon Source (APS, 
beamline 24IDC) at cryogenic temperature (100 K) using an ADSC Quantum 315 
CCD-based detector. The beam size was 50 X 20 mm.  
THE CmeR REGULATOR 
 Campylobacter jejuni is the leading cause of food-borne enteritis to humans in 
the USA as well as other developed countries (58). C. jejuni is able to infect animal 
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hosts, and colonize the intestinal tracts of these animals. To withstand the various 
deleterious conditions both in vitro and in vivo, this Gram-negative microorganism 
harbors 13 putative MDR transporter genes (according to the genomic sequence of 
NCTC 11168) that may be used to extrude antimicrobial compounds that 
Campylobacter may encounter in the intestinal tract (59) and (60). Some of these 
multidrug transporters have been linked to the intrinsic and acquired resistance of 
Campylobacter to various antibiotics (61). Currently, CmeABC and CmeDEF 
(belonging to the RND-family of MDR proteins) are the only two, of the 13 predicted, 
antibiotic-resistance transporters that have been functionally characterized in this 
Gram-negative microorganism (62-65). 
 A primary contributor to antibiotic resistance in C. jejuni is the CmeABC efflux 
system. CmeABC is a tripartate RND efflux transporter (63). It consists of an inner 
membrane efflux pump, CmeB, a periplasmic membrane fusion protein, CmeA, and 
an outer membrane channel, CmeC. Together, these three proteins effectively 
mediate the extrusion of commonly used antibiotics, metal ions, and lipophilic 
compounds out of the bacterial cell (63-67). Importantly, CmeABC is a key player in 
C. jejuni for resistance to bile salts, which are ubiquitously present in the intestinal 
tract. CmeABC deletion mutants are unable to colonize in the intestinal tract of 
chickens (68), indicating the essential role of CmeABC in adapting to the in vivo 
environment. Expression of the CmeABC efflux complex is inducible by bile salts 
(67) and potentially by other unidentified ligands. Understanding the regulation of 
cmeABC is an important step in the elucidation of the mechanism of multi-drug 
extrusion in Campylobacter. 
 Transcription of cmeABC is controlled by the transcriptional regulator CmeR 
(69). The gene for cmeR is located immediately upstream of cmeABC and encodes 
a 210 amino acid protein that shares N-terminal sequence and structural similarities 
to members of the TetR family of transcriptional repressors (19) and (70). CmeR is a 
two-domain protein with an N-terminal DNA-binding region and a predicted C-
terminal ligand-binding domain. The 16 bp IR sequence, 
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5′TGTAATAAATATTACA3′, located between cmeR and cmeABC is shown to be 
the operator site of CmeR binding and transcriptional repression (69). 
Transcriptional repressors of the TetR family bind their IR operator sites which 
generally overlap the promoter sequences of the regulated genes. This interaction 
inhibits RNA-polymerase from binding or blocks the transcriptional initiation event to 
repress gene expression. Alterations that affect CmeR–operator binding, including 
deletions of CmeR and single nucleotide mutations in the operator site, releases the 
repression of CmeR and results in overexpression of CmeABC (69) and (71). In 
addition, CmeR–DNA interactions are inhibited when inducing ligands, such as bile 
salts, interact with CmeR and cause a conformational change in the protein that 
renders it unable to bind to its operator DNA. Guo et al. (72) used DNA microarrays 
and real-time quantitative reverse transcription-PCR to analyze the regulatory 
network of cmeR. The results showed that in addition to repressing the transcription 
of cmeABC, CmeR functions as a pleiotropic regulator and modulates the 
expression of at least 28 other genes in C. jejuni (72). The array of genes regulated 
by CmeR outlines the important role this regulator plays in the adaptive response to 
the intestinal environment. 
 Crystal structure of CmeR: Recently, the crystal structure of CmeR has 
been determined (Fig. 5a) (32). This work revealed novel structural features of a 
TetR family regulator, and has brought new insights into the mechanisms of 
transcriptional regulation and ligand recognition. Like AcrR, CmeR is a dimeric two-
domain molecule with an entirely helical architecture with similar topology to other 
members of the TetR family. Distinct from the other members of the TetR family, 
CmeR exhibits a unique crystal structure that lacks the α3 helix (replaced by a 
random coil) which is involved in DNA recognition. Along with this unique 
characteristic, a large center-to-center distance (54 Å as measured by the 
separation between Cα atoms of Y51 and Y51′ from the other subunit) was observed 
between the two N-termini of the dimer. In addition, a large flexible ligand-binding 
pocket is found to form in the C-terminal domain of CmeR. Each monomer forms a 
20 Å long tunnel-like cavity in the ligand-binding domain of CmeR and occupies a 
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volume of about 1000 Å3 (Fig. 5b), which is approximately three times of that of 
AcrR. As CmeR recognizes anionic and neutral ligands, the structure offers the first 
glance on how anionic and uncharged ligands are bound by a regulator from the 
TetR family. 
 The crystal structure of the dimeric CmeR regulator is shown in Fig. 5a. This 
structure revealed that each subunit of CmeR is composed of nine α helices, in 
which the short recognition α3 helix, presumably formed by residues 47–53, is 
missing (32). To facilitate comparisons with other TetR members, α3 was excluded 
from the numbering of the α-helical segments. Thus, helices α1, α2, and the random 
loop (residues 47–53) form the N-terminal DNA-binding domain, and helices α4 
through α10 form the C-terminal ligand-binding domain. 
 The N-terminal DNA-binding domain of CmeR exhibits several distinct 
features compared with the rest of the TetR family members. First, helix α1, 
consisting of 23 residues, is relatively long among all structurally known TetR 
regulators. For example, the corresponding helices α1 in QacR (49), TetR (48), and 
EthR (50) are composed of only 16, 13, and 17 residues, respectively. As mentioned 
above, the structure of CmeR does not consist of the third N-terminal helix. This is, 
perhaps, the most striking feature that makes CmeR distinct from the other TetR 
family members. To date, the CmeR regulator is the only observed case of a random 
coil replacing helix α3 in a TetR family member. Presumably, the TetR regulators 
possess a HTH DNA-binding motif formed by helices α2 and α3. Owing to its 
important role in recognizing target DNA, helix α3 is named the “recognition helix” 
(19). Thus, we reasoned that the flexible coil might need to transform into a helix 
when the regulator binds target DNA (Fig. 5c). Since CmeR is a pleiotropic regulator 
of a large set of genes and is predicted to bind multiple operator sites, with many of 
those not being of the consensus IR sequence located in the promoter region of 
cmeABC (72), it could be postulated that the flexibility of the DNA-binding domain 
permits CmeR to recognize multiple cognate DNA sites. 
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 One other unique feature of the CmeR structure is its large center-to-center 
distance between the two N-termini of the dimer. This center-to-center distance 
(according to the separation between Cα atoms of Y51 and Y51′) was measured to 
be 54 Å (32). The corresponding distances are 39 Å and 35 Å in the apo forms of 
QacR (49) and TetR (73). These center-to-center distances increase upon ligand 
binding. For the ligand-bound dimers of QacR (49), TetR (48), EthR (51), and YfiR 
(74) these distances become 41 Å, 38 Å, 52 Å and 54 Å, respectively. Thus, the 
relatively large center-to-center distance observed for CmeR reflected the fact that 
CmeR was liganded (32). Indeed, the crystal structure indicated that a glycerol 
molecule was bound in each subunit of the CmeR dimer (Fig. 5a) (32). 
 The C-terminal domain of CmeR consists of helices α4 through α10, with 
helices α4, α5, α7, α8 and α10 forming an anti-parallel five-helix bundle. In view of 
the crystal structure, helices α6, α8, α9 and α10 are involved in the formation of the 
dimer. Dimerization occurs mainly by couplings between pairs of helices (α6 and α9′, 
α8 and α10′, and their identical counter pairs). A surface area of 1950 Å2 per 
monomer is buried in the contact region of the dimer (32). The interaction surface is 
mostly hydrophobic in character. The C-terminal domain of CmeR is distinct in that 
helix, α9, which is between the two anti-parallel helices α8 and α10, deviates from 
the direction of α8 by 40°. Thus, helix α9 bends toward the next subunit of the dimer, 
interacting with α6′ and α7′a to secure interaction between the dimer. 
 The C-terminal domain forms a large tunnel-like cavity in each subunit of 
CmeR. This tunnel, surrounded by mostly hydrophobic residues of helices α4–α9, 
opens horizontally from the front to the back of each protomer. The length of this 
tunnel is approximately 20 Å. Helices α7 and α8 from one subunit, and α9′ from the 
other subunit of the regulator make the entrance of the tunnel. Helices α4–α6, 
however, contribute to form the end of this hydrophobic tunnel. Each hydrophobic 
tunnel, occupying a volume of about 1000 Å3, spans horizontally across the C-
terminal domain and can be seen through from the front to the back of the dimer 
without obstruction. This unique feature, not found in other structures of the TetR 
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family of regulators, highlights the flexibility of the CmeR regulator (32). As indicated 
above, the crystal structure of CmeR revealed the presence of a glycerol molecule 
inside this large ligand-binding tunnel. Glycerol binds identically in each subunit, as 
indicated by the crystallographic two-fold symmetry of the CmeR dimer (32). This 
ligand-binding mode is different from that of QacR in which one dimer of QacR binds 
one drug (49), but similar to that of TetR, which interacts with tetracycline in a 
manner of 1:1 monomer-to-drug molar ratio (48). The volume of the ligand-binding 
tunnel of CmeR is large enough to accommodate a few of the ligand molecules. 
Additional water molecules fill the portion of the large tunnel that is unoccupied by 
ligand. The structure suggests that CmeR might be able to bind more than one drug 
molecule at a time, or possibly accommodate a significantly larger ligand that spans 
across the entire binding tunnel. Indeed, a docking study showed that the 
hydrophobic tunnel of CmeR should be able to accommodate large, negatively 
charged bile acid molecules, such as taurocholate and cholate (32). Fig. 5d 
demonstrates the extensive predicted ligand-binding site, and important residues 
that are critical for ligand recognition in the tunnel. The bound bile acids are 
predicted to anchor to several hydrophobic, polar and positively charged residues, 
including H72, F99, F103, F137, S138, Y139, V163, C166, T167, K170 and H174. 
These anionic ligands were predicted to span almost the entire length of the ligand-
binding tunnel of the regulator, respectively. The flexibility of this large ligand-binding 
tunnel suggests that CmeR is a multiple ligand binding protein (32). 
CONCLUSIONS AND PERSPECTIVES 
In the past decade, several crystal structures of the TetR family of regulators have 
been determined. These structures have allowed us to glance through the 
phenomenon of multidrug recognition. In particular, the structures of six QacR–drug 
complexes (48) and QacR simultaneously bound by two drugs (75) revealed the 
presence of multiple binding sites within an extensive, sizeable drug-binding pocket 
of the regulator. It is quite conclusive that QacR recognizes a combination of drugs, 
both positively charged and neutral, by using multiple, proximal and distinct drug 
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binding sites. Based on the structures of AcrR, it is very likely this regulator employs 
a similar mechanism that QacR uses for drug binding. It is expected that AcrR binds 
cationic and neutral charged drugs by utilizing aromatic and acidic residues. The 
predicted drug-binding pocket at the C-terminal domain of AcrR indeed consists of 
multiple hydrophobic and aromatic residues with a buried glutamate critical for drug 
binding. A similar drug-binding pocket has been found in BmrR in which multiple 
aromatic side chains are stacked against the positively charged 
tetraphenylphosphonium ligand (76). The charge of the bound ligand was further 
neutralized by negatively charged acidic residue(s) in the ligand-binding site (49, 75-
77). 
In the case of CmeR, CmeR tends to bind anionic and uncharged ligands, including 
the large bile salts such as cholate and deoxycholate. Based on the crystal structure, 
the mechanisms by which CmeR employs to recognize anionic compounds seem to 
be an “analog” to those of QacR and AcrR. The C-terminal domain of CmeR forms a 
large, sizable drug-binding tunnel that occupies a volume of 1000 Å3 (32). This 
tunnel, possibly consisting of multiple mini-pockets for different ligands, is rich in 
aromatic residues and contains three positively charged amino acids (two histidines 
and one lysine). It is very likely that CmeR uses these positively charged residues, in 
an analogous manner, to recognize negatively charged ligands. 
The structure of CmeR indicated that anionic bile acids, such as cholate and 
deoxycholate, are probably bound in the large hydrophobic tunnel via hydrophobic 
and aromatic stacking interactions. These bound ligands presumably are further 
neutralized by one or more of the positively charge residues, including lysine and 
histidine, in the binding tunnel to secure the binding. This binding mode is quite 
different from that shown in the MarR-salicylate structure in which the anionic 
salicylates are not bound in hydrophobic pockets, but in openings that are exposed 
to solvent (78). Although the binding sites for salicylates possess positively charged 
arginines to neutralize the formal negative charge of salicylates, they do not contain 
any aromatic residue. Thus, the crystal structures of the CmeR–ligand complex and 
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other regulatory proteins bound by anionic ligands are needed to provide a clearer 
understanding on the mechanisms of anionic ligand recognition utilized by these 
regulators. 
CmeR possesses a very unique structural feature at the N-terminal domain, in which 
it does not have the recognition α3 helix. It is not yet known if this unique feature is 
related to its function. CmeR acts as a pleiotropic regulator and modulates the 
expression of many other genes in C. jejuni. As helix α3 is critical for contacting with 
target DNA, the lack of helix α3 in the structure of CmeR could explain the fact that 
CmeR binds its IR in a much weaker fashion when compared with the binding of 
TetR, QacR and AcrR to their target DNAs (19). Detailed interaction between CmeR 
and target DNA awaits the atomic resolution structure of the CmeR–IR complex. 
 Knowledge of how these proteins are able to recognize multiple, diverse 
ligands may prove beneficial to understanding how the MDR transporters, 
themselves, bind and extrude these deleterious compounds.  Structural comparisons 
from the ligand bound conformations of AcrB (79, 80) with that of QacR (24, 26-29) 
and the predicted drug bound AcrR (30, 31) conformations reveal similar 
mechanisms of ligand recognition.  Much like AcrR and QacR, AcrB interacts with its 
various ligands inside a large central cavity utilizing an overlapping but distinct 
subset of residues for each of the specific ligands to create a multi-faceted binding 
domain.  The major contributors to protein-ligand interactions in AcrB, AcrR, and 
QacR seem to be aromatic residues providing hydrophobic interactions that secure 
the drug molecule in the binding cavity.  QacR and AcrR require electrostatic 
interactions from negatively charged amino acids to neutralize the positive charges 
on the inducing ligands, while neutralization of the positive charges is not necessary 
for the interaction of these ligands with AcrB.  These binding variations may be due 
to the functional differences of these proteins, in which tight electrostatic interactions 
may hinder the ability of AcrB to expel the compounds at an adequate rate, but are 
beneficial to the binding of the transcriptional repressors.  Although similar features 
exist for multi-drug recognition between the regulator and protein pump, multidrug 
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binding is not identical and must be further explored.  At this time, it is critical to 
determine the structure of other multi-drug binding proteins to reveal specific 
features that are required for ligand recognition and to determine if other TetR family 
regulators have similar drug binding patterns as the proteins they regulate.  
With the structures of AcrR, CmeR, and other multidrug binding proteins, Information 
may be extracted from the structural data that will aid in the rational design of drugs 
which are able to inhibit the function of MDR pumps and combat multidrug resistant 
bacteria.  Multidrug export may be blocked in two distinct fashions.  First, an anti-
MDR drug can be manufactured that directly blocks the pumping mechanism.  This 
direct method will inhibit drug export by either blocking the opening to the central 
cavity and not allowing the drug to enter, allosterically inhibiting ligand binding by 
interfering with the binding site, or by holding the protein in single conformation that 
disrupts drug expulsion.  If multidrug binding sites are similar between the regulator 
and MDR pump then information garnered from the repressor can be utilized in the 
design of some of these drugs.  A second, indirect method of drug design would 
inhibit multidrug transport by blocking the expression of the MDR pumps.  This can 
be achieved by not allowing derepression of the TetR regulator by either blocking 
the opening to the binding cavity or by blocking the ligand binding event.  The latter 
would require a drug designed to bind within the cavity that does not induce the 
conformational change required for operator release.  A plausible design to inhibit 
AcrR-operator is a drug that binds and overlaps both predicted binding sites but 
features a negatively charged group that blocks the amino acid E67 from 
transitioning to the binding cavity.  Blocking the transition of E67, which is the switch 
that drives operator release, would allow AcrR to maintain in its state of 
transcriptional repression and block polymerase binding to inhibit expression of AcrB 
(30, 31).  With the advent of these new drugs, other antibacterial agents that have 
previously been deemed ineffective may once again become a useful treatment to 
fight bacterial infections.      
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Figure d  
Fig.1. Structure of AcrR. (a) Crystal structure of AcrR in space group of P2221. 
Ribbon diagram of the AcrR homodimer generated by crystallographic symmetry. 
The hydrogen bonds at the interface between the C-terminal and N-terminal 
domains of each subunit AcrR, shown as dotted lines in the left subunit, are between 
Glu67 and Arg106; between Gln14 and Arg105; and between Asp18 and Arg105. 
These H-bonds are absent in the P31 structure. (b) Speculative model of AcrR in its 
DNA-bound form. The N- and C-terminal domains of the ligand-bound dimeric AcrR 
were individually aligned with those of the DNA-bound QacR (1JT0) to generate the 
DNA-bound form of AcrR. The model of the 24 bp IR model is shown as a space-
filling model. It is expected that two dimers of AcrR (in orange and deep olive 
ribbons) bind one double-stranded IR. (c) Electrostatic surface potential of one 
subunit of AcrR. This view shows the large cavity spanning from the side surface 
(front) to the subunit interface (back) of the C-terminal domain of one subunit of 
AcrR. Blue (+15 kBT) and red (−15 kBT) indicate the positively and negatively 
charged areas, respectively, of the protein. (d) Binding site prediction for AcrR. 
Residues, W63, E67, I70, F114 and Q130, which are predicted to be important for 






Fig. 2. Structural comparison of the P31 and P2221 structures of AcrR. 
Superimposition of the dimeric AcrR structures was performed using the program 
ESCET (green, P31 structure; orange, P2221 structure). Residue E67 in each 



















Figure 3.  AcrR-IR2 crystal in a mother solution containing PEG6000, as the 
precipitant.  Resolution extended to approximatel 3.2Å (Fig. 5) although crystal 

























Figure 4   
 
Figure 5.  Representative diffraction pattern of AcrR-IR2 crystals with resolution 
reaching 3.2Å.  A synchrotron light source was utilized at the Argonne National 


































Fig. 5. Structure of CmeR. (a) Crystal structure of CmeR. Ribbon diagram of the 
ligand bound CmeR homodimer generated by crystallographic symmetry. The bound 
glycerols were shown as space-filling models. (b) Electrostatic surface potential of 
one subunit of CmeR. This view shows the long tunnel spanning through the C-
terminal domain of CmeR. Blue (+15 kBT) and red (−15 kBT) indicate the positively 
and negatively charged areas, respectively, of the protein. (c) Speculative model of 
CmeR in its DNA-bound form. The N- and Cterminal domains of the ligand-bound 
dimeric CmeR were individually aligned with those of the DNA-bound QacR (1JT0) 
to generate the DNA-bound form of CmeR. The two DNA recognition α3 helices 
(red) in the dimer of CmeR are included in the model. Each helix of the bound DNA 
is shown in orange thread. (d) Binding site prediction for CmeR. Residues, H72, 
F99, F103, F137, S138, Y139, L163, C166, T167, K170 and H174, which are 
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 The TetR family of transcriptional regulators are diverse proteins capable of 
sensing and responding to various structurally dissimilar antimicrobial agents. Upon 
detecting these agents, the regulators allow transcription of an appropriate array of 
resistance markers to counteract the deleterious compounds. Campylobacter jejuni 
CmeR is a pleiotropic regulator of multiple proteins, including the membrane-bound 
multidrug efflux transporter CmeABC. CmeR represses the expression of CmeABC 
and is induced by bile acids, which are also substrates of the CmeABC tripartite 
pump. The multiligand-binding pocket of CmeR has been shown to be very 
extensive and consists of several positively charged and multiple aromatic amino 
acids. Here we describe the crystal structures of CmeR in complexes with the bile 
acids, taurocholate and cholate. 
These structures reveal how negatively charged compounds are bound by a TetR 
family member. Taurocholate and cholate are structurally similar, differing by only 
the anionic charged group. However, these two bile acids bind distinctly in the 
binding tunnel. Cholate spans the novel bile acid binding-site adjacent to and without 
overlapping with the previously determined glycerol-binding site. The negatively 
charged pentanoate group of cholate is neutralized by a charge-charge interaction. 
Unlike chloate, taurocholate binds in an anti-parallel orientation and its anionic 
aminoethanesulfonate moiety interacts with polar side chains to neutralize the formal 
negative charge. These structures underscore the promiscuity of the multifaceted 
binding pocket of CmeR. 
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INTRODUCTION 
 The ability of bacteria to adapt and respond to diverse classes of toxic 
compounds allows these organisms to survive in a variety of harsh environments. 
Campylobacter jejuni, the leading bacterial cause of food-borne enteritis in humans, 
is able to flourish in the intestinal mucosa due to its rapid response to bile acid 
intrusion (1, 2). This Gram-negative enteric pathogen has become increasingly 
resistant to common antibacterial agents encountered during the course of an 
infection. The intrinsic and acquired resistance to these diverse classes of toxic 
chemicals is facilitated through the expression of multidrug resistant (MDR) efflux 
transporters. The MDR pumps are capable of effectively lowering the intracellular 
concentration, thus compromising the effectiveness of the antibacterial compounds. 
Based on the genomic sequence of C. jejuni NCTC 11168, this organism harbors 13 
putative MDR transporters that belong to five different classes, including the ATP-
binding cassette (ABC) superfamily, the resistancenodulation- division (RND) family, 
the multidrug and toxic compound extrusion (MATE) family, the major facilitator (MF) 
superfamily, and the small multidrug resistance (SMR) family (3, 4). Currently, only 
two RND efflux transporters, CmeABC and CmeDEF, in C. jejuni have been 
functionally characterized (5-8).  
 Among these five different families of transporters, members of the RND 
superfamily exhibit the broadest range of substrate specificity and are usually the 
primary contributor to the intrinsic multidrug resistance associated with Gram-
negative organisms (9, 10). CmeB, a prototypical RND family transporter, is the 
major efflux transporter in C. jejuni. This inner membrane efflux pump functions as a 
tripartite protein complex along with a periplasmic membrane fusion protein, CmeA, 
and an outer membrane channel, CmeC, to extrude deleterious compounds from the 
bacterial cell (6). The CmeABC complex recognizes and protects C. jejuni from a 
diverse set of antibacterial compounds, including commonly used antibiotics, metal 
ions, and lipophilic compounds (2, 6-8, 11). In addition, CmeABC plays a major role 
in conferring resistance to bile acids, which are ubiquitously present in the intestinal 
tract (2, 12). It has been reported that mutant strains of C. jejuni lacking a functional 
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CmeABC are unable to colonize in the intestinal tract of chickens (2). The essential 
role of CmeABC for the growth of C. jejuni in the intestinal mucosa highlights the 
importance of this efflux complex to the pathogenicity of the bacterium.  
 The expression of CmeABC is controlled by the transcriptional regulator 
CmeR, whose open reading frame is located immediately upstream of the cmeABC 
operon and is transcribed divergently (13). Transcription of the cmeR gene gives rise 
to a 210 amino acid protein, which shares N-terminal sequence and structural 
similarities to members of the TetR family (14, 15). CmeR is a two-domain protein 
with an N-terminal DNAbinding motif and a C-terminal multiligand-binding domain. 
Experimental evidence suggests that the 16 base pair palindromic inverted repeat 
(IR) sequence, 5′TGTAATAAATATTACA3′, located between cmeR and cmeABC is 
the operator site for CmeR binding and transcriptional repression (13). Bile acids 
induce the expression of cmeABC by inhibiting the binding of CmeR to this operator 
(12).  
 The crystal structure of CmeR revealed that CmeR exhibits a unique 
secondary structural feature among all known structures of the TetR family of 
regulators (16). To date, CmeR is the only regulator in the TetR family that lacks the 
N-terminal helix-turnhelix (HTH) DNA-binding motif, in which the recognition helix α3 
is replaced by a random coil (16, 17). Along with this unique characteristic, a large 
center-to-center distance (54 Å as measured by the separation between Cα atoms of 
Y51 and Y51′ from the other subunit) was observed between the two N-termini of the 
dimer, making it incompatible with the distance between two consecutive major 
grooves of B-DNA. Each monomer of CmeR consists of nine helices, and numbered 
with helix α3 being skipped to facilitate comparisons to other member of the TetR 
family. As a result, the N-terminal domain of CmeR comprises helices α1 and α2 
along with this random coil (Fig. 1). The larger C-terminal domain is composed of 
helices α4-α10, forming a very large hydrophobic tunnel for substrate binding. This 
tunnel is about 20 Å long with a volume of approximately 1000 Å3, which is distinctly 
larger than the binding pockets of many other members of the TetR family. 
Surprisingly, a fortuitous glycerol molecule was found to bind in the binding tunnel of 
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each monomer (16). Residues F99, F103, F137, S138, Y139, V163, C166, T167 
and K170 are responsible for forming this glycerol binding site. The structure also 
suggests that CmeR binds glycerol in a manner of 1:1 monomer-to-ligand molar 
ratio. Although glycerol may not be a natural inducer, the binding may mimic that of 
natural ligands, such as the C4-dicarboxylates.  At this point, the C4-dicarboxylates 
have not been identified as transcriptional inducers, but Recent evidence suggests 
CmeR acts as a pleiotropic regulator by modulating the expression of up to 28 
genes, including many of those for C4-dicarboxylate transport and utilization (18).  
The volume of the ligand-binding tunnel of CmeR is large enough to accommodate a 
few of the ligand molecules. Additional water molecules fill the portion of the large 
tunnel that is unoccupied by ligand. Thus, CmeR might be able to bind more than 
one drug molecule at a time, or possibly accommodate a significantly larger ligand 
that spans across the entire binding tunnel. This tunnel, possibly consisting of 
multiple binding sites for different ligands, is rich in aromatic residues and contains 
four positively charged amino acids (three histidines and one lysine). Based on the 
structural information and the fact that bile acids induce transcription of cemABC, we 
hypothesize that CmeR may utilize these positively charged residues to recognize 
negatively charged ligands, like bile acids. To elucidate how CmeR recognizes these 
large anionic ligands, we here report the crystal structures of CmeR in complexes 
with taurocholate and cholate, respectively. 
 
MATERIALS AND METHODS 
 Preparation and crystallization of the CmeR-ligand complexes: 
Recombinant CmeR containing a 6 x His tag at the N-terminus was overexpressed 
in Escherichia coli strain JM109 using the pQE30 vector. The cloning, expression 
and purification procedures have been described previously (16, 19). The purified 
protein was extensively dialyzed against buffer containing 10 mM Na-phosphate pH 
7.2 and 100 mM NaCl and concentrated to 10-15 mg/ml. Prior to crystallization trials, 
taurocholate or cholate was added to the protein solution at a final concentration of 2 
mM and then incubated overnight at 4º C.  
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 The CmeR-taurocholate and CmeR-cholate complexes were crystallized at 
room temperature using hanging-drop vapor diffusion. Briefly, a 4-µl drop containing 
equal volume of protein-ligand solution and reservoir buffer (24% PEG 3350, 0.1 M 
Tris-HCl pH 8.5, 5% JM 600 pH 7.0, 20 mM sodium acetate) was equilibrated 
against 500 µl of reservoir buffer. Crystals of the CmeR-bile acid complexes 
appeared within two weeks with typical dimensions of 0.2 x 0.2 x 0.2 mm. 
 
 X-ray data collection, processing, and structural refinement: X-ray 
intensity data were collected at 100 K using beamline-24IDC at the Advanced 
Photon Source. The crystals were cryoprotected with a solution containing 32% PEG 
3350, 0.1 M Tris-HCl pH 8.5, 5% JM 600 pH 7.0, 20 mM sodium acetate. Diffraction 
data sets were processed with DENZO and scaled with SCALEPACK (20). Both the 
CmeR-taurocholate and CmeR-cholate crystals took the space group of P21212 with 
unit cell dimensions that were isomorphous to the previously determined 
CmeRglycerol complex (Table 1).  
 The structures of the CmeR-taurocholate and CmeR-cholate complexes were 
determined using the PHENIX suite of programs for crystallographic computing (21). 
The initial phases were calculated by molecular replacement as implemented in 
Phaser (22) using the previously determined CmeR-glycerol structure (2QCO) with 
the bound glycerol and water molecules removed as the starting model. Model 
building was performed using the program Coot (23). Refinement of both structures 
was carried out using CNS (24) and PHENIX (23). The final model was verified by 
inspection of the simulated annealing composite omit maps. The simulated 
annealing electron density omit maps of the bound taurocholate and cholate are 
shown in Fig. 2. In the final models of both taurocholate and cholate bound 
structures, 100% of the residues are within either the most favored or additional 
allowed regions of the Ramachandran plot analysis, as defined by the program 
PROCHECK (25). 
 Polarization: Fluorescence polarization assays were used to determine the 
drug binding afiinity of CmeR to the conjugated bile acid cholyllysyl fluroscein (CLF) 
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(BD Biosciences). The experiments were done using a ligand binding solution 
containing 20 mM Phosphate buffered saline (pH 7.2) and 2 µM CLF. The CmeR 
protein solution and 2 µM CLF was titrated into the ligand binding solution until the 
polarization (P) became saturated. In this assay, the protein–drug interaction would 
reach equilibrium within 1 min. As this is a steady-state approach, fluorescence 
polarization measurement was taken after incubation for 5 min for each 
corresponding concentration of the protein and drug to ensure that the binding had 
reached equilibrium.  All measurements were performed at 25 °C using a 
PerkinElmer LS55 spectrofluorometer equipped with a Hamamatsu R928 
photomultiplier. The excitation wavelength was 480 nm.  Fluorescence polarization 
signals (in ∆P) were measured at an emission wavelength of 517 nm, respectively.  
Each titration point recorded was an average of 15 measurements. Data were 
analyzed using the equation,                                                    P={(Pbound-Pfree) 
[protein]/(KD+[protein])}+Pfree, where P is the polarization measured at a given total 
protein concentration, Pfree is the initial polarization of free ligand, Pbound is the 
maximum polarization of specifically bound ligand, and [protein] is the protein 
concentration. The titration experiments were repeated for three times to obtained 




 To understand how CmeR recognizes anionic ligands, we solved the crystal 
structure of CmeR in complex with the conjugated and non-conjugated bile acids, 
taurocholate (Tch) and cholate (Chd), respectively. Crystals of the bile acid bound 
complexes belonged to the space group P21212, with the asymmetric unit being 
occupied by one CmeR molecule. The symmetry operators were used to identify the 
dimeric state of CmeR. These bile acids were found to bind within the ligand-binding 
tunnel and interact with the regulator using a surprisingly novel binding site which 
does not overlap with the previously determined glycerol-binding site. However, the 
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overall conformation of the bile acid bound CmeR structures are very similar to that 
of the CmeR-glycerol structure. 
 
 Structure of the CmeR-Taurocholate complex: The crystal structure of the 
CmeR-Tch complex was refined to 2.49 Å resolution with a final Rwork of 23.5% and 
Rfree of 28.9%, revealing that Tch binds within the ligandbinding tunnel in a position 
adjacent to the previously identified glycerol-binding site (Figure 1). The Tch binding 
site utilizes a distinct set of amino acids to accommodate the elongated structure of 
the bile acid, while leaving the glycerol-binding site unoccupied.  
 The four-ring system of the bound Tch is completely buried in the CmeR 
binding tunnel, leaving its negatively charged 2-aminoethanesulfonate group in the 
5β position oriented at the entry point and exposed to the solvent. This four-ring 
skeleton, mimicking the steroid backbone, consists of three hydroxyl groups located 
at the 3α, 7α and 12α positions. The CmeR-Tch structure demonstrates that the 3α-
hydroxyl group in the A ring makes a hydrogen bond with the positively charged 
residue H72 (Fig. 3). The C ring and the 12α-hydroxyl group of Tch, however, face 
directly toward helix α8 in the binding tunnel. This orientation facilitates the 
interaction between the 12-hydroxyl oxygen and K170 of α8, allowing them to form a 
second hydrogen bond to anchor the bound Tch. Interestingly, the 7α-hydroxyl group 
of the B ring does not have a hydrogen- bonded partner. With the closest polar 
residue not within 5 Å, this hydroxyl group seems to be left behind in the binding 
tunnel without making dipole-dipole interaction with any residues that form the wall 
of this binding site.  
 Perhaps the most striking feature for Tch binding is found at the other end of 
the molecule which harbors the anionic, conjugated ethanesulfonate tail. Tch is 
bound in such a way that the long 2-aminoethanesulfonate moiety at the 5β position 
is extended slightly out of the binding tunnel exposed to the solvent, while still in 
close enough proximity to interact with residues forming the entrance of the tunnel. 
Within 5 Å of this negatively charged sulfonate group, there are no positively 
charged histidines, lysines or arginines available to neutralize the formal negative 
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charge of this sulfonate moiety. Instead, this conjugated acidic tail is engaged to 
interact with the side chain hydroxyl oxygen atom of residue Y137 and the side chain 
carbamoyl nitrogen of residue Q134, thus forming two additional hydrogen bonds 
with these residues. The repressor protein further anchors this bound bile acid 
molecule through a water-mediated hydrogen bond between T167 and carbonyl 
oxygen of the 2-aminoethanesulfonate group of Tch tosecure the binding.  
 Surprisingly, the large molecule of Tch does not occupy the entire volume of 
the tunnel. The four-ring backbone and the 2-aminoethanesulfonate tail of the bound 
Tch are not linear in shape, but rather curve upward and result in a concave 
conformation. Thus, the end-to-end length of the molecule is significantly shorter 
than it was expected and only reaches 16.1 Å. In doing so, CmeR is able to 
accommodate and create a novel bile acid-binding pocket for Tch. This new binding 
pocket is distinct from the previously determined glycerol-binding site. Thus, the 
bound Tch only spans this bile acid-binding site and leaves the glycerol-binding site 
unoccupied. As the binding tunnel of CmeR is mostly hydrophobic in nature, the 
bound Tch is also found to make extensive hydrophobic contacts with residues 
forming the wall of this tunnel. It is observed that at least nine hydrophobic amino 
acids, including four aromatic residues (F103, W129, F137 and Y139), that line the 
inside wall of the tunnel are involved in Tch binding (Table 2). 
 
 Structure of the CmeR-Cholate complex: The crystal structure of the 
CmeR-Chd complex was refined to a resolution of 2.57 Å, resulting in Rwork and Rfree 
of 21.5% and 27.3 %, respectively. This structure revealed that the binding mode for 
Chd, which differs from Tch by its 5β-cholanoate group, is very distinct (Figure 2b). 
Surprisingly, the bound Chd was found to orient in an opposite direction when 
compared with Tch. Thus, the bound Chd and Tch are anti-parallel to each other. 
For Chd binding, Chd is completely buried within the hydrophobic tunnel in a way 
that its non-conjugated 5β-cholanoate tail is inserted into the end of the tunnel, 
leaving its four-ring steroid backbone anchored closer to the entrance. In this 
manner, the anionic pentanoate moiety of Chd directly interacts with the positively 
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charged H174 of helix α9, forming a hydrogen bond (Fig. 4). Unlike Tch, in which its 
anionic ethanesulfoate group is stabilized by charge-dipole interaction, the structure 
of CmeRChd suggests that the negatively charged end of Chd is neutralized by this 
positively charged histidine residue. A second interaction between CmeR and the 
pentanoate group of the bound Chd is established through the backbone carbonyl 
oxygen of A108 from helix α6, forming another hydrogen bond to anchor this bile 
acid. Important interactions were also found at the 3α and 12α-hydroxyl groups of 
the four-ring system. These two hydroxyl groups contribute two hydrogen bonds with 
C166 and K170 of helix α8, respectively, to stabilize the steroid backbone. Like Tch, 
the 7α-hydroxyl group of Chd does not form a hydrogen bond with any amino acid. 
The bound Chd molecule is significantly curved upward and exhibits a boat-like 
conformation. As a result, the endto- end length of the molecule is only 12.5 Å. The 
curved structure of Chd also makes interactions with nine different hydrophobic 
amino acids, including four aromatic residues (F103, W129, F137 and Y139) that 
create the wall of the tunnel (Table 2).  
 Overall, Chd and Tch share the same ligand-binding pocket. These bile acids 
do not span the entire tunnel, but rather bend into a concave structure. In this 
conformation, these bile acids occupy a novel distinct binding site that is not 
overlapped with the previously determined glycerol-binding site (Fig. 5). Based on 
the structures of CmeR-bile acid complexes, it is observed that the glycerol-binding 
site in the tunnel remains unoccupied upon bile acid binding. Instead, several 
solvent molecules are found in this glycerol site. Thus, it is very likely that the large 




 With the rising incidences of multidrug resistant strains of bacteria, it has 
become increasingly important to understand how individual proteins are able to 
recognize such diverse substrates. The crystal structures of the QacR multidrug 
binding protein in complex with its respective ligands have provided many insights 
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into the mechanism of multidrug binding (27, 28), but these reports have primarily 
involved positively charged compounds. The CmeR-bile acid complexes reveal how 
a TetR family protein specifically interacts with anionic ligands, whereby a primarily 
hydrophobic tunnel with appropriately spaced polar and charged residues is used to 
stabilize bile acid binding.  
 Prior to this structural data, the crystal structure of MarR-salicylate has 
provided evidence on how regulatory proteins recognize anionic compounds (29). 
The negatively charged salicylate binds to MarR within a solvent exposed crevice, 
rather than a large pocket, and interacts with arginines to neutralize its formal 
charge. The binding crevice lacks the familiar aromatic residues that are critically 
important in other multidrug binding proteins (15, 17, 27). It is intriguing that the 
multidrug binding protein TtgR seems to utilize a different mechanism to recognize 
negatively charged antibiotics and plant antimicrobials (30). The hydrophobic 
environment is provided in the ligand binding pocket at the C-terminal regulatory 
domain. In addition, a positively charged histidine and a polar asparagine are also 
found to involve in the binding.  
 For CmeR, this regulator seems to share a similar mechanism with TtgR to 
recognize negatively charged bile acids. Within the multifaceted binding tunnel there 
are at least seven aromatic residues, five phenylalanines, one tyrosine and one 
tryptophan, lining the hydrophobic surface to accommodate staking interactions with 
the ligands. In addition, charge neutralization is observed in bile acid binding, 
whereby the positively charged histidine interacts with the negatively charged 
cholanoate group of Chd. In fact, within the binding tunnel of CmeR, we have found 
four positively charged residues, including H72, K170, H174 and H175′ (Table 2). 
These residues, which underscore the diversity of the CmeR binding tunnel, 
probably function to neutralize charges and accommodate the binding of anionic and 
neutral ligands. This phenomenon is clearly demonstrated in the structures of 
CmeR-Tch and CmeR-Chd, in which the negatively charged ligands are secured in 
the binding tunnel by residue K170. Surprisingly, the two elongated bile acids did not 
bind in the same orientation inside the tunnel of CmeR, but were actually bound anti-
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parallel to each other. Chd was bound in an orientation where its A ring was located 
close to the tunnel opening. However, the bound Tch molecule displayed a 
contrasting orientation, whereby the corresponding A ring was buried deeply inside 
the far end of the tunnel. Because of the difference in orientation, the conserved 
four-ring systems of Tch and Chd were found to bind in different environments.  
 Intriguingly, only one hydrogen bond is conserved in both structures. Residue 
K170 forms an important hydrogen bond with the 12α-hydroxyl group in the C ring of 
both Tch and Chd to anchor the steroid backbone and create an overlapping site 
with very dissimilar binding modes for these molecules. In the case of Chd, CmeR 
further anchors this ligand by using the positively charged H72 residue. For Tch 
binding, the regulator chooses H174 at the other side of the tunnel to interact with 
the ligand. Tch and Chd are similar in chemical structure and have identical charge. 
The different binding modes of these two bile acids indeed highlight the promiscuity 
of the multiligand-binding tunnel of CmeR.  
 To demonstrate that purified C-6XHis CmeR indeed interacts and tightly binds 
to bile acids, we performed fluorescence polarization assays with the fluroscein 
conjugated bile acid CLF.  Using this method, we were able to determine the binding 
affinity of the ligand.  The observed dissociation constant of 50.2 ± 5.8 µM appears 
similar to those kD values obtained for AcrR to its inducing ligands proflavin, 
rhodamine 6G, and ethidium bromide (31).  The approximate five-fold reduction in 
affinity of Cmer-CLF compared to AcrR-ligand is most likely do to the nature of the 
ligand, whereby the large fluroscein moiety may interfere with the molecule entering 
the cavity.  It is worth noting that the high number of hydrogen bonds formed 
between CmeR and bile acids (compared to AcrR) may be required to provide the 
desolvation energy to initiate ligand binding.   
 Previously, the crystal structure of CmeR was fortuitously resolved in complex 
with a glycerol molecule (16). This structure suggested that at least two distinct 
binding sites existed within the tunnel. Indeed, one of these predicted binding sites 
was occupied by the bound glycerol. Interestingly, the CmeR-bile acid structures 
indicated that the large molecules of Chd and Tch did not span both predicted 
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binding sites, but instead took the distinct second site and left the glycerol-binding 
site unoccupied. On the basis of these crystal structures, it is possible that CmeR 
can accommodate a bile acid and a glycerol molecule at the same time (Fig. 5).  
Indeed, positive electron density was observed in the glycerol binding site.  Since 
glycerol was purposely not used in crystallization trials, we could not unambiguously 
identify the density.  If this is indeed a natural ligand, it is fascinating to note the 
ability of CmeR to recognize such a large bile acid molecule and simultaneously bind 
a second natural inducer.  Such a phenomenon has been previously observed with 
the crystal structure of QacR simultaneously bound to two ligands, proflavin and 
ethidium (28), and has been predicted through biochemical analysis to occur in 
many other proteins, including AcrR (31, 32), TtgV (32) and MdfA (34).  
 The plasticity and promiscuity of the multiligand-binding tunnel of CmeR were 
further underscored by these CmeR-ligand complex structures. As mentioned 
previously, glycerol and bile acids have distinct binding sites within the tunnel. In the 
glycerol-bound structure, the bile acid binding site was unoccupied and filled with 
water molecules. This empty site was surrounded with several aromatic residues, 
including F61, F103, F111, W129, F137 and Y139. When Tch occupied this bile acid 
site, which was observed from the CmeR-Tch structure, all of these aromatic 
residues shifted outward and seemingly participated to expand the internal size of 
this binding site, probably accommodating the large size of the bile acid. It is worth 
noting that the formal negative charge of Tch was not neutralized by positively 
charged residues. Instead, electrostatic neutralization was achieved by interactions 
between the anionic Tch and the positive dipoles of two side chains, Y139 and 
Q134. Thus, charge-charge electrostatic interaction is not essential for binding 
negatively charged ligands. Similar drug-regulator interaction has been found in 
QacR, in which the QacR regulator neutralized one end of the positively charged 
pentamidine by using carbonyl and side chain oxygen atoms (35). Interestingly, the 
bound Chd rather employed another mechanism to neutralize its formal negative 
charge, whereas the anionic pentanoate group was compensated by the formal 
positive charge of H72. 
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 CmeR is able to create a binding pocket that can discern between bile acids 
and other ringed compounds by employing helices α4, α5, α6, α7, α8, and α9 to 
create a curved hydrophobic binding pocket with appropriately placed charged/polar 
residues that are able to associate with the unique structure and amphipathic 
properties of the bile acids.  Similar binding architectures have previously been 
observed for bile acids binding to the nuclear receptor FXR (36) and the binding 
inhibition observed in the interaction to pancreatic phospholipase A2 (37).  Our 
structures indicate at least two possible orientations of bile acids whereby the 
sulfonic group of TCH is facing the exterior and the 3-α-hydroxyl of the A ring is 
facing this direction in CHD.  The disparate binding of modes of the molecules is 
most likely associated with the increased lenth of TCH as the steroid backbone is 
identical in both molecules with hydroxyl groups at positions 3α, 7α, and 12α for 
each.  Interestingly, only the 3α and 12α hydroxyl groups make hydrogen bond 
contacts with CmeR while the hydroxyl group at 7α does not make any contacts.  
Presumably the 7-α-dehydroxylated derivatives of CHD and TCH, deoxycholate and 
taurodeoxycholate, would ligand to CmeR in an identical fashion.  Whether an 
analogous binding mechanism is observed for the 12-α-dehydroxylated derivatives, 
chenodeoxycholate and taurochenodeoxycholate, or if they utilize an entirely 
different orientation to form hydrogen bond contacts is an intriguing question. 
 In summary, the ability of CmeR to bind two very similar bile acids in quite 
distinct manners highlighted the plasticity and promiscuity of the ligand-binding 
tunnel of this regulator. This plasticity is very likely applicable to other multiligand 
binding proteins, including the AcrR multidrug regulator. Further, neutralization of the 
negatively charged bile acids can take place using the proximal positively charge 
residues or the nearby polar groups. The proximal and distinct bile acid and glycerol-
binding sites of CmeR highlights the capacity of this regulator, whereby the sizeable 






Coordinates and structural factors have been deposited in the Protein Data Bank 
with accession numbers 3HGY (CmeR-taurocholate) and 3HGG (CmeR-cholate). 
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Figure 1. Structure of a CmeR-ligand complex. Ribbon diagram of the taurocholate-
bound CmeR homodimer generated by crystallographic symmetry.  TCH interacts 
within an ~20 Å long tunnel that resides in the CmeR interior.  The interaction is 
stabilized through polar and hydrophobic interactions. The taurocholate is shown as 




















Figure 2. Electron density maps of the bile acid binding pocket. A, Stereoview of the 
simulated annealing electron density omit map of the bound taurocholate contoured 
at 1.5 σ. The electron density map is shown as grey mesh. The structure of 
taurocholate is shown as a stick model (cyan, carbon; blue, nitrogen; red, oxygen). 
The surrounding secondary structural elements are shown as slate ribbons. B, 
Stereoview of the simulated annealing electron density omit map of the bound 
cholate contoured at 1.5σ. Theelectron density map is shown as grey mesh. The 
structure of cholate is shown as a stick model (green, carbon; blue, nitrogen; red, 
oxygen). The surrounding CmeR secondary structural elements are shown as slate 
ribbons. The electron density omit maps were calculated with a starting temperature 
















Figure 3. The taurocholate binding site. A, Amino acid residues within 4.2 Å from the 
bound taurocholate (cyan, carbon; blue, nitrogen; red, oxygen; orange, sulfur). The 
side chains of selected residues are shown as slate sticks (slate, carbon; blue, 
nitrogen; red, oxygen). Residues from the next subunit of CmeR are shown as 
magenta sticks (magenta, carbon; blue, nitrogen; red, oxygen). A water molecule 
(OW) hydrogenbonded with the bound taurocholate is shown as red sphere. B, 
Schematic representation of the CmeR and taurocholate interactions shown in panel 















Figure 4. The cholate binding site. A, Amino acid residues within 4.2 Å from the 
bound cholate (green, carbon; blue, nitrogen; red, oxygen). The side chains of 
selected residues are shown as slate sticks (slate, carbon; blue, nitrogen; red, 
oxygen). Residues from the next subunit of CmeR are shown as magenta sticks 
(magenta, carbon; blue, nitrogen; red, oxygen). B, Schematic representation of the 














Figure 5. The bile acid and glycerol-binding sites of CmeR. This is a composite 
figure showing the locations of the bound ligands in the ligand binding tunnel. The 





























Figure 6. A) Representative fluorescence polarization of CmeR with CLF. Statistical 
analysis revealed a KD of 50.3 ± 5.8 µM. B) schematic representation of the CLF 
molecule used in binding studies. Cholate moiety is to the left while the fluorescein 
moiety os on the right.     
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CHAPTER 6: CONCLUDING REMARKS 
RND TRANSPORTERS AND AcrD 
 Although much progress has been made to understand the mechanism of 
facilitated drug export by RND transporters, only minimal information exists for AcrD 
and the transport of aminoglycosides and anthracylines.  Numerous structural 
models are available for the RND transporters AcrB and MexB, but these proteins do 
not readily recognize hydrophilic ligands such as aminoglycosides.  Therefore, it is 
important to develop a model for transport of hydrophilic ligands, compounds which 
do not readily cross the cellular membrane.  With an aim to develop novel antibiotics 
against these pumps, it is important to understand the nature of ligand recognition in 
the transporters along with the proteins that regulate their expression. 
 The structures we have modeled for AcrD and previous structures for AcrB 
indicate that drug binding is localized primarily within the central binding cavity or a 
periplasmic binding cleft located 15 Å above the membrane plane (tunnel 2) (1-7).   
It is hypothesized that the binding pocket in the binding cleft is more relevant based 
on previous experiments using domain swapping of AcrD and AcrB (8).  It was 
shown in homology studies that, as expected, the binding cleft region of AcrD is 
distinctly more polar, allowing interation with the hydrophilic character of 
aminoglycosides.  Alternatively, AcrB exhibits a hydrophobic surface in the same 
area (1-5, 7).  Importantly, either instance indicates that substrate binding occurs 
through overlapping but distinct sites to discriminate between dissimilar 
compounds. Furthermore, the recognition sites of multidrug binding proteins are 
composed of hydrophobic and aromatic residues that recognize the specific shape 
of inducing ligands.  In some instances, polar residues are recruited to stabilize 
ligand-binding through hydrogen bonds, which seems to be the case in 
aminoglycoside binding by AcrD.   
 Although the hydrophilic aminoglycosides are quite distinct from the 
hydrophobic AcrB substrates, it is intrigueing that these ligands bind with strikingly 
similar affinities.  Through fluorescent polarization (FP) experiments it was observed 
that AcrB binds Ethidium Bromide (Et), Proflavin (Pf), and Rhodamine-6-G (R6G) 
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with dissociation constants of 8.7, 14.5, and 5.5 µM (9), respectively, while AcrD, as 
displayed through ITC and FP experiments, binds gentamicin and daunorubicin-HCl 
with dissociation constants of 3 and 6 µM (Chapter 3).  Presumably, transport in this 
binding range inhibits the antibacterial compound from reaching toxic levels.  
Furthermore, if binding affinities were increased into the nM scale, it could be 
surmised that export of important metabolites would be a deleterious side effect. 
 As continued exploration of RND proteins has shed new light and insights into 
the structure and function of these proteins, the functional rotating mechanism has 
emerged as the leading model (3-6).  Recent structures of AcrB and MexB have 
pointed to an asymmetric model that seemingly contradicted previous symmetric 
structures (1, 2, 7). Some evidence indicated that the symmetrical AcrB structures 
represent a resting state of the trimer.  It is also likely that the observed symmetry is 
just an artifact of the crystallization process, whereby, as suggested by Seeger et al. 
2006 (4), merohedral twinning was present in the R32 spacegroup.  These crystals 
were in fact twinned R3 crystals with noncrystallographic symmetry.  As a result, 
seemingly suitable models were observed with higher than expected R-factors.  A 
high twinning fraction results in a blurred electron density, which cannot be 
computationally deconvoluted, and explains the difficulties encountered with the 
trigonal crystal form.   
 Of note is the recent crystallization of CusA by our group, which crystallized in 
a symmetric conformation (10).  The heavy-metal transporter CusA crystallized in 
the R32 spacegroup in both the liganded and unliganed state.  Although CusA 
represents a different subfamily of RND transporters, a distinct functional 
mechanism could be suggested which highlights the need to obtain additional 
structural information of RND proteins in hopes of fully understanding the transport 
mechanism.  Another interesting case exists, whereby MdtBC, an RND transporter 
in the same subfamily as AcrB and MexB (HAE1), functions as a heterotrimer. For 
MdtBC, the only functional state exists as a B2C trimer (11).  This poses a question 
as to whether this trimer can function through the same bi-site activation method, in 
which ligand interaction to the neighboring protomer is used to initiate 
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conformational changes.  The AcrB model assumes that each monomer plays an 
equal role in the three-stage cycle.  Additionally, why does this protein only function 
in this B2C trimeric state?  It is intriguing that inactivation of MdtC, by mutating the 
proton-relay-network, did not alter substrate transport, which indicates that it may 
play a unique role from that of MdtB or even AcrD monomers.   
 As it stands, the asymmetric model provides the only reasonable transport 
mechanism.  The model suggested a functionally rotating mechanism to describe 
transport, whereby each protomer of the trimer cycles through successive states. 
The mechanism is said to resemble Boyer’s binding change mechanism of the F1Fo 
ATPase, where conformational cycling of α and β subunits through the various 
states, loose, tight and open, leads to the synthesis of ATP (12).  Intriguingly, the 
F1Fo ATPase utilizes a rotational mechanism in which proton translocation in the Fo 
portion drives an internal rotation of the single-copy γ-subunit of F1, which causes 
the asymmetry and drives the sequential conformational changes.  The counterpart 
RND systems do not have a comparable γ-subunit to drive the asymmetry; therefore 
it is unknown how this asymmetry occurs.  Indeed, the γ-rod of the ATPase is tilted 
towards one of the three α/β subunits.  Likewise, in one monomer of the AcrB trimer 
the pore α-helix is tilted towards the neighbouring monomer's PN2 subdomain (3-5). 
Presumably, ligand interaction can trigger the asymmetric transport mechanism.   
 Recently, an AcrB structure revealed a novel binding partner with an unknown 
function (13).  A transmembrane protein YajC co-crystallized with AcrB and this 
complex induced a functionally significant rotation of the porter domain of AcrB 
relative to the transmembrane domain which could drive the asymmetry of AcrB.  
Deletion of YajC only slightly reduced ampicillin resistance, which suggests this 
protein is not critical for drug transport. 
 The most intriguing issues of the efflux mechanism arrise while discussing 
topics encompasing the entire tripartite complex.  The flexible multidomain 
membrane fusion protein AcrA seems to be critical to drug efflux (14).  How this 
protein initiates AcrD facilitated aminoglycoside efflux is an unexplored question.  Is 
AcrA required to interact with ligands or is it critical for initiating conformational 
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changes to AcrD?  Furthermore, molecular dynamics experiments have suggested 
that membrane fusion proteins may initiate a twisting motion in the outer membrane 
channel in addition to the role in activating the RND transporter (15).  Presumably, 
once AcrA is bound to AcrD, TolC is recruited and the twisting motion initiated By 
AcrA opens the TolC channel.  The twisting motion may also lead to a peristaltic 
action aiding in the movement of substrates along TolC.  As yet, these are untested 
ideas. To unravel these enticing questions, new and ingenious experiments using 
cross-linking, NMR, and mutational studies must be explored on AcrD, AcrB and 
other RND transporters.  
 
TetR REGULATORS, AcrR AND CmeR 
 Through the work on AcrR and CmeR, a model can be suggested to describe 
transcriptional regulation and multidrug binding by proteins of the TetR family.  The 
studies indicate that AcrR utilizes a random coil-to-helix transition, which is initiated 
by a glutamic acid residue 67 (16-18).  The coil-to-helix transition shortens helix α4 
resulting in separation of the N-terminal domains.  Separation of the N-terminal 
domains is a critical factor in repressor release.  This mechanism contrasts what is 
seen in the repressor TetR, whereby contacts are made between tetracycline-Mg2+ 
and a loop region formed between helices α6 and α7 (19, 20).  The movements of 
α6, due to interaction with tetracycline-Mg2+, and subsequently α4 act as a pendulum 
to separate helix α3 and α3´ by 3Å in the ligand-bound conformation.  These 
conformational changes force the release of TetR from the operator.  It is important 
to note that, as revealed by the QacR, TetR, and AcrR crytstal structures, proteins 
that are homologous in structure and function may utilizize slightly different 
mechanisms to perform the same task, i.e., transcriptional repression (21).  
 Multidrug recognition is a critical factor in MDR proteins.  The transporters 
and regulators must be able to discern between deleterious compounds and 
beneficial metaboloites.  Based on our crystallization studies on CmeR, We provide 
evidence that the overall shape and size of the binding pocket along with 
appropriately spaced polar or charged residues is a vital feature to discriminate 
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between molecules (22, 23).  The most intriguing feature of the CmeR crystal 
structures is the overall size and shape of the CmeR binding pocket, which seems to 
perfectly accommodate the ~20 Å-long bile acids.  With the charged residues 
located on the more C-terminal half of the pocket and aromatic residues on the 
other, the pocket seems to be engineered precisely to bind the aliphatic bile acid 
compounds.  Prior to the CmeR-bile acid structure, AcrB-deoxycholate crystals have 
provided the only evidence to how multidrug binding proteins recognize these 
ligands (24).  The structure suggests deoxycholate is stabilized within AcrB through 
4 van der Waals contacts with Phe665 and a hydrogen bond to a Ser715 with no 
charge neutralizing residues in the vicinity of the carboxyl group.  This contrasts 
CmeR, which does utilize charge neutralization to associate with negatively charged 
bile acids.  Furthermore, CmeR also employs aromatic residues to form additional 
hydrophobic interactions.  This suggests that CmeR may be more adapted to 
specifically interact with these anionic ligands.  Indeed, within the multifaceted 
binding pocket there are at least four aromatic residues (three phenylalanines and 
one tryptophan), three positively charge His and one positively charged Lys residue 
that function in neutralizing formal charges. A question emerges as to whether other 
multidrug binding proteins recognize anions through aromatic stacking and charge 
neutralization, or if CmeR has optimized its binding for these bile acids?      
 As a multidrug binding protein, CmeR binds the same series of bile acids as 
CmeABC, the transporter it regulates.  CmeABC is a multidrug binding protein 
capable of recognizing and extruding many structurally dissimilar antibiotics, in 
addition to bile acids (25-30). Interestingly, antibiotics have not been shown to 
initiate CmeABC expression or bind CmeR.  Initially, this seems counterintuitive, but 
during the time when C. jejuni is being inundated with antibiotics, expression of 
CmeABC would have already initiated due to the presence of bile acids in the 
colonized intestinal tract.  This places selective pressure on CmeABC to recognize 
these molecules but places minimal emphasis on CmeR to do the same.  Therefore, 
CmeABC has evolved to recognize antibiotics while there is little advantage if CmeR 
were to recognize the same drugs. 
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              How structurally different molecules, including glycerol, TCH, and CHD 
initiate the same conformational changes in CmeR remains an unresolved question. 
Currently, only the ligand-bound crystal structures have been solved for this TetR 
family regulator.  Homology models indicate that ligand binding within the binding 
pocket initiates a conformational shift throughout the molecule resulting in separation 
of the N-terminal domains to the 54Å center-to-center distance identified in the 
crystal structures.  Whether a coil-to-helix transition initiates these changes as it 
does with QacR and AcrR by elongating helices 5 and 4, respectively, or if a 
completely distinct mechanism exists is unknown.  The crystal structures of apo-
CmeR and the CmeR-DNA complex are needed to further resolve these important 
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